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ABSTRACT 
Fat cell development is a dynamic cellular transition process in which committed 
preadipocytes convert to adipocytes. The initial goal of my resea'rch was to identify 
repressed gene programs in adipogenesis, and to test the hypothesis that these repressed 
gene programs suppress adipogenesis. Using microarray analyses of 3T3-Ll cells, we 
found that the expression of gene programs, most notably cytokines/chemokines, 
correlated inversely with the differentiation state. We analyzed the effect of different 
components of the adipogenic hormonal cocktail in 3T3-Ll preadipocytes. It was found 
that dexamethasone (Dex) acting through the glucocorticoid receptor (GR) was a major 
suppressor of the cytokine expression. In our efforts to characterize roles for 
glucocorticoid signaling in adipogenesis, we found that glucocorticoid-induced leucine 
zipper (Gll...Z), a target of GR, was required for adipogenesis in both 3T3-Ll 
preadipocytes and C3H10Tl/2 mesenchymal stem cells (MSCs). We also showed that 
v 
GILZ was required for bone morphogenic protein 4 (BMP4)-induced white adipocyte 
differentiation and BMP7-induced brown differentiation in C3H10Tl/2 MSCs. In a gain-
of-function study, GILZ overexpression (OE) had minimal effects on normal 
adipogenesis in 3T3-Ll preadipocytes, but increased adipogenic gene expression in 
C3H10Tl/2 MSCs. Oncostatin M (OSM} is an anti-adipogenic cytokine. When exploring 
mechanisms governing the anti-adipogenic activity of OSM and testing the hypothesis 
that GILZ is a target for OSM, we found that while OSM inhibited the expression of 
endogenous GILZ, ectopically expressed GILZ overrode OSM's effect in suppressing 
adipocyte development, suggesting GILZ is a target of the anti-adipogenic activity of 
OSM. During our studies to find signaling pathways regulating the interplay between 
GILZ and OSM, we found that OSM induced both ERK and STAT5 phosphorylation, but 
only inhibition of ERK activity by U0126 partially abolished OSM's inhibition on GILZ 
expression. Taken together, we identified a cytokine/chemokine program that is down-
regulated in adipogenesis. Dex-GR-GILZ signaling pathway played an essential role in 
suppressing the cytokine program and is required for adipogenesis. OSM inhibited 
adipogenesis by suppressing expression of GILZ, which is mediated by the activation of 
ERK phosphorylation. These findings highlighted the critical role of GILZ m 
adipogenesis and can contribute to combating metabolic disorders such as obesity. 
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INTRODUCTION 
Obesity 
Obesity has become a national and world epidemic plaguing millions of people. 
Obesity is defined as body mass index (BMI) of 30 or higher (Allison et al. 1999). During 
the past two decades, the number of obese American people has risen significantly and 
currently 36% of United States adults and 17% of children and adolescents aged 2-19 
years of age are obese (Sherry et al. 2010). 
An escalating number of obese people in the world gives rise to many health and 
social issues, especially in the rising economies, like China and India. It is estimated that 
5% of China's 1.4 billion population is obese and rates are almost 20% in some cities 
(Wu 2006; Li et al. 2007). Although the percentage of obese people is lower in China 
than in the United States, the large overall population in China means that one fifth of 
world's obese people are in China. 
Aside from the aesthetic issues associated with this epidemic, obesity has 
significant co-morbidities, such as increased incidences of type 2 diabetes, cardiovascular 
diseases, hypertension, hyperdyslipidemia, and hyperglycemia (Allison et al. 1999; Chen 
et al. 2010; Dixon 2010). 
It is generally believed that several factors contribute to the obesity pandemic, all 
of which cause the increase of energy consumed and/or the decrease of energy expended. 
The high fat, high glucose diet, a staple of the fast and prepared food industry, rather than 
prudent diets including lean meats, vegetables, and fruit, is believed to be an important 
source of excessive energy consumption (Nielsen et al. 2002; Drewnowski 2004; 
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Drewnowski et al. 2004). To make things worse, diminishing exercise m our daily 
activities, partially due to the sedentary nature of work, and the prevalence of cars for 
transportation, among others, reduces the energy we bum every day (Williams et al. 
2005; Hills et al. 2007). Tipping the energy balance towards accumulation of excessive 
energy in our body leads to expansion of adipose tissue, which is known to be a major 
organ for energy storage (Mohamed-Ali et al. 1998; Klaus 2004). 
Besides the abovementioned factors contributing to the obesity pandemic, 
genetics contributes to obesity. Several genes have been linked with obesity, such as 
adiponectin, beta-1 adrenergic receptor (ADRB 1 ), leptin (LEP), leptin receptor (LEPR), 
peroxisome proliferator activated receptor gamma (PP ARy), and uncoupling protein 1 
(UCP1) and abnormalities in these genes predispose people to obesity (Oppert et al. 
1994; Deeb et al. 1998; Mammes et al. 1998; Dobson et al. 2001; Yiannakouris et al. 
2001; Dionne et al. 2002; Menzaghi et al. 2002; Bell et al. 2005). 
Obesity, type 2 diabetes and insulin resistance 
Of the many co-morbidities associated with obesity, insulin resistance and type 2 
diabetes are the most prevalent (Kahn et al. 2006). Type 2 diabetes is a chronic metabolic 
disorder with persistent elevated levels of blood sugar. Type 2 diabetes has become a 
national and world-wide epidemic: according to the American Diabetes Association, 25.8 
million people in the United States have type 2 diabetes, which represents 8.3% of the 
population. It has been shown that there is a direct correlation between the incidence of 
obesity and type 2 diabetes. The immediate link of obesity to type 2 diabetes is that 
2 
obesity causes insulin resistance (Dandona et al. 2004; Golay et al. 2005; Kahn et al. 
2006). 
Insulin IS a hormone secreted by the pancreas. It plays an essential role in 
regulating blood glucose and fatty acid levels by stimulating their absorption into 
peripheral tissues, including muscle and adipose tissue, for energy consumption or 
storage (Saltiel et al. 2001; Marshall 2006). Incidentally, it is also required for the 
induction of adipocyte differentiation in vitro (Klemm et al. 2001). Insulin exerts its 
biological function by binding to its receptor and inducing several downstream signaling 
pathways including phosphoinositide 3-kinase (PI3K), AMP-activated protein kinase 
(AMPK), and mammalian target ofrapamycin (mTOR) (Pirola et al. 2004; Avruch et al. 
2006; Fisher 2006; Long et al. 2011). Insulin resistance arises when these downstream 
pathways are blunted or resistant to the insulin stimulation, resulting in dysregulation of 
glucose and lipid metabolism (Moller et al. 1991; Shulman 2000; Morisco et al. 2006). 
The underlying molecular and biochemical mechanisms through which obesity 
leads to insulin resistance are not totally clear. Some evidence indicates that high 
circulating glucose or free fatty acids may trigger the increase of detrimental 
intermediates like cytokines, or adipokines (like resistin); while at the same time, they 
trigger the decrease of beneficial intermediates such as adiponectin, among others 
(Samuel et al. ; Olefsky et al. 201 0; Ziemke et al. 201 0; Holland et al. 2011; Park et al. 
2011). 
Studies have shown a direct correlation between obesity and type 2 diabetes, and 
suggested that obesity may contribute or lead to type 2 diabetes. In an epidemiologic 
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study, it was demonstrated that 8% weight loss results in a 16% increase of cardiac 
fitness and reduction of insulin resistance (Ross et al. 2000). Identifying the mechanisms 
regulating adipocyte development is important for our understanding of the etiology of 
obesity and will shed light on the prevention and treatment of associated diseases. 
While obesity is tightly linked to type 2 diabetes, the extent of the association 
differs among individuals depending on the locations of the stored fat (adipose depots) 
(Montague et al. 1998; Tray hum et al. 2004 ). Visceral fat is thought to be the major 
adipose depot associated with insulin resistance since it secretes many detrimental 
mediators, including adipokines (resistin), chemokines (ccl2) and cytokines (TNFa) that 
lead to inflammation. The subcutaneous depot, on the other hand, is thought to be benign; 
working as an organ to store fat and secrete insulin-sensitizing adipok:ines such as 
adiponectin (Ibrahim 2010). It has been shown that TNFa expression is increased in the 
obese mouse and it is a mediator for obesity-induced insulin resistance (Hotamisligil et 
al. 1993). The blockade ofTNFa in mice by either mutating the gene or deleting the gene 
results in the improvement or the restoration of insulin sensitivity (Uysal et al. 1997; 
Ventre et al. 1997). However, there appears to be no difference in the expression of 
TNFa between the visceral and the subcutaneous depots of adipose tissue (Montague et 
al. 1998). 
White adipose tissue (WAT) 
Adipose tissue works as a major lipid storage tissue in the body. Lipids and fatty 
acids are stored in the form of triglycerides where three fatty acids are covalently-bound 
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to a glycerol backbone. Compared to other energy storage tissues such as muscle and 
liver, which store protein and carbohydrate, adipose tissue stores more energy in the form 
of fat since every gram of fat corresponds to 9 kilocalories while protein or carbohydrate 
each correspond to approximately 4 kiloc~ories. Adipose tissue is composed of the fat-
storing adipocyte and many other cell types located within a stromal vascular 
compartment which includes preadipocytes, vascular progenitors, inflammatory cells 
such as macrophages as well as others (Ahima 2006). Besides the common subcellular 
structures shared with other cell types, a unique feature of the adipocyte is the presence of 
a unilocular lipid droplet (in white adipocytes), which occupies a large majority of the 
cellular space. 
While it has been thought for a long time that adipose tissue functions as an inert 
energy storage organ, studies in the past decades showed that adipose tissue also acts as 
an endocrine organ secreting crucial hormones (adipokines), such as adiponectin and 
leptin, that regulate important metabolic processes (Galic et al. 2010). Adipokines can 
exert biological functions in local adipose tissues or peripheral tissues such as liver, 
muscle, pancreas, and brain. More and more evidence suggest that adipose tissue is an 
important organ governing energy homeostasis in the body (Rajala et al. 2003; Kershaw 
et al. 2004; Trayhum et al. 2004). 
There are two types of adipose tissues in mammals with different locations and 
functions: white adipose W AT and brown adipose tissue. W AT is the most abundant 
adipose tissue, with its biological functions of energy storage and adipokine secretion 
contributing to metabolic homeostasis (Trayhurn et al. 2001). 
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Brown adipose tissue (BAT) 
BAT takes up a smaller portion of total fat tissues, and it resides mostly in 
newborn infants, and kidney and neck regions in adults (Heaton 1972; Seale 2008). BAT 
adipocytes share similar functions as W AT adipocytes, but with some unique features 
such as containing multiple lipid droplets of relatively small sizes and the presence of 
more mitochondria than WAT,which contributes to the brown color ofBAT (Hul11966). 
High concentration of mitochondria in BAT dictates the unique function of BAT to 
metabolize stored lipid. The proton gradient generated by lipid catabolism through the 
electron transport chain (ETC) gives rise to heat rather than adenosine triphosphate 
(ATP), due to presence of a BAT specific uncoupling protein-! (UCP-1) in the inner 
membrane ofthe mitochondria (Trayhum et al. 2001; Bartelt et al. 2012). 
Adipogenesis 
Adipocyte determination starts from the commitment of MSCs, stromal cells that 
have the ability to self-renew and also exhibit multilineage differentiation, to the 
adipocyte lineage giving rise to adipoblasts/preadipocytes, which have the potential to 
form adipocytes (Gregoire et al. 1998; Ding et al. 2011; Tang et al. 2012). Upon proper 
stimulation, these preadipocytes differentiate into mature adipocytes. 
Adipogenesis is a dynamic cellular transition process in which committed 
preadipocytes (fibroblastic cells that secrete an extracellular matrix rich in collagen and 
other macromolecules) convert to adipocytes characterized by acquisition of several 
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associated biological processes including lipid droplets accumulation, extracellular 
matrix remodeling, immune response reduction and adipokine production (Gregoire 
2001; Rosen et al. 2006; Lefterova et al. 2009; Mariman et al. 2010). Successful 
adipocyte formation is controlled by the up-regulation of transcription factors including 
PPARy and CCAAT/Enhancer Binding Protein a (C/EBPa), and terminal differentiation 
is marked by the induction of adipokines such as adiponectin and fatty acid binding 
protein 4 (F ABP4) (Farmer 2006). 
In vivo adipocyte differentiation 
The increase in the mass of adipose tissue during obesity is the result of two types 
of growth, one is hypertrophy, which is the enlargement of existing adipocytes; the other 
is hyperplasia, which is the increase in the adipocyte numbers (Sjostrom 1972; Hirsch et 
al. 1976). It has been known that mature adipocytes are postrnitotic, meaning that these 
cells are not capable of undergoing mitosis. Therefore, precursor cells are needed for 
hyperplasia in vivo. Studies have shown that adipocyte-derived stem cells (ADSCs), 
which reside in the stromal-vascular fraction (SVF) of adipose tissues, are the precursor 
cells for adipocytes (Unguryte et al. 201 0; Zimmerlin et al. 201 0). ADSCs are pluripotent 
and can differentiate into different lineages. After the commitment steps, the cells 
become preadipocytes and are able to undergo differentiation (Otto et al. 2005; Tang et 
al. 2012). It has been suggested that BMP and Wnt family members are important 
mediators for the commitment of ADSCs to preadipocytes (Ross et al. 2000; Tang et al. 
2004; Bowers et al. 2006; Bowers et al. 2008). 
7 
Hormone pathways also contribute to the development of fat cells and/or obesity 
in vivo. It has been shown that chronic glucocorticoids production leads to Cushing's 
syndrome (Shibli-Rahhal et al. 2006; Hatipoglu 2012). Cyclic adenosine monophosphate 
(AMP) and cAMP response element-binding protein (CREB) signaling pathway has been 
demonstrated to contribute to fat cell development and insulin resistance (Qi et al. 2009; 
Reusch et al. 2000). Insulin induces weight gain in human (Russell-Jones et al. 2007; Aas 
et al. 2009). 
The up and down regulated gene programs in adipogenesis 
The activation programs in adipogenesis are extensively studied and well 
characterized, which include transcription factors such as the CCAAT/enhancer binding 
protein (CEBP) family C/EBP8, C/EBP~, C/EBPa, peroxisome proliferator-activated 
receptor gamma (PPARy), and terminal differentiation factors like fatty acid binding 
protein (FABP4), adiponectin, among others (Ringold et al. 1986; MacDougald et al. 
2002; Farmer 2006; Lefterova et al. 2009). 
The regulatory programs responsible for suppressing preadipocyte genes have 
also been studied. Some genes repressed during adipogenesis have been identified and 
the functions of the corresponding proteins in some cases have been extensively studied. 
For instance, the extracellular proteins preadipocyte factor 1 (Pref-1) and tissue inhibitor 
of metalloproteinases 3 (TIMP3) (Kim et al. 2007; Bernat et al. 2010), as well as 
transcription factors GATA2 and Sox9 (Schupp et al. 2009; Wang et al. 2009), play very 
important roles in controlling the fate of preadipocytes. Pref-1 inhibits adipogenesis by 
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inducing Sox9, which binds to the promoter regions of C/EBP~ and C/EBP8 to suppress 
their activity (Wang et al. 2009). TIMP3 suppresses adipogenesis by targeting Kriippel-
like factor 4 (Klf4), early growth response 2 (Egr2/Krox20), and C/EBP~ (Bernot et al. 
201 0). GAT A2 transcription factor needs to be down-regulated in adipogenesis because 
its constitutive expression traps cells at the preadipocyte stage (Tong et al. 2000). 
Depletion of PP ARy in mature adipocytes by siRNA facilitates re-expression of GAT A2, 
which induces expression of genes characteristic of a preadipocyte phenotype (Schupp et 
al. 2009). Runt-related transcription factor 1 (Runx1 t1) inhibits expression of C/EBPa by 
directly binding with C/EBP~ and inhibiting its DNA binding activity to the C/EBPa 
promoter (Rochford et al. 2004). 
Besides the studies of the individual suppressed genes, high throughout methods 
such as microarray and chromatin immunoprecipitation sequencing (ChiP-seq) have also 
been used to elucidate the suppressed genes (Burton et al. 2002; Burton et al. 2004; Yu et 
al. 2010). Using microarray analysis, Burton et al. studied the early regulation of 
adipogenesis (before 24 hours after induction) in 3T3-L1 cells. In the study, a total of285 
genes with more than a fivefold change were grouped according to their expression 
patterns (Burton et al. 2002). Later on, Burton et al. identified 1686 transcripts that have 
more than a twofold change in 3T3-Ll adipogenesis and grouped them into 12 clusters 
based on the expression pattern (Burton et al. 2004). In both studies Burton et al. showed 
the group of genes and briefly discussed several genes and their known biological 
function. However, not too much focus was put on the possible implication of the 
biological significance of the individual clusters as a whole or part of the clusters. On the 
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other hand, Yu et al. identified genome-wide GR binding regions (GBRs) in 3T3-L1 
cells. Additionally using functional analysis, it is shown that many GBRs are in 
proximity of genes involved in triglyceride (TG) synthesis, lipolysis, lipid transport and 
storage (Yu et al. 2010). 
Besides identifying the genes that are suppressed in adipogenesis and grouping 
the genes according to their expression pattern as Burton et al. showed, my study was 
intended to put more effort on the biological function and test the hypothesis that these 
genes suppress adipogenesis. 
In vitro cultured cell models 
To better understand the development of obesity, several in vitro cultured cell 
models have been established and some were extensively used in my studies. One of the 
most well-characterized models is the 3T3-L1 preadipocyte cell line, which was 
established in 1974 (Green et al. 1974; Green et al. 1975). 3T3-L1 preadipocytes were 
derived from an immortalized 3T3 cell line which was isolated from primary mouse 
embryonic fibroblast cells (Todaro et al. 1963). It was found that when culturing the cells 
for an extended period of time after reaching confluency, some cells automatically 
differentiated into lipid droplet bearing adipocytes. Additionally, treating the cultures 
with hormonal inducers could significantly accelerate this auto-adipogenesis process. 
Rubin et al. established the model system by developing a differentiation protocol, which 
included treatment of cells with synthetic glucocorticoid Dex, cAMP signaling activator 
methylisobutylxanthine (MIX) and insulin for two days after the cells reach confluency 
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(Rubin et al. 1978). After two days of induction, these hormones are removed and cells 
are differentiated for four to ten more days with insulin to ensure terminal differentiation. 
This is the standard 3T3-L1differentiation protocol used by most researchers in this field 
today. 
While 3T3-L1 preadipocytes are committed to differentiate into adipocytes and 
not other lineages, C3H10Tl/2 MSCs, established in 1973 by Heidelberger group 
(Reznikoff et al. 1973), are pluripotent and are able to differentiate to several lineages 
including fat, bone, and muscle, depending on the induction conditions (Gimble et al. 
1995; Gregoire et al. 1998). To induce C3H10Tl/2 MSCs into adipocytes, they are 
treated with BMPs for three days before reaching con:fluency, and are then treated with 
hormone inducers Dex, MIX, insulin and Indomethacin for two days. The cells are then 
replenished with insulin and differentiated for two to six more days into mature 
adipocytes. It has been shown recently that C3H1 OTl/2 MSCs can also differentiate into 
brown or white adipocytes depending on the BMP pretreatments: BMP7 can induce the 
former while BMP4 can induce the latter (Tseng et al. 2008). 
Glucocorticoid function 
Glucocorticoid is a class of steroid hormones including cortisol in humans, 
corticosteroid in rodents, and synthetic ones including Dex. They all bind to the 
glucocorticoid receptor with high affinity (Warriar et al. 1994). Cortisol and 
corticosteroids are synthesized in and secreted by the adrenal cortex. They are known to 
be stress hormones with a wide range of biological functions including immune response, 
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metabolism, development, cell proliferation, and apoptosis (de Kloet et al. 1999; Ashwell 
et al. 2000; Newton 2000; Sapolsky et al. 2000). Glucocorticoids also have significant 
medical values; since the initial discovery by Dr. Phillip S. Hench as a treatment for 
rheumatoid arthritis in the 1940s, they have been used for treating autoimmune diseases 
and allergies (Neeck 2002). 
The synthetic glucocorticoid Dex is a hormone inducer for in vitro adipogenesis 
in different preadipocyte cell lines (Smas et al. 1995). In the absence of glucocorticoid, 
adipocyte differentiation is dramatically attenuated or significantly delayed (Ringold et 
al. 1986; Wolf 1999; Pantoja et al. 2008). It is also used to induce adipogenesis in 
primary cells isolated from different mammals including rodents, rabbits, pigs and 
humans (Harmer et al. 1989; Reyne et al. 1989; Gregoire et al. 1991; Litthauer et al. 
1992; Suryawan et al. 1997). Besides its important roles in the induction of fat cell 
development in the in vitro cultured model system, prolonged exposure to excess 
glucocorticoids can lead to Cushing's syndrome in humans, whose symptoms include 
multiple metabolic disorders including obesity, hyperglycemia, and hypertension (Shibli-
Rahhal et al. 2006; Hatipoglu 2012). It is suggested that excess fat deposition for patients 
with Cushing's syndrome is due to elevated adipocyte lipoprotein lipase activity and low 
lipolytic activity (Rebuffe-Scrive et al. 1988). Due to the importance of glucocorticoids in 
the development of fat cells or tissues in vitro and in vivo, Chapter 2 of my studies was 
intended to identify novel players in the glucocorticoid pathway that contribute to 
adipogenesis using in vitro cultured cell systems. 
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Glucocorticoid signaling and glucocorticoid receptor (GR) 
Glucocorticoids function through non-genomic or genomic actions (Stahn et al. 
2008). While the genomic action involves the modification, either activation or 
suppression, of multiple genes, the non-genomic action does not. The non-genomic action 
is characterized by rapid onset and short duration (Alangari 2010). There are seveal 
mechanisms for the non-genomic action of glucocorticoids, including interactions with 
cellular membranes; membrane-bound GR-mediated non-genomic effects; and cytosolic 
GR-mediated non-genomic effects (Song et al. 2006). Glucocorticoids exert their major 
genomic biological function by modifying gene expression and this is through the GR (or 
NR3C1). Glucocorticoids diffuse through the cell membrane and bind to GR in the 
cytosol. The binding of glucocorticoid to GR dislodges heat shock protein 90 (HSP90) 
and other factors that associate with unliganded GR. Ligand-bound GR translocates into 
the nucleus and drives changes in gene expression by direct contact with the GR response 
element (GRE) on DNA, or by protein-protein interactions with other transcription 
factors (Hayashi et al. 2004; Lowenberg et al. 2007; Revollo et al. 2009). 
In the in vitro cultured cell systems of adipogenesis, Dex induces expression of an 
early stage transcriptional inducer C/EBPo (Cao et al. 1991). It also primes the 
preadipocytes to a committed state, while MIX and insulinhave no such capability 
(Pantoja et al. 2008). It is shown that Dex's effect on adipogenesis is, at least in part, 
through the acetylation ofC/EBP~ by GCN5 (Wiper-Bergeron et al. 2007). 
It has been shown that alternative splicing occurs on human GR pre-mRNA, and 
two isoforms have been identified, named GR-a and GR-b. Both isoforms have DNA 
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binding and ligand binding domains. But GR-a protein has a unique 50 amino acids 
sequence at the carboxyl terminus (Hollenberg et al. 1985; Oakley et al. 1996). GR-a and 
GR-b have different tissue distributions and distinct biological activities and functions. 
GR-a is the major isoform and has been shown to bind ligand, bind DNA, and interact 
with other transcription factors. Therefore, it can modulate the transcription of its 
downstream target genes (Hollenberg et al. 1985). GR-b, however, does not bind to 
ligand and cannot transactivate target genes (Hollenberg et al. 1985; Hecht et al. 1997). It 
is shown that GR-b can interact with GR-a and DNA, and some researchers suggest a 
dominant negative role for GR-b by binding and inhibiting GR-a's activities (Bamberger 
et al. 1995). Some studies also found that the relative levels of GR-b may determine the 
sensitivities of cells to glucocorticoid signaling: the higher the amount of GR-b, the lower 
the sensitivity ofthe cells to glucocorticoid (Bamberger et al. 1996; Pujols et al. 2002). 
Glucocorticoid induced leucine zipper (GILZ) 
GILZ, a target of glucocorticoid, was identified in 1997 as a factor shown to be 
induced by Dex and to protect T cells from apoptosis following treatment with the anti-
CD3 monoclonal antibody (D'Adamio et al. 1997). GILZ was also shown to be an 
important mediator of glucocorticoid functions. Therefore, it was chosen as a target for 
the potential candidate that mediate glucocorticoid's function in the development of fat 
cells. The GILZ gene promoter has five GRE sequences for the binding of GR (Asselin-
Labat et al. 2004). As a target of glucocorticoid and GR, GILZ serves as a crucial 
mediator of GR's effect on downstream targets, with immunomodulation as one 
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important role. It has been shown that GILZ plays an important role in mediating T-cell 
activation, cell proliferation, and apoptosis (Ayroldi et al. 2001; Delfino et al. 2004; 
Ayroldi et al. 2007). 
GILZ mRNA and protein expression can be found in many murine and human 
tissues, most notably the lung, spleen, lymph nodes, and thymus. It has been shown that 
glucocorticoids induce both murine and human GILZ expression rapidly (D'Adamio et al. 
1997; Cannarile et al. 2001). 
GILZ is able to interact with and inhibit NF-KB, and certain targets of GILZ have 
been identified, including activator protein 1 (AP-1), Raf-1, and Ras (Ayroldi et al. 2001; 
Ayroldi et al. 2002; Ayroldi et al. 2007). It has also been shown that OE of GILZ inhibits 
3T3-L1 preadipocyte differentiation by binding to a C/EBP site on the PP ARy promoter 
(Shi et al. 2002). 
It has been shown that GILZ interplays with interleukin-6 (IL-6). Reduced 
expression of GILZ correlates with high IL-6 levels in major depressive disorder patients 
(Frodl et al. 2012). It has been suggested that annexin-1 regulates IL-6 via GILZ in 
macrophages; and IL-6 inhibits GILZ up-regulation induced by Dex in multiple myeloma 
(Grugan et al. 2008; Yang et al. 2009). 
The interleukin-6 (IL-6) family of cytokines 
The IL-6 family of cytokines plays many important biological roles, including 
tissue development and remodeling, cell proliferation, immune response, and 
hematopoietic activity (Taga 1997; Taga et al. 1997; Wong et al. 2003; White et al. 
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2011). The IL-6 inflammatory cytokine family includes IL-6, IL-11, OSM, leukemia 
inhibitory factor (LIP), ciliary neurotrophic factor (CNTP), Neuropoietin (NP) and 
cardiotrophin-1 (CT-1). Their receptors are dimerized, and they all share one common 
receptor subunit: glycoprotein 130 (gp130). 
Several studies have suggested roles for the IL-6 family of cytokines in regulating 
adipocyte development. IL-6 was shown to inhibit adipogenesis and was thought to be an 
important link between obesity and type 2 diabetes (Gimble et al. 1994; Lagathu et al. 
2003; Dandona et al. 2004). IL-11 was shown to inhibit adipogenesis in 3T3-Ll 
preadipocytes (Yin et al. 1992). LIP is used commonly to maintain the developmental 
potential of stem cells and inhibit differentiation (Williams et al. 1988; MacDougald et al. 
2002). Stephens group has shown that NP suppresses adipogenesis in a dose- and time-
dependent manner in 3T3-Ll cells, it blocks insulin action in adipose tissue in vivo and 
induces insulin resistance (White et al. 2008). NP activates signal transducer and 
activator of transcription 3 (STAT3), and this is through the phosphorylation of gp130 
rather than leukemia inhibitory factor receptor (LIFR) (White et al. 2010). No reports 
have shown the effect of CNTP or CT -1 on adipogenesis (White et al. 2008). 
Extracellular-signal-regulated kinase and STA T5 cascades are two of the 
signaling pathways activated by IL-6 family members (Heinrich et al. 2003; White et al. 
2011). This is different from other inflammatory cytokines like TNFa or IL-l, which 
exert their biological functions mainly through NF-KB and other signaling pathways 
(Bomsztyk et al. 1990; Darnay et al. 1997). 
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In adipocyte biology, IL-6 family members show different patterns of crosstalk in 
vitro and in vivo: in the in vitro 3T3-L1 cell model, CT-1 , LIF, and OSM suppress 
subsequent signaling activity initiated by IL-6 family cytokines, while IL-6 and CNTF 
are not able to do so; in the in vivo tissues extracted from rats, CT-1, LIF, and OSM have 
been shown to change the subsequent signaling of other family members (Zvonic et al. 
2005; White et al. 2011). 
Oncostatin M (OSM) 
OSM belongs to the IL-6 family. OSM was first identified in differentiating 
lymphoma cells that inhibits the replication of melanoma and other human tumor cells in 
1989 (Malik et al. 1989). It has been found that immune cells such as activated T 
lymphocytes, monocytes, and neutrophils secrete OSM during inflammatory related 
disorders (infections and sepsis) (Grenier et al. 1999; Luyckx et al. 2009). As introduced 
before, studies have suggested that IL-6 inhibits GILZ (Grugan et al. 2008), and it was 
hypothesized in my study that OSM targets GILZ for its biological function in 
adipogenesis. 
Several studies suggest that OSM plays an important role in adipocyte 
development and adipocyte function: OSM suppresses adipogenesis (Gimble et al. 1994; 
Yanai et al. 2001); OSM was the most potent IL-6 family member to inhibit preadipocyte 
differentiation in murine preadipocytes in vitro (Miyaoka et al. 2006); OSM inhibited 
expression of adipogenic genes such as PP ARy and adiponectin in mature fat cells (Song 
et al. 2007). The inhibition is through the MEKIERK and STAT5 signaling pathways 
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(Miyaoka et al. 2006). Studies in the Stephens group have demonstrated that OSM is a 
potent inducer ofSTAT3 but less so of STAT I (Balhoff et al. 1998; Stephens et al. 1998; 
Richard et al. 2011). 
While OSM inhibits adipogenesis, a study showed that it can promote 
osteogenesis in human adipose tissue derived mesenchymal stem cells (Song et al. 2007) 
and the same group reported that OSM induces proliferation of the-se cells via MEK/ERK 
and JAK3/STAT5 signaling pathways (Song et al. 2005). 
MAPKIERK kinase (MEK) and extracellular signal-regulated kinase (ERK) signaling 
Mitogen-activated protein kinase (MAPK) pathways are evolutionarily conserved 
mechanisms to transduce extracellular stimuli to the cell. They have been extensively 
studied during the past two decades and show important roles in adipogenesis (A vruch 
2007). The MAPK family is comprised of four members: ERKI /2, c-Jun N-Terminal 
kinase (JNK), p38, and ERK5. They are at the center of pathways to mediate signal 
transduction that facilitate important biological functions, such as the response to stress, 
cell proliferation and differentiation, tissue and organ development, cell survival, 
senescence, apoptosis and necrosis, cell cycle, and cancer (Sale et al. 1995; Prusty et al. 
2002; Keshet et al. 2010). 
The ERK signaling pathway is the most extensively studied of the MAPK 
pathways. It has been shown to link to one third of human cancers (Dhillon et al. 2007). 
ERK is activated by many extracellular stimuli, including growth factors , mitogens, and 
stress. The mediators between extracellular signals to ERK include G-protein coupled 
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receptors (GPCR) and tyrosine kinase receptors, among others (Sturgill 2008; Keshet et 
al. 2010). 
It has been suggested that the ERK signaling pathway plays important roles in 
adipogenesis, but the precise role has been the topic of much debate during the past 
decades. One of the first reports showed that knocking down ERK1 and ERK2 eliminates 
adipocyte differentiation by more than 90%, and this suggests ERK1 and ERK2 are 
required for adipogenesis (Sale et al. 1995). But later studies showed that PP ARy is a 
target for ERK, and can be phosphorylated by ERK. The phosphorylation of PPARy by 
ERK decreases PPARy's transcriptional activity (Camp et al. 1997). By ectopically 
expressing a nonphosphorylatable mutant of PPARy (S 112A), they show that it resists 
ERK suppression and increases adipogenesis (Hu et al. 1996; Camp et al. 1997). A 
previous study in our lab found that a transient increase of ERK phosphorylation 
temporally correlated with C/EBP expression in 3T3-L1 preadipocyte. Treatment of the 
cells with a MEK inhibitor U0126 prior to the hormone induction attenuates the 
expression of transcription factors PP ARy, C/EBPa, and also the terminal differentiation 
genes such as perilipin and F ABP4 (Prusty et al. 2002). One explanation for the 
requirement of ERK activation during the first couple of hours in adipogenesis is that 
ERK is only required for mitotic clonal expansion, which is the process that post-
confluent growth-arrested preadipocytes coordinately reenter cell cycle and express 
adipogenic genes after the hormonal induction (Mandrup et al. 1997; Tang et al. 2003; 
Yanagiya et al. 2007). 
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In the in vivo studies, ERK plays an important role in general development. ERK2 
knock out mice are embryonic lethal (Saba-El-Leil et al. 2003). ERK1 knock out mice, 
on the other hand, are viable and fertile, suggesting different roles of the two isoforms 
(Mazzucchelli et al. 2002). However, ERK1 has been shown to play important roles in 
the development of fat cells in vivo as ERK1 knock out mice show less adipocytes and 
decreased adiposity compared to the wild-type animals. Moreover, ERK1-/- mice are 
more resistant to obesity and have improved insulin sensitivity when challenged with a 
high-fat diet (Bost et al. 2005). Similar to the mouse study, it was found that ERK 
activity was higher in type 2 diabetes patients (Carlson et al. 2003). 
Signal transducer and activator of transcription (STAT) signaling 
STAT was originally identified as the transcription factor that responds to 
interferon (IFN) and other signaling polypeptides such as epidermal growth factor (EGF) 
and platelet-derived growth factor (PDGF) (Darnell et al. 1994). Seven STAT family 
members have been identified in mammalian systems. The proteins consist of 750 to 900 
amino acids. They all have DNA binding domains, SH2, SH3, and a transactivation 
domain (Darnell 1997). STAT is linked to human diseases such as immunodeficiency, 
asthma, and cancer (Schindler 2002). Disruptions of mouse STAT genes suggested their 
important roles in innate response to infection, development, and immune cell function 
(Hou et al. 2002). 
The activation of the STAT signaling pathway requires phosphorylation of a 
tyrosine located at residue 700 of the STATs (Darnell et al. 1994). This phosphorylation 
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occurs either through the tyrosine kinase receptors such as EGF and PDGF, or through 
receptors without tyrosine kinase activity that are linked with Janus kinases (JAKs) (Ihle 
et al. 1995; Leaman et al. 1996). There are several groups of polypeptides that can 
activate STAT signaling, including members of the IFN family, gpl30 family, gamma 
chain receptor (y-c) family, gp140 family, the growth hormone family and the receptor 
tyrosine kinase family. The phosphorylation recruits another STAT, and they then initiate 
reciprocal tyrosine phosphorylation to activate each other. Activated STATs are then 
disassociated from the receptor, dimerize with each other, and translocate to the nucleus 
to facilitate gene transcription (Schindler et al. 1995). 
ST A T5 signaling has been shown to be important for adipose tissue development 
(Nanbu-Wakao et al. 2002). STAT5 expression occurs relatively late in adipogenesis, but 
its activation (phosphorylation) occurs early during the frrst couple of hours after 
hormonal induction (Floyd et al. 2003). Ectopically expressed dominant-negative (DN) 
STAT5 renders 3T3-Ll preadipocytes unable to differentiate (Nanbu-Wakao et al. 2002). 
Another study, however, showed that cells expressing either constitutively active (CA) or 
DN STAT5 differentiate less than normal wild-type cells, implying that the balance of 
ST AT5 is crucial for adipogenesis (Miyaoka et al. 2006). 
Many studies have investigated the interaction between GR and STAT5 (Stocklin 
et al. 1996). It has been shown that GR binds to STAT5, resulting in enhancement of 
STAT5's DNA binding activity without affecting STAT5 protein expression 
(Wyszomierski et al. 1999). Additional studies by others, including Stephens and 
coworkers also showed that STAT5A forms a complex with GRin 3T3-Ll adipocytes, 
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and it is phosphorylated in the complex found in nucleus (Baugh et al. 2007). Therefore, 
it is interesting to examine if STAT5 and glucocorticoid signaling pathways work 
together. 
In summary, high throughput methods have been used to elucidate the suppressed 
genes in adipogenesis of 3T3-Ll cells (Burton et al. 2002; Burton et al. 2004; Yu et al. 
201 0). Besides identifying the specific genes that are suppressed during adipogenesis, 
one objective of my study was to define biological functions of the identified gene 
programs and to test the hypothesis that these genes/gene programs inhibit preadipocyte 
differentiation if their expression is not down-regulated. 
Glucocorticoid signaling pathways play a crucial role in the in vitro development 
of fat cells, and are associated with the metabolic syndrome. A second objective of my 
study was to understand how glucocorticoid signaling, especially GILZ, can affect these 
aforementioned processes. Additionally, I wanted to explore the interplay between OSM 
and GILZ, and test the hypothesis that GILZ is a target of the anti-adipogenic activity of 
OSM. The hope was to verify whether GILZ is a pro-adipogenic factor so as to contribute 
to our understanding of various metabolic diseases, including, obesity, insulin resistance 
and Cushing's syndrome. 
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MATERIALS & METHODS 
Materials 
Specific reagents were purchased from various vendors as listed: dexamethasone, 
3-isobutyl-1-methylxanthine, and insulin from Sigma~Aldrich (St. Louis, MO); 
Dulbecco's Modified Eagle Medium (DMEM) from Mediatech, Inc. (Herndon, VA); fetal 
bovine serum (FBS) from Gemini Bio-Products (Calabasas, CA); calf serum from 
Invitrogen (Carlsbad, CA); troglitazone from Biomol International (Plymouth Meeting, 
PA); BMP4 and BMP7 from R&D Systems (Minneapolis, MN); mouse recombinant 
OSM from R&D Systems (Minneapolis, MN); U0126, AG490, JAK3 Inhibitor I!WHIP 
from EMD Chemicals (Cambridge, MA). 
Cell culture 
C3H10T1/2 mesenchymal stem cells (MSCs) and 3T3-L1 preadipocytes were 
from American Type Culture Collection (Manassas, VA), and both were grown in 
DMEM containing 10% FBS (C3H10T1/2 MSCs) or 10% calf serum (3T3-L1 
preadipocytes). For 3T3-L1 preadipocytes differentiation, cells were kept in the same 
medium for an additional2 days after reaching confluency (this was denominated as day 
0). Then cells were induced at day 0 by adding fresh DMEM containing 10% FBS, 0.5 
mM 3-isobutyl-1-methylxanthine, 1 JlM dexamethasone, and 1.67 JlM insulin. The cells 
were refed every 2 days with 10% FBS and 0.42 JlM insulin (Rubin et al. 1978). For 
C3H10T1/2 MSCs, they were pretreated with 3.8 nM BMP4 (for white adipocyte 
differentiation) or 6.3 nM BMP7 (for brown adipocyte differentiation) for three days until 
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they reached confluency (day 0). Then BMP were removed and cells were differentiated 
with normal differentiation cocktail plus 12.5 J..LM Indomethacin (and 2 nM thyroid 
hormone T3 for brown adipogenesis). Two days after induction, cells were replenished 
with 10% FBS plus 0.42 J..LM insulin (Tang et al. 2004; Tseng et al. 2008; Huang et al. 
2009). Samples were processed (RNA or protein) on indicated days. For chemical 
inhibitors experiments, the cells were pretreated with inhibitor for 18 hours, and then 
were induced with hormonal cocktails along with the inhibitors. 
Plasmids and viruses 
Expression vectors corresponding to mouse GILZ were generated according to the 
protocol that has been previously used in our lab to generate cell lines stably expressing 
other genes (Wang et al. 2008). pBabe-Puro OE GILZ (GILZ OE) or pBabe empty vector 
with puromycm resistance element (Puro) were stably incorporated into 
C3HlOT112MSCs and 3T3-Ll preadipocytes by the following methods: 10 em plates of 
human embryonic kidney 293 EcoPack cells (Clontech) were transiently transfected with 
10 J..Lg of the pBabe empty vectors or GILZ OE vectors by TransiT-Express transfection 
reagent (Mirus Bio Corp., Madison, WI). 24 hours after transfection, medium was 
replenished and then 24 hours later virus-containing medium was collected and passed 
through a 0.45 J..Lm pore size syringe filter. Polybrene (12 J..Lg/ml) (American 
Bioanalytical, Natick, MA) was added to the medium and then the medium was used to 
treat 30% confluent growing 3T3-Ll preadipocytes or C3HlOTI /2MSCs.Cells were 
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replenished with normal proliferating medium with 2.5 ).tg/ml puromycin as the selection 
antibiotic 48 hours after infection. 
pLKO system was used to stably knock down genes. One pLKO vector 
expressing short hairpin RNA (shRNA) targeting GILZ or eGFP were purchased from 
Open Biosystems (Lafayette, CO) and the mature antisense sequence 1s 
ATAGGAACAGTCATTGTCAGG. The shRNA is targeting both isoforrns of mouse 
GILZ (NM_001077364, NM_010286). Another GILZ pLKO shRNA knockdown (KD) 
vector was kindly provided by Dr. Mi-Jeong Lee (Fried lab, Boston 
University).Transfection and infection procedures are the same as making OE cells, but 
293FT (Life Technologies), rather than 293 EcoPack, cells were used to generate virus. 
Western blot analysis 
The following antibodies were used for western blotting: monoclonal PP ARy 
antibody and C/EBPa antibody were from Santa Cruz Biotechnology (Santa Cruz, CA) 
(1: 1000 dilution for working solution); polyclonal adiponectin antibody from Pierce 
Biotechnology (Rockford, IL) (1 :2000); monoclonal adipocyte P2 (F ABP4) antibody 
from Cell Signaling Technology (Danvers, MA) (1 :2000); polyclonal GILZ antibody 
from Santa Cruz Biotechnology (Santa Cruz, CA) (1: 1 000); polyclonal GR antibody from 
Santa Cruz Biotechnology (Santa Cruz, CA) (1: 1000); polyclonal cyclophilin A antibody 
from Millipore (Billerica, MA) (1 :5000); monoclonal ~ Actin antibody from Sigma-
Aldrich (St. Louis, MO) (1 :5000); polyclonal phospho ERK antibody (targeting pTEp Y 
residues) from Prom ega (Madison, WI) (1: 1000); polyclonal phospho ST AT5 antibody 
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(targeting p Y694 residue) from Cell Signaling Technology (Danvers, MA) (1: 1 000); 
monoclonal ERK antibody from BD Biosciences (Franklin Lakes, NJ) (1 :2000); 
polyclonal STAT5a antibody from Santa Cruz Biotechnology (Santa Cruz, CA) ( 1: 1 000). 
After quantification by bicinchoninic acid (BCA) assay, equal amounts of protein 
extracts were separated on 10% or 12% sodiuni dodecyl sulfate-polyacrylamide gels and 
transferred to polyvinylidene difluoride membranes (PerkinElmer Life Sciences, Boston, 
MA). After transfer, the membranes were blocked with 5% nonfat dry milk in phosphate 
buffered saline (PBS) (pH 7.4) and 0.1% Tween 20 and probed with the corresponding 
primary antibodies. Membranes were then incubated with mouse or rabbit horseradish 
peroxidase conjugated secondary antibodies (Sigma-Aldrich). Enhanced 
chemiluminescence substrate kit (PerkinElmer Life Sciences) was used for detection of 
specific proteins. Autoradiography films (Denville Scientific, South Plainfield, NJ) were 
used to detect chemiluminescence signals in the western blot. 
Microarray analysis 
Microarray has been done by Dr. Wang (Wang et al. 2008). MOE430A gene chip 
Affymetrix microarray analysis was performed by with RNAs isolated from 3T3-L1 
preadipocytes undifferentiated or differentiated for four days. Supervised hierarchical 
clustering was done by Dr. Wang and heat maps were generated. 
Raw microarray data in Microsoft Excel format was kindly provided by Dr. Hong 
for my independent analysis. Genes were sorted according to the induction or suppression 
levels in the different comparisons. Genes with more than two fold of suppression in the 
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differentiated state were uploaded to DAVID Bioinformatics Resource (Huang da et al. 
2009) to conduct the gene clustering and functional analysis. Gene programs 
overrepresented in each of the rnicroarrays were identified and listed in the table. The 
gene programs were ranked according to the statistical significance with the most 
significantly overrepresented program on top. And the top overrepresented gene 
programs were highlighted in grey. 
The statistical analysis used in DAVID Bioinformatics Resource is a modified 
Fisher Exact P-Value (EASE score), which is more conservative and stringent than the 
original P-Value (Huang da et al. 2009). The EASE score is calculated by removing one 
gene within the given category (gene program in my study) from the list and calculating 
the resulting Fisher exact probability for that category (Hosack et al. 2003). The goal of 
the test is to examine whether the ratio of the number of genes in the overrepresented 
gene program (e.g. cytokine activity gene program) divided by the total number of genes 
in the uploaded list (e.g. down-regulated more than two fold in 3T3-Ll adipogenesis) is 
more than random chance comparing to the background (mouse genome or total RNA in 
my study), i.e. the ratio of number of genes in mouse genome for that certain program 
(e.g. cytokine activity gene program) divided by the total number of genes in mouse 
genome. 
Gene expression analysis 
RNA was isolated from cultured cells usmg TRizol reagent (Invitrogen) 
according to the manufacturer's protocols. Using a protocol routinely used in the lab, 
27 
RNAs were not DNase treated. Extracted total RNA was then used to produce eDNA by 
a high-capacity eDNA reverse transcription kit (Applied Biosystems, Foster City, CA). 
Relative gene expression level was measured using Maxima Sybr Green Q-PCR master 
mix (Fermentas Life Sciences, Glen Burnie, MD) with the PRISM 7300 sequence 
detector (Applied Biosystems) for the following cycles: 95 °C for 10 sec; 95 °C for 15 
sec, 60 °C for 20 sec, and 72 °C for 30 sec for a total of 40 cycles. Melt curve analysis 
was done by an extra step (68 °C and then 95 °C) to check the integrity of eDNA and 
quality of primers. TATA binding protein (TBP), cyclophilin, ?r glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as endogenous controls. Relative 
quantification Delta-Delta-Ct (ddCt) method was used with the software program in the 
Applied Biosystems qPCR system. Most of the qPCR experiments (except Figures 6 and 
7) were repeated with at least two or three biological samples, which are samples from 
different cell culture wells or plates of cells. For each of the biological replicate, at least 
two or three technical replicates were done, which are the replicate on different wells of 
qPCR 96-well-plate from one biological sample (one cell culture well or plate). 
Primer sequences used for the qPCR were previously reported (Wang et al. 2008) 
and as follows: 
GENE SEQUENCE 
Adiponectin F: AGCCTGGAGAAGCCGCTT ATATGT; R: GTAGAGTCCCGCAATGTTGCAGT 
CCL2 F: GAAGGAA TGGGTCCAGACAT; R:ACGGGTCAACTTCACATTCA 
CXCLl F: TGGCTGGGATTCACCTCAAGAACA; R:TGTGGCTATGACTTCGGTTTGGGT 
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CXCL5 F: CGCTGGCATTTCTGTTGCTGTTCA; R:ACGGTTAAGCAAACACAACGCAGC 
C/EBPa F: CAAGAACAGCAACGAGTACCG; R: GTCACTGGTCAACTCCAGCAC 
C/EBP~ F: CAAGTTCCGCAGGGTGCT; R:CCAAGAAGACGGTGGACAA 
Cyclophilin F: TGGAGAGCACCAAGACAGACA; R:TGCCGGAGTCGACAATGAT 
FABP4 F: AATGTGTGATGCCTTTGTGG; R: ACGCCCAGTTTGAAGGAA 
GATA2 F: AGACGACAACCACCACCTTA; R:TCCTTCTTCATGGTCAGTGG 
GILZ F: TGTGGTGGCCCTAGACAACAAGAT; R:TGGGAGTTCTTCTCAAGCAGCTCA 
GR F: TCAGGCAGATTCCAAGCAG; R:CTGTGGGTAGCCCAAGTCAT 
PPARy F: GTGCCAGTTTCGATCCGTAGA; R:GGCCAGCATCGTGTAGATGA 
TBP F:GAAGCTGCGGTACAATTCCAG; R:CCCCTTGTACCCTTCACCAAT 
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Chapter 1: Identification of down-regulated gene programs in 
adipogenesis, and their primary hormonal regulators 
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Introduction 
The activation programs m adipogenesis are extensively studied and well 
portrayed, including the identification of crucial players such as C/EBP8, CIEBP~, 
CIEBPa, PP ARy, among others (Ringold et al. 1986; MacDougald et al. 2002; Farmer 
2006; Lefterova et al. 2009). The regulatory programs responsible for suppressing 
preadipocyte genes have received relatively less attention (Burton et al. 2002; Burton et 
al. 2004). Some repressed factors have been shown to play crucial roles in preventing 
adipogenesis, such as pref-1, TIMP3, and GATA2 (Kim et al. 2007; Schupp et al. 2009; 
Bemot et al. 2010). 
As mentioned previously, high throughput methods have been used to elucidate 
the suppressed genes in adipogenesis of 3T3-L1 cells (Burton et al. 2002; Burton et al. 
2004; Yu et al. 2010). Using microarray analysis, Burton and associates identified genes 
whose expression changes during the differentiation of 3T3-L1 cells (Burton et al. 2002). 
The genes were grouped into different clusters based on their expression pattern. The 
possible biological function of these genes was briefly discussed without further analysis 
of them. 
Besides identifying the genes that are suppressed during adipogenesis, this study 
rums to define biological functions of the identified gene programs and to test the 
hypothesis that these genes/gene programs will inhibit preadipocyte differentiation if 
their expression is not down-regulated. 
The goal of these studies was to first identify the gene programs suppressed 
during early adipogenesis. The idea as mentioned above is that while the up-regulated 
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genes, such as C/EBP~ and PP ARy, need to be activated to promote adipogenesis, some 
of the down-regulated gene programs need to be suppressed to permit adipogenesis. 
Since many genes are likely to exist in any single gene program, representative genes 
were chosen to test if they express anti-adipogenic activity. A second goal was to identify 
the inducers responsible for suppression of the down-regulated programs and to defme 
the molecular mechanisms controlling the process. This involved exposing preadipocytes 
to recombinant proteins following treatment with the adipogenic hormones. The proteins 
investigated in the current study are secreted and commercially available since the plan, 
at this stage, is not to over-express the corresponding gene(s) in the preadipocytes. 
The extensive increase in adipocyte size during obesity causes inflammation of 
adipose tissue by stimulating infiltration of macrophages that then secrete a host of 
cytokines (Chavey et al. 2009; Olefsky et al. 201 0). The stimulatory signals include the 
increased release of free fatty acids as well as secretion of chemokines such as ccl2 from 
the large adipocytes (Suganami et al. 2005; Tilg et al. 2006). Adipocytes, however, are 
not the major source of the inflammatory cytokines; instead, they are produced as 
mentioned by infiltrating macrophages as well as resident immunocytes, vascular and 
stromal cells (Coppack 2001). It has been shown that adipocytes and non-fat cells of 
adipose tissue secrete different factors. For example, adipocytes are the major source for 
the production of leptin, haptoglobin, nerve growth factor (NGF), macrophage migration 
inhibitory factor (MIF), and plasminogen activator inhibitor-! (PAI-l), among others. 
Non-fat cells, on the other hand, produce IL-8, monocyte chemoattractant protein-
l(MCP-1), vascular endothelial growth factor (VEGF), IL-6, TNFa, resistin, C-reactive 
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protein (CRP), among others (Fain 2006). High throughput methods such as mass 
spectromtery have been used to elucidate the secretome of preadipocytes and adipocytes 
(Kratchmarova et al. 2002; Molina et al. 2008). Using mass spectrometry and antibody 
arrays, Zhang et al. studied the secretome of differentiating human adipocytes and found 
that cytokines such as members of the eel family (like ccl2, ccl3 and cc15), cxcl family 
(like cxcl1, cxcl2 and cxcl12), and IL family (like IL-8, IL-10 and IL-12) are secreted by 
human preadipocytes (Zhong et al. 2010). Consequently, the stromal vascular 
compartment of inflamed adipose tissue is rich in cytokines, chemokines and acute phase 
reactants. Gustafson et al. proposed that such an environment will inhibit adipogenesis 
and, therefore, prevent production of new, healthy adipocytes. Importantly, it has also 
been shown that a significant proportion of the inflammatory reactants arise from 
preadipocytes as well as macrophages in obese adipose tissue (Gustafson et al. 2009). 
Consequently, it is important to consider the secretion of cytokines from preadipocytes 
when investigating the development of adipocytes in vivo. 
The goal of this study was to test one aspect of this process using an in vitro 
adipocyte system. One limitation of this system is that it may only capture the cytokines 
secreted by adipocytes, but not the non-fat cells. Therefore, an understanding of its 
physiological significance will eventually require in vivo studies. However, the focus of 
this study was on the cytokine/chemokine gene program in adipocytes, which induces 
inflammation. 
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Results 
Identification of gene programs down-regulated in the differentiated state 
To identify the gene programs down regulated during adipogenesis, microarray 
data that had been obtained by colleagues in the lab were analyzed to determine 
expression of mRNAs in confluent 3T3-L1 preadipocytes just prior to differentiation (0 
day) and at 4 days following induction of adipogenesis (Wang et al. 2008). This 4-day 
period is considered to represent the early phase of differentiation of 3T3-L1 
preadipocytes; the time in which the major adipogenic transcription factors (i.e. C/EBP8, 
C/EBP~, C/EBPa and PP ARy) are induced as part as an elaborate network of factors that 
activate expression of the many genes during terminal adipogenesis (i.e. adiponectin and 
F ABP4) (Ntambi et al. 2000). By comparing these 0 and 4 day arrays, genes that need to 
be turned off to facilitate the action of the factors promoting adipogenesis should be 
identified (Figure 1 ). 
Previously, Wang et al. employed supervised hierarchical clustering to identify 
gene programs that changed in response to differentiation of 3T3-Ll preadipocytes 
(Wang et al. 2008). The heat map shown in Figure 1 illustrates the level of expression of 
select mRNAs in differentiated cells (right column) compared to their relative expression 
in undifferentiated cells (left column) and arranged in descending order of their relative 
abundance. In this way, the top half of the microarray corresponds to genes that are 
increased during the four-day differentiation period, while the bottom half corresponds to 
genes that are down-regulated during adipogenesis, with the most significantly repressed 
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Figure 1. Multiple gene groups are down-regulated in the differentiated state. 
MOE430A gene chip Affymetrix rnicroarray analysis was performed by Dr. Wang with 
RNAs isolated from 3T3-Ll preadipocytes undifferentiated or differentiated for four days 
(Wang et al. 2008). Supervised hierarchical clustering was used to identify gene programs 
that are down-regulated in the differentiated state compared to the undifferentiated state. The 
blue color indicates low expression while the red color indicates high expression. The red 
boxes highlighted the down-regulated gene programs in the differentiated state and show the 
entire down-regulated program. Arrows indicate the position of some representative genes. 
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genes at the very bottom. Genes in the middle of the microarrays are those whose 
expression does not change significantly. 
Cytokines/chemokines are the most significantly down-regulated gene programs 
DAVID bioinformatics tools were applied (Huang da, Sherman et al. 2009; 
Huang da, Sherman et al. 2009) to identify down-regulated gene programs in the 
differentiated state. Genes down-regulated more than two fold during differentiation were 
uploaded and analyzed using the DAVID tools to identify the overrepresented gene 
clustering (gene ontology) and pathways (Table 1). The analysis identified many gene 
programs with the cytokine/chemokine genes being repressed particularly in the 
differentiated state (Table 1 and Table 2). Among these gene programs, some programs 
corresponded to common (growth factor activity) or more general factors (pattern 
binding); therefore, they were not selected as potential anti-adipogenic candidates. 
Cytokines/chemokines were at the top of the list and therefore were chosen for further 
study. Another prominent group was that corresponding to the cytoskeleton of the cell. 
Suppression of cytoskeleton proteins occurs during adipogenesis and studies demonstrate 
that remodeling of the cytoskeleton plays an important regulatory role during 
preadipocyte differentiation (Spiegelman et al. 1982; Feng et al. 2010; Mikkelsen et al. 
2010). 
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Table 1. Bioinformatic analysis of the down-regulated gene programs in the 
differentiated state. 
Raw microarray data in Microsoft Excel format was provided by Dr. Hong. Genes then 
were sorted according to the induction or suppression levels in the different comparisons 
as described before. Genes with more than two fold of suppression in the differentiated 
state were uploaded to DAVID Bioinformatics Resource to conduct the gene clustering 
and functional analysis. Gene programs overrepresented in each of the microarrays were 
identified and listed in the table. The gene programs were ranked according to the 
statistical significance (P value). The P value used in DAVID Bioinformatics Resource is 
modified Fisher Exact P Value (Expression Analysis Systematic Explorer 
[EASE] score), which is more conservative and stringent than the original (Huang da et 
al. 2009). The most significantly overrepresented program is on top. And the top 
overrepresented gene programs were highlighted in grey. 
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Table 1. 
3T3-Ll microarrav: D4 VS time 0 
Function Cateeories Gene Count PValue 
cvtokine activity 33 3.00E-07 
chemokine activity 13 3.90E-06 
chemokine receptor binding 13 5.30E-06 
antigen binding 17 6.40E-05 
hormone activity 20 1.60E-04 
calcium ion binding 83 2.80E-04 
polysaccharide binding 21 3.10E-04 
pattern binding 21 3.10E-04 
heparin binding 16 3.50E-04 
transcription factor activity 75 l.lOE-03 
sequence-specific DNA binding 57 1.30E-03 
peptide YY receptor activity 4 2.70E-03 
glycosaminoglycan binding 17 3.70E-03 
serine-type endopeptidase activity 24 3.80E-03 
actin fi lament bindine 10 4.60E-03 
actin binding 32 5.70E-03 
endopeptidase activity 43 5.80E-03 
neuropeptide Y receptor activity 5 6.30E-03 
protein tyrosine phosphatase activity 15 7 . 10E~03 
serine-type peptidaSe activity 25 7.70E-03 
serine hydrolase activity 25 8.20E-03 
ephrin receptor activity 5 1.20E-02 
neuropeptide bindino 8 1.20E-02 
neuropeptide receptor activity 8 1.20E-02 
carbohydrate binding 33 1.20E-02 
growth factor activity 18 1.30E-02 
palmitoyl-CoA hydrolase activity 5 l.50E-02 
transcription regulator activity 100 1.70E-02 
cvtoskeletal protein bindino 40 l.80E-02 
cGMP bindine 4 1.80E-02 
growth factor binding II 2.10E-02 
CoA hydrolase activity 6 2.30E-02 
peptidase activity 56 2.30E-02 
chemorepellent activity 3 2.40E-02 
GMPbinding 4 2.50E-02 
carboxylesterase activity 14 2.80E-02 
guanyl nucleotide binding 35 2.80E-02 
guanyl ribonucleotide binding 35 2.80E-02 
transmembrane receptor protein tyrosine kinase activity 9 3.10E-02 
peptidase activity, acting on L-amino acid peptides 53 3.30E-02 
metalloendopeptidase activity 14 4.00E-02 
acyl-CoA thioesterase activity 5 4.10E-02 
protein tyrosine kinase activity 18 4.70E-02 
cyclic nucleotide binding 5 S.SOE-02 
neurotransmitter transporter activity 5 5.50E-02 
symporter activity 15 5.70E-02 
alkali metal ion binding 21 5.90E-02 
neurotransmitter binding 11 6.40E-02 
neurotransmitter receptor activity 11 6.40E-02 
passive transmembrane transporter activity 33 6.80E-02 
channel activity 33 6.80E-02 
transcription repressor activity 21 7.10E-02 
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Table 2. 
Cytokine Activity in 3T3-Ll microarray: D4 VS time 0 
UniGene Gene name time O/ D4 
Mm.42228 CD70 antigen 5.0 
Mm.3355 Pas ligand (TNF superfamily, member 6) 3.2 
Mm.6780 cerberus 1 homolog (Xenopus laevis) 5.4 
Mm.4686 chemokine (C-C motif) ligand 11 38.1 
Mm.867 chemokine (C-C motif) ligand 12 5.2 
Mm.41988 chemokine (C-C motif) ligand 17 4.5 
Mm.290320 ciiemokine (C~c motif) ligand 2 5.1 
Mm.ll6739 chemokine (C-C motif) ligand 20 6.9 
Mm.l43745 chemokine (C-C motif) ligand 28 5.2 
Mm.341574 chemokine (C-C motif) ligand 7 4.5 
Mm.42029 chemokine (C-C motif) ligand 8 8.8 
Mm.21013 chemokine cc::x~c motif) llgand f 3.8 
Mm.303231 chemokine (C-X-C motif) ligand 12 3. 1 
Mm.l238 colony stimulating factor 3 (granulocyte) 3.0 
Mm.l66318 gremlin 1 15.4 
Mm.258280 growth differentiation factor 1 5.1 
Mm.97 14 growth differentiation factor 9 4.3 
Mm.l4091 interferon alpha 2 4.2 
Mm.377088 interferon alpha 4 3.3 
Mm.377090 interferon alpha 6 3.8 
Mm.l03585 interleukin 22 3.3 
Mm.4392 interleukin 15 5.7 
Mm.l0137 interleukin 16 8.3 
Mm.59313 interleukin 17B 4.5 
Mm.125482 interleukin 23, alpha subunit p19 5.5 
Mm.l96691 interleukin 24 5.3 
Mm.1715 lymphotoxin B 3.7 
Mm.332490 platelet factor 4 29.4 
Mm.27630 secreted Ly6/Plaur domain containing 1 3.8 
Mm.288474 secreted phosphoprotein 1 9.7 
Mm.4660 . chemokine (C-X'C.motif) ligand5 13.8 
Mm.l31723 chemokine (C-X-C motif) ligand 11 10.9 
Mm.I062 tumor necrosis factor (ligand) superfamily, member 10 7.0 
Table 2. Microarray analysis of the cytokine/chemokine gene program that is the 
most prominent group of down-regulated genes during adipogenesis. 
Gene ontology analysis was performed using the DAVID Bioinformatics Resource to 
identify the overrepresented gene programs in the undifferentiated state. For the 
micro array comparison, genes in the top cluster namely Cytokine Activity (or Chemokine 
Activity), were listed in the table. 
The actual fold repression for each of the cytokine/chemokine genes in the microarrays is 
shown in the right column of the table. The fold repression in the table is the ratio of gene 
expression in the undifferentiated state divided by that in the differentiated state for the 
respective genes. Ccl2, cxcll , and cxcl5 (highlighted in grey) were chosen as 
representatives of the cytokine/chemokine gene program for follow-up function and 
regulation studies. 
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QPCR confirmed the down-regulation of ccl2, cxcll, and cxcl5 during early 
adipogenesis 
The cytokine/chemokine gene program was identified in the microarrays as the 
most down-regulated gene program in the differentiated state. However, the results need 
to be confirmed as they only reflect a snapshot of a four-day period, and the temporal 
pattern of expression must be obtained by other means. QPCR was employed to confirm 
the microarray fmdings showing that the RNA expression of the cytokines was 
downregulated during adipogenesis in 3T3-Ll preadipocytes. Ccl2, cxcll and cxcl5 were 
chosen from the list as representatives of the chemokine/cytokine program for 
confirmation. 
Firstly, cytokine expression at time 0 and D4 were compared to the microarray 
data as shown in Figure 2. The qPCR indicated that there was significant suppression 
(more than 5 fold), which is comparable to the 3T3-L1 cell microarray. Here, time 0, and 
D 1 were chosen to assess the expression during early adipogenesis; D2 and D4 were used 
to check the effect of the removal of hormonal inducer Dex and MIX (removed at D2). 
Figure 2 shows that all three genes were suppressed significantly at day 4 compared to 
day 0. The expression profiles were almost identical with minor differences. Specifically, 
ccl2 and cxcl5 expression began to decrease at D 1 and then gradually decreased to their 
lowest level, while cxcl5 expression dropped precipitously to its lowest level between D 1 
and D2. The different patterns of expression suggest that different detailed regulatory 
mechanisms may be specific to each of the genes. 
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Figure 2. 
Figure 2. qPCR confirmed the down-regulation of cytokines. 
3T3-Ll preadipocytes were differentiated for different times during adipogenesis. RNA 
was extracted by Trizol reagent from these 3T3-Ll cells after differentiation for the 
respective times. Reverse transcription was conducted to make eDNA from the RNA and 
qPCR was used to measure the relative expression of the cytokine genes compared to the 
endogenous control. The Y-axis corresponds to relative RNA expression. X-axis shows 
the respective times post adipogenesis induction, and the gene expression relative to the 
time 0 baseline control is shown at the bottom of each figure. Results are mean + 
standard deviation (SD) (n = 5). All the replicates were from individual biological 
experiments, which were from different wells or plates of cells, and from different time 
of the experiments. For each of the replicates, the expression at different time points was 
normalized to its respective time 0 baseline control. Therefore all the values of "time 0" 
are 1.00. Single factor analysis of variance (ANOVA) test was conducted in each of the 
three cytokines and statistically significant difference was observed with P<O.OS in all of 
them. The results suggest that at least one of the mean RNA expressions in the different 
time points is statistically different. And this is the case for all the three cytokines. 
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Dexamethasone suppressed chemokinelcytokine expression 
After identifying the chemokine/cytokine gene program and its representatives, 
studies were commenced by first delineating the molecular mechanisms regulating its 
suppression and secondly by determining possible biological functions of the program 
that are relevant to the adipogenic process. The goal focused on identifying the hormones 
and corresponding signaling pathways responsible for suppression of the genes during the 
differentiation of 3 T3-L 1 preadipocytes. 
As mentioned in the introduction, treating 3T3-Ll preadipocytes with induction 
hormones Dex, MIX and insulin for two days is the first step to initiate adipogenesis. 
Figure 2 shows that the down-regulation of ccl2, cxcll , and cxcl5 occurred between time 
0 and D2 and after this time period, there was minimal further suppression. Due to the 
temporal correlation, it was hypothesized that hormonal inducers and their related 
signaling pathways constitute the mechanistic processes by which the cytokines are 
suppressed in the in vitro 3T3-Ll cell system. 
To investigate the importance of each of the individual components of the 
adipogenic cocktail in regulating expression of ccl2, cxcll and cxcl5, 3T3-Ll 
preadipocytes were treated with different combinations of hormones for 24 hrs, and then 
expression of the genes was analyzed. It was shown that of the three hormones, Dex was 
the principal suppressor of all three genes. This result was as expected since it is 
generally accepted that Dex suppresses inflammation (McManus 2003). 
As described in the introduction, Dex is a synthetic glucocorticoid, which is a 
class of stress hormones with a wide range of biological functions including immune 
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responses, metabolism, development, cell proliferation, and apoptosis (de Kloet et al. 
1999; Ashwell et al. 2000; Newton 2000; Sapolsky et al. 2000). Surprisingly, Figure 3 
shows that MIX alone induced the genes (an average of 7 fold induction) while insulin's 
effect was considerably smaller (about 1 fold induction). However, the effect of DMI 
was to suppress cytokine expression as it promoted adipogenesis. It is worth noting that 
when Dex was present with MIX, it neutralized or counteracted the inductive effect of 
MIX on expression of the cytokines, bringing the values down for each gene to 50% to 
90% of original expression levels. Insulin's effect on MIX activity was modest compared 
to Dex. It is known that MIX and cAMP signaling are required for adipogenesis. 
However, the results suggest that not all the required components are needed to suppress 
cytokine expression. 
Dex and GR are required for adipogenesis 
The next step in studying the role of glucocorticoid signaling was to demonstrate 
that Dex and the GR are required for adipogenesis in the 3T3-L1 preadipocytes used in 
the laboratory. Some preadipocytes such as F422A cells do not require Dex or MIX since 
insulin alone is a potent adipogenic factor for those cells (Green et al. 197 4 ). Experiments 
were performed to confirm the findings by others showing that Dex and GR are essential 
for adipogenesis in the in vitro cultured cell system (Green et al. 1974; Green et al. 1975). 
The first was to examine if Dex was required 
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Figure 3. Dexamethasone, a major hormonal inducer of adipogenesis, suppresses 
cytokine/chemokine gene expression. 
3T3-Ll preadipocytes were differentiated with the indicated hormonal inducer or inducer 
combinations for 24 hours. QPCR was performed to assess gene expression. Y -axis 
shows the relative RNA expression. Results are mean+SD (n = 4). All the replicates were 
the RNA extracted from different wells or plates of cells, and different passages of cells. 
One way ANOV A test has been conducted to test whether the mean RNA expression are 
the same across different treatments (DO, D, M, I, DM, DI, MI and DMI). One way 
ANOV A results suggest that the difference of the gene expression are statistically 
significant in all 3 panels with P<O.OS. The results suggest that at least one of the mean 
RNA expressions in the different treatment is statistically different. And this is the case 
for all the three cytokines. 
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for adipogenesis. As Figure 4 shows, 3T3-Ll preadipocytes were differentiated with 
conventional induction media DMI versus MI only (without the addition of Dex 
throughout adipocyte differentiation process) for seven days, and it was found that DMI 
but not MI was able to induce adipogenesis based on the enhanced expression of PP ARy 
and adiponectin (compare lane 3 to lane 1 ). These data demonstrate the critical 
importance of the glucocorticoid in stimulating adipogenesis in 3T3-Ll preadipocytes. 
And without the presence of synthetic glucocorticoid Dex, adipogenesis could not be 
initiated. 
To confirm that GR was required for adipogenesis, a line of 3T3-Ll 
preadipocytes were obtained from Dr. Mi-Jeong Lee in which GR was stably knocked 
down (Lee et al. 2007). Both empty vector control and GR knock down cells were 
induced with the normal adipogenic cocktail, DMI. Protein samples were extracted from 
cells at D4 or D6 of differentiation. Figure 5 confirms that the knock out cells lack GR 
and shows that DMI was incapable of inducing PP ARy, the marker of adipogenesis, in 
the absence of GR. The single band detected by the anti-PP ARy antibody (Santa Cruz 
Biotechnology) likely corresponds to PP ARyl (molecular weight 54kD). This isoform is 
induced earlier than PP ARy2 (molecular weight 57kD), which appears in the 
differentiating preadipocytes as they progress into terminal adipogenesis (Fajas et al. 
1997; Morrison et al. 1999; Farmer 2006). Consequently, the presence of a single isoform 
suggests that in this experiment the adipogenic process was significantly delayed. 
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Figure 4. Dex is required for adipogenesis. 
Confluent 3T3-Ll preadipocytes were treated with induction media MIX and insulin with 
or without Dex for adipogenesis. Cells were differentiated for seven days and adipogenic 
gene expression was measured by western blotting. Western blotting results were 
representative of two biological repetitions showing similar results. The replicates were 
from individual biological experiments, which were from different wells or plates of 
cells. In each of the experiment, one set of samples (DO, +Dex, and -Dex) was examined. 
Only one of the two replicates was shown. 
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Figure 5. GR is required for adipogenesis. 
3T3-Ll preadipocytes with stable knock down of GR (GR KD cells) or control vector 
were differentiated with normal induction cocktails Dex, MIX, and insulin for the 
indicated times. Proteins were separated by polyacrylamide gel and western blotting was 
performed to assess protein expression. Western blotting results were representative of 
two experimental repetitions (biological samples from different wells and plates of cells) 
showing similar results. Only one of the two replicates was shown. 
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GR was required for suppression of cytokines during adipogenesis 
From the data shown in Figure 3, it was concluded that among the three inducers 
of adipogenesis, the synthetic glucocorticoid Dex was the rriost effective at suppressing 
the expression of the chemokine and cytokine genes. To determine if this process 
involved GR, the preadipocytes employed in Figure 5 were exposed to DMI and levels of 
expression of ccl2, cxcll and cxcl5 were analyzed by qPCR. Interestingly, Figure 6 
shows that knock down of GR caused an increase in cytokine expression in non-
stimulated preadipocytes (0 day), and significantly attenuated their repression following 
exposure to the hormones, suggesting GR is required for suppression of the genes. The 
enhancement of ccl2, cxcll, and cxcl5 expression at day 0 in the knock down cells, 
suggests GR might function in 3T3-Ll preadipocytes to maintain an appropriate level of 
cytokine/chemokine expression. 
Importantly, absence of GR maintained the control levels of both cxcll and cxcl5 
genes during a two-day exposure to DMI compared to their repression in the presence of 
GR (Figure 6). However, ccl2 expression was still repressed in GR KD cells after two 
days of differentiation. These data strongly suggest that GR was required not only for 
maintaining cytokine (cxcll and cxcl5) expression in preadipocytes, but also for their 
suppression in response to induction of adipogenesis by DMI. Factors other than GR may 
also contribute to the suppression of the chemokine, ccl2 during that time-frame of 
adipogenesis. 
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Figure 6. GR is required for suppression of select chemokines and cytokines. 
3T3-Ll preadipocytes were infected with lentiviruses containing either a GR shRNA or 
control shRNA to generate stable GR KD cell lines. The cells were differentiated for the 
indicated times and qPCR was performed on extracted RNA to assess gene expression. 
Y -axis showed the relative RNA expression. Results were mean+SD (n = 3 for cxcll, and 
cxcl5, *, P<O.OS, NS, not significant; n = 1 for GR and ccl2). For cxcll and cxcl5, the 
replicates were from individual biological experiments, which were from different wells 
or plates of cells, and from different time of the experiments. Two way ANOV A was 
conducted for cxcll and cxcl5 . And the difference between control and GR KD are not 
statistically significant with P > 0.05 . Student's t-test was used to evaluate the statistical 
significance with the 3 biologically replicated samples available for cxcll, and cxc15 . 
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Recombinant ccl2, cxcll, and cxcl5 fail to suppress adipocyte differentiation 
Preadipocytes as well as macrophages, produce many chemokines and cytokines 
during inflammation of adipose tissue (Gustafson et al. 2009; Chavey et al. 2009; Olefsky 
et al. 2010). Such a response can also induce their secretion from adipocytes; 
consequently, the stromal vascular compartment of inflamed adipose tissue is rich in 
cytokines and chemokines. It is proposed that the increased production of adipocyte, 
preadipocyte and macrophage derived chemokines/cytokines will create an environment 
that will prevent adipogenesis and reduce the production of new, healthy adipocytes 
(Gustafson et al. 2009). 
As shown by others and above, Dex and glucocorticoid signaling plays an 
important role in suppressing cxcll and cxcl5 during adipogenesis (Green et al. 1974; 
Green et al. 1975; Pantoja et al. 2008). It was of interest to determine ifthis suppression 
1s required for adipogenesis. To test whether the most down-regulated 
chemokines/cytokines ccl2, cxcl1 , and cxcl5 produced by preadipocytes inhibited 
adipogenesis, 3T3-L1 preadipocytes were treated with a combination of all three effectors 
during their differentiation. The results show, however, that these effectors had no 
significant effect on the differentiation of the preadipocytes (Figure 7) as indicated by 
maintenance of control levels of PP ARy, F ABP4 and adiponectin throughout a 5 day 
exposure of the differentiating cells to the chemokine and cytokines. 
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Figure 7. 
Figure 7. Treatment of 3T3-Ll preadipocytes with a combination of ccl2, cxcll, and 
cxclS has a minimal effect on adipogenesis. 
3T3-Ll preadipocytes were treated with a mixture of recombinant proteins 0.36 nM ccl2, 6.25 
nM cxcll , and 6.25 nM cxcl5 (Chavey et al. 2009) from the onset of adipogenesis. Adipogenic 
gene expression was measured by qPCR at different time points during adipogenesis as shown in 
the X-axis. Y-axis shows the relative RNA expression. RNA expression treated with both vehicle 
and cytokines is shown. The experiments were performed once and no statistical tests were 
conducted. 
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The data shown in Figure 7 suggest that a requirement for glucocorticoid in 
adipogenesis is not to suppress a potential anti-adipogenic activity of ccl2, cxcll , or 
cxcl5. Consequently, the subsequent studies focused on other roles and mechanisms of 
glucocorticoid signaling in adipogenesis. 
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Discussion 
In this study, microarrays were compared and it was found that the expression of 
different gene programs, most notably cytokines/chemokines, correlated inversely with 
the differentiation state. To identify the mediator regulating the down-regulation of the 
cytokines gene programs, the effect of different components of the adipogenic hormonal 
cocktail were analyzed and Dex acting through the GR was found to be a major 
suppressor of the cytokines. In a preliminary study, recombinant ccl2, cxcll , and cxcl5 
were used to treat preadipocytes or adipocytes, but no suppression of adipogenic gene 
expression was seen, suggesting that a requirement for glucocorticoid in adipogenesis 
was not to suppress a potential anti-adipogenic activity of ccl2, cxcll or cxcl5. 
After knowing the nature of these programs, two simple questions were asked: 
how is the suppression of select genes regulated and why are they down-regulated during 
the initial phase of adipogenesis (0-4 days). To this end, a focus was on the 
cytokine/chemokine program since it was the most significantly down-regulated group of 
genes. 
Researchers have previously performed microarray analysis of mRNAs expressed 
during adipogenesis with the goal of identifying potential regulators of the process 
(Soukas et al. 2001; Burton et al. 2002; Burton et al. 2004; Pantoja et al. 2008). Burton et 
al. studied the very early phase of adipogenesis during the first 24 hours after induction of 
3T3-Ll cells. In the study, a total of 285 genes with more than a fivefold change were 
grouped according to their expression patterns (Burton et al. 2002). In a subsequent 
study, Burton et al. identified an additional 1686 transcripts whose expression changed 
53 
more than twofold during adipogenesis, which were grouped into 12 clusters based on 
their pattern of expression (Burton et al. 2004). In both studies, Burton and collaborators 
simply identified the genes and clusters with only a brief discussion of their biological 
functions. In another study, Yu et al. identified genome-wide GBRs in 3T3-L1 cells and 
many of the GBRs were in close proximity to genes involved in triglyceride synthesis, 
lipolysis, lipid transport and storage (Yu et al. 2010). In addition to identifying clusters of 
genes that are suppressed during early adipogenesis as per Burton et al., this study was 
focused on testing the hypothesis that these genes are down-regulated thereby facilitating 
differentiation. 
Burton and collaborators did identify and discuss several potential adipogenic 
genes including: transcriptional enhancer and activator domain 4 (TEAD 4), a disintegrin 
and metalloprotease domain-8 (ADAM 8), and latexin, all belonging to cluster 2, which 
showed a rapid induction during the first eight hours. Testis/thymus inhibitor of apoptosis 
(TIAP) belonged to cluster 3, which contains genes whose expression peaked at 24 hours. 
Besides the activated genes, some genes in cluster 6 such as myelin basic protein 
expression factor 2 (Myef2) were transiently suppressed during the first two hours of 
adipogenesis and their expression recovered to baseline by 24 hours (Burton et al. 2004 ). 
This study, on the other hand, focuses more on the group of genes, rather than the 
specific genes and it was shown that cytokine/chemokine related genes are on the top for 
all groups of genes as Table 1 shows. Interestingly, Myef2 is also on our list of genes, 
and similar to the result from Burton's fmding, its expression recovered and it shows a 
slight induction at D4 compare to time 0 in our 3T3-Ll microarray. Choosing time 0 and 
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D4 will not enable capture of the genes like myef2 whose expression only has a temporal 
change between time 0 and D4, and then recovers to baseline. However, the focus on 
groups of genes offers a different perspective for the analysis of these genes. 
Using DAVID bioinformatical tools, the cytokine/chemokine gene program was 
identified as the most overrepresented gene cluster suppressed in the differentiated state. 
From this cluster, three genes - cc12, cxcll , and cxcl5 - were chosen as representatives to 
study the function and regulation of the cytokine/chemokine gene program. Unlike other 
studies that select one candidate from the high throughput screening (i.e. microarray) to 
study the function and regulation (Bogner-Strauss et al. 201 0), three genes were chosen 
as representatives of the cytokine/chemokine gene program as studying three genes might 
reveal a more general mechanism(s) through which a particular cytokine group affects the 
differentiation of preadipocytes. But of course, this method has its own limitations. For 
example, the selected genes may not be truly representative of the cytokine gene 
program, but rather may represent a sub-group of the program (eel family or cxcl family 
of chemokines and cytokines). CC chemokines are also known to be the largest family of 
all chemokines with the most members (Charo et al. 2006). It is also possible that the 
genes may be so different that it is not possible to find a common regulatory mechanism. 
An ideal way is to study all (or most of) the genes in the cytokine program to generalize 
its regulation and function, which requires more resources. However, the method used in 
the current study of choosing three genes as representatives of the cytokine program has 
its validity as mentioned before. 
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A few studies have been performed to elucidate the functions and secretion of 
these cytokine representatives. Ccl2 is known to be a potent attractant for monocytes to 
leave the circulation and differentiate into tissue macrophages, which then promotes 
inflammation (Rull et al. 2010). In the in vitro cultured cell system, it has been shown 
that ccl2 can suppress both glucose uptake and adipogenic gene expression (Sartipy et al. 
2003). One study showed that adipocytes account for less than 12% of total ccl2 
production in human adipose tissue and the major source comes from non-fat cells (Fain 
2006). No studies have been done to study the function of cxcll in adipogenesis. The 
production of cxcl1 by the adipocyte has been shown in one report that studied the 
interaction between macrophage and adipocytes. It was found that exposure of co-
cultures of macrophages and adipocytes to lipopolysaccharide (LPS) increases the 
expression of cxcll in adipocytes (Yamashita et al. 2008). Expression of cxcll is mainly 
by neutrophils, monocytes, and microvascular endothelial cells (Charo et al. 2006). Cxcl5 
is produced mainly by the macrophage fraction of white adipose tissue. Its expression 
decreases in adipogenesis. Cxc15 blocks insulin signaling, however, treatment of 
preadipocytes with cxc15 does not inhibit adipogenesis (Chavey et al. 2009). As 
mentioned before, the choice of these three cytokines was based on their high suppression 
levels in the microarray. Current knowledge indicates that adipocytes are not the major 
production source for these cytokines (Fain 2006). However, by studying these genes as a 
group or program, it was hoped that a general pattern of regulation and biological 
function in adipocyte system might be revealed; therefore it could verify this 
methodology of studying group of genes rather than a single gene. 
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It is generally accepted that glucocorticoids including Dex suppress inflammation 
(Bournpas et al. 1993; Tracey 2002; Barnes et al. 2009). However, no studies have been 
conducted to examine whether Dex affects ccl2, cxcll or cxcl5 expression in the context 
of adipogenesis. It had been known that Dex and GR are involved in the suppression of 
inflammation in other systems (Smas et al. 1995; Asada et al. 2011), and data in this 
study also showed that Dex was the major suppressor for the cytokine representatives 
ccl2, cxcll , and cxcl5 in adipogenesis. Interestingly, Pantoja et al. showed that Dex itself 
suppresses different gene programs (at 2 hand 36 h after treatment) in 3T3-Ll cells. One 
of the programs corresponds to the "immune response", which includes ccl2, cxcll, and 
cxcl5, among others (Pantoja et al. 2008). This result is in accordance with the fmdings 
reported here, which indicated that Dex, acting through GR, suppressed the 
cytokine/chemokine ccl2, cxcll and cxcl5. 
It is important to point out that the change in expression of the genes in the 
microarrays occurs over a four-day period and the temporal pattern of expression needs 
to be obtained by other means. For instance, quantifying each of the mRNAs by qPCR 
may reveal that some genes are repressed rapidly while others decrease slowly during the 
four-day period. It is also possible that some genes may initially be induced then 
precipitously decreased. With these scenarios in mind, the most expeditious means to 
identify genes of interest was to compare changes in gene expression during 
differentiation and then to determine the temporal changes in their gene expression using 
more quantitative means (e.g. qPCR). The alternative method was to perform a more 
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refined microarray comparison with multiple time points as conducted by others for 3T3-
L 1 cells (Souk.as et al. 2001; Burton et al. 2002; Burton et al. 2004; Pantoja et al. 2008). 
After identifying cytokines as a prominent down-regulated gene program in the 
differentiated state, studies were conducted to identify the mechanisms regulating their 
suppression. In Figures 3 and 4, it is shown that Dex, acting through GR, was a major 
effector for the suppression of cytokines in 3T3-L1 preadipocytes. Of course, this system 
may not completely reflect the in vivo development of fat cells; however, it has been used 
successfully to identify many regulators of adipogenesis that have been shown to have a 
direct physiological function (Singh et al. 2009). Attempts have previously been made to 
identify regulators of early development in fetuses and neonates with only little success 
(Boulton et al. 1978). It is important to mention that the effectors regulating early adipose 
development have not been identified; they probably consist of many growth and 
development factors as well as hormones. 
Green and associates working to achieve maximum differentiation of 3T3-L1 
preadipocytes in culture established the components of the adipogenic cocktail of 
hormones (glucocorticoids, MIX and insulin) (Green et al. 1974; Green et al. 1975). The 
extent to which these hormones participate in early development of adipose tissue in vivo 
is not known, but they may contribute to the expansion of adipocytes during obesity. 
Prolonged exposure to excess glucocorticoids can lead to Cushing's syndrome in humans, 
whose symptoms include multiple metabolic disorders including obesity, hyperglycemia, 
and hypertension (Shibli-Rahhal et al. 2006; Hatipoglu 2012). It is suggested that excess 
fat deposition for patients with Cushing's syndrome is due to elevated adipocyte 
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lipoprotein lipase activity and low lipolytic activity (Rebuffe-Scrive et al. 1988). MIX 
stimulates the cAMP pathway to activate CREB, which is necessary for induction of 
adipogenesis (Reusch et al. 2000}. In mice, it has been found that CREB is activated in 
adipose tissue during obesity. Additionally, transgenic obese mice expressing a dominant 
negative CREB show better insulin sensitivity (Qi et al. 2009). It has been known for a 
long time that insulin plays an important role in the homeostasis of glucose in humans 
(Reaven 1988; Plum et al. 2006). It was found that obesity correlated with insulin 
resistance and type 2 diabetes as mentioned in the introduction (Kahn et al. 2006). On the 
other hand, clinical studies have shown that insulin can also induce weight gain in 
humans, which is often seen in type 1 and type 2 diabetes patients (Russell-Jones et al. 
2007; Aas et al. 2009). 
It is worth mentioning that microarray and qPCR data shown here determine the 
RNA expression of the genes. In order for the genes to be functional and exert their 
biological functions, RNA has to be translated to protein and possibly undergo post-
translation modification and/or secretion. As described before, in the in vivo 
physiological settings, non-fat cells of the adipose tissue such as immunocytes, vascular 
and stromal cells rather than adipocytes are the major source of production for these 
cytokines (Coppack 2001 ), Therefore, I did not use conditional media that harvest the 
cytokines secreted by adipocytes since cytokines produced by adipocytes are low 
compare to nonfat cells. Instead, recombinant cytokine proteins were used in my study to 
rnimic in vivo adipose tissue environment that has cytokines produced by nonfat cells. 
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Another way of doing the study is to co-culture the adipocytes with immune cells such as 
macro phages (Yamashita et al. 2008). 
Unexpectedly, treating differentiating 3T3-Ll preadipocytes with the three 
recombinant cytokines had minimal effect on adipogenesis. It has been hypothesized that 
inflammation is one of the most important processes contributing to obesity induced type 
2 diabetes (Duncan et al. 2003; Pickup 2004; Donath et al. 2011), and many studies have 
been performed to shed light on this topic. Cytokines, such as TNFa, IL-l , IL-11 , OSM, 
and ccl2, have been shown to inhibit adipogenesis or adipocyte function in different 
model systems (Keller et al. 1993; Sartipy et al. 2003; Suzawa et al. 2003 ; Miyaoka et al. 
2006; Cawthorn et al. 2007). Sartipy et al. have shown that mature 3T3-Ll adipocytes 
respond to an acute treatment with ccl2 by reducing expression of some adipogenic genes 
(Sartipy et al. 2003). In the experiment shown in Figure 7, the preadipocytes were 
exposed to ccl2 throughout adipocyte differentiation. It is possible, therefore, that this 
chemokine only affects adipocyte gene expression in the mature fat cell and not during its 
formation. 
To conclude, these studies have demonstrated that the cytokine gene program was 
robustly suppressed during the differentiation of 3T3-Ll preadipocytes. Dex was the 
major suppressor of three representatives, ccl2, cxcll , and cxcl5, of this program. It is 
suggested that the choice of these three representatives is acceptable for studying 
glucocorticoid-associated gene regulation, but not for understanding the role of 
glucocorticoids in mediating the early phase of adipogenesis. It was hoped to demonstrate 
60 
that one of the pro-adipogenic activities is to suppress anti-adipogenic effectors as was 
the case for Prefl (Smas et al. 1999). 
These results suggested that the combination of recombinant ccl2, cxcll and cxcl5 
did not inhibit adipogenesis. Other data demonstrated that the treatment of recombinant 
ccl2 failed to inhibit adipocyte differentiation or adipocyte function (data not shown). 
Our results along with previous literatures (Chavey et al. 2009) suggested that the 
selection of the most responsive gene program as candidates for anti-adipogenic factors 
was not the ideal strategy. Several other programs were suppressed by exposure of the 
preadipocytes to Dex, MIX and insulin. It is conceivable that genes that were inhibited by 
MIX or insulin rather than Dex might express a greater anti-adipogenic activity. In 
hindsight, if I were to repeat these experiments I would select candidates ·from other 
programs such as components of the extracellular matrix. It is possible that such factors 
respond more effectively to MIX or insulin. It is also very likely that revisiting the gene 
array data to fmd new candidates could have resulted in selection of another set of factors 
that have minimal effect on adipogenesis. Therefore, I decided to pursue my interest in 
glucocorticoid signaling by attempting to identify novel target genes that have the 
potential to promote adipogenesis by activating pro-adipogenic processes as well as 
inhibit differentiation. 
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Chapter II: Identification of novel roles for GILZ in regulating 
adipogenesis 
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Introduction 
GILZ was identified as a factor shown to be induced by Dex, which protects T-
cells from apoptosis following treatment with anti-CD3 monoclonal antibodies 
(D'Adamio et al. 1997). GILZ is an important mediator of glucocorticoid's biological 
function, such as activation ofT-cells and regulation of cell proliferation and apoptosis 
(Ayroldi et al. 2001; Delfino et al. 2004; Ayroldi et al. 2007; Fan et al. 2012). However, 
few studies have explored the role of GILZ in adipogenesis. Early studies by Shi et al. 
found that GILZ suppressed adipogenesis by binding to the PP ARy promoter (Shi et al. 
2002; Shi et al. 2007). Another report suggested that GILZ might be a link between 
circadian mechanisms and obesity due to its circadian oscillation pattern in adipose tissue 
(Gimble et al. 2009). Other studies have suggested that GILZ can function to regulate the 
fate of mesenchymal stem cells in response to glucocorticoids (He et al. 2012). 
As stated at the end of Chapter 1, the role of glucocorticoid signaling pathway in 
adipogenesis was of interest, and an attempt was made to identify mediators for 
glucocorticoid's pro-adipogenic activity. Studies by others (Smas et al. 1995; Asada et al. 
2011 ), as detailed in Chapter 1, have shown that both glucocorticoid and GR are required 
for adipogenesis, and that GILZ is a target of both glucocorticoid and GR (D'Adamio et 
al. 1997; Asselin-Labat et al. 2004). Since Dex and GR are pro-adipogenic, GILZ is more 
likely to be a positive regulator of adipogenesis than a repressor as suggested by others 
(Shi et al. 2007). Preliminary data and a previous report (Shi et al. 2002) show that GILZ 
expression is transiently induced during the first one to two days of adipogenesis in 3T3-
Ll preadipocytes, and this expression pattern is very similar to other pro-adipogenic 
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transcription factors such as C/EBP~ and C/EBP8 (Cao et al. 1991; Wu et al. 1996). 
These observations lead to the hypothesis that GILZ is pro-adipogenic and is required for 
adipogenesis. 
Several GILZ mouse models have been generated, although none of them 
evaluate the potential role of GILZ in regulating adipocyte development or function. In 
studies using GILZ transgenic mice, it was shown that GILZ suppressed B-cell 
lymphoma-extra large (Bcl-xL) expression and its associated apoptosis of thymocytes 
(Delfino et al. 2004). The same group also showed that OE of GILZ protects mice with 
Th1-mediated colitis from inflammatory bowel disease by inhibiting cell death and NF-
KB activity (Delfino et al. 2006; Cannarile et al. 2009). Another study demonstrated that 
GILZ is important for spermatogonial survival and spermatogenesis (Romero et al. 
2012). 
It appears, therefore, that GILZ functions in various mouse tissues to suppress 
inflammation. It is becoming more apparent that expansion of adipose tissue in obese 
individuals leads to chronic inflammation that impacts both adipocyte function as well as 
preadipocyte differentiation (Duncan et al. 2003; Rajala et al. 2003; Dandona et al. 2004; 
Pickup 2004; Heilbronn et al. 2008; Gustafson et al. 2009; Olefsky et al. 2010). 
Consequently, identifying roles for GILZ in adipocyte biology might lead to greater 
insight into obesity-associated disorders. If GILZ is a mediator of glucocorticoid 
signaling which facilitates adipogenesis as well as suppression of inflammatory 
processes, then GILZ should act in a pro-adipogenic manner. To test this hypothesis, both 
loss- and gain-of-function approaches were taken, using 3T3-Ll preadipocytes as well as 
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C3Hl OTl/2 MSCs as in vitro models for adipogenesis. GILZ was knocked down in both 
cell lines using shRNA technology and over-expressed using retroviral-mediated trans 
expression. The resulting data support the hypothesis by showing that GILZ is required 
for stimulation of adipogenesis by glucocorticoids in committed preadipocytes (3T3-Ll 
cells) as well as uncommitted MSCs. 
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Results 
GILZ expression increases early during adipogenesis and is a target of glucocorticoid 
. and its receptor 
Studies in Chapter 1 indicated that both Dex and GR were required for 
adipogenesis. Since GILZ is a target of both these effectors, whether it also has a positive 
role to play in the differentiation of preadipocytes was questioned. Consistent with it 
being a pro-adipogenic factor, the data in Figure 8a demonstrate that its expression was 
rapidly upregulated within 3 h after hormonal induction and continued to rise for the 
following 2 days, but then gradually declined during terminal differentiation (days 2-6). 
When compared with MIX and insulin, Dex was the principal component of the 
adipogenic cocktail that induced GILZ expression (Dex versus MIX versus insulin) and 
was required for its induction by the complete hormonal cocktail (DMI versus MI) 
(Figure 8b ). Therefore, it is likely that the drop in GILZ expression following 
replacement of the media at day 2 with one containing only insulin was due to the 
removal of Dex. Additionally, the absence of GR not only prevented adipogenesis 
(Figure 5), it also abolished GILZ expression (Figure 8c ). Despite the fact that the pattern 
of GILZ expression in control cells shown in Figure 8c is not identical to that in Figure 
8a, the collective results presented in Figure 8 clearly show that the transient induction of 
GILZ during early adipogenesis requires Dex and GR. This result is also consistent with 
previous findings showing that GILZ is a target of both glucocorticoid and GR in other 
cell types (D'Adamio et al. 1997; Asselin-Labat et al. 2004). 
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Figure 8. GILZ expression increases early during adipogenesis and is a target of 
glucocorticoid and GR. 
(a) 3T3-Ll preadipocytes were differentiated for the indicated time. RNA was extracted 
to generate eDNA by reverse transcription as described in the methods. QPCR was 
performed to assess GILZ expression. Y-axis shows the relative RNA expression. Results 
are shown as mean (n = 2). All the replicates were from individual biological 
experiments, which were from different wells or plates of cells. No statistics were used 
and results show the expression pattern. 
(b) 3T3-Ll preadipocytes were differentiated with the indicated hormonal inducer or 
inducer combinations for 24 hours. QPCR was performed to assess GILZ expression. Y-
axis shows the relative RNA expression. Results were mean+SD (n = 3). All the 
replicates were from individual biological experiments, which were from different wells 
or plates of cells. One way ANOVA was conducted and the difference are statistically 
significant with P < 0.05. 
(c) 3T3-Ll preadipocytes stable GR KD cells or control cells were differentiated for the 
indicated time from time 0 to D6, and qPCR was performed to assess GILZ expression. 
Y -axis shows the relative RNA expression. Two way ANOV A was conducted and the 
difference between control and GR KD were statistically significant with P < 0.05. 
Student's t-test was then conducted. Results were mean+SD (n = 3; *, P < 0.05). All the 
replicates were from individual biological experiments, which were from different wells 
or plates of cells. 
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GILZ is required for adipogenic gene expression in 3T3-Ll preadipocytes 
To test the hypothesis that GILZ is required for adipogenesis, GILZ was stably 
knocked down using a lentivirus expressing GILZ shRNA in 3T3-Ll preadipocytes and 
C3H10Tl/2 MSCs. 
The level of expression of GILZ mRNA was significantly reduced in the 
corresponding knock down 3T3-Ll preadipocytes when compared to control cells and 
remained that way throughout the period of adipocyte differentiation (Figure 9a). It was 
difficult to detect the reduction of GILZ protein by western blot analysis of cellular 
proteins extracted from the knock down preadipocytes (Figure 9b). This is likely due to 
the relatively low amounts of GILZ in confluent 3T3-Ll cells. Importantly, the reduction 
of GILZ protein and mRNA became more apparent when the knock down and control 
cells were induced to differentiate. In the latter case, the transient pattern of GILZ 
expression (Figure 9b) during adipogenesis followed closely that observed for its mRNA 
(Figure 8c and Figure 9a). Expression of GILZ shRNA completely blocked the transient 
increase in both GILZ protein and mRNA and their expression remained at essentially 
preadipocyte levels during the entire differentiation time course. 
Expression of adipogenic mRNAs coding for PP ARy and adiponectin were 
reduced dramatically during adipogenesis in response to GILZ knock down. Expression 
of the corresponding proteins was also reduced, but not as dramatic as the mRNAs. 
Western blot analysis showed a transient pattern of expression of PPARy during 
adipogenesis consisting of a dramatic increase at 24 hrs, peaking at 48 hrs, and then 
falling extensively after day 4 to undetectable amounts by day 10. This pattern has been 
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Figure 9. 
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Figure 9. GILZ is required for adipogenic gene expression in 3T3-Ll preadipocytes. 
3T3-Ll preadipocytes were infected with lentivirus corresponding to GILZ shRNA or 
control eGFP shRNA to generate a stable GILZ KD cell line. The cells were 
differentiated for the indicated times and (a) qPCR or (b) Western blotting was performed 
to assess RNA or protein expression. For qPCR results, Y-axis shows the relative RNA 
expression. Results were mean (n = 2). Western blotting results were representative of 
two biological repetitions showing similar results. All the replicates were from individual 
biological experiments, which were from different wells or plates of cells. One of the two 
replicates was shown here. (c) Phase contrast microscopic photos were taken of the cells 
differentiated at day 10. 
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observed many times by others (Prusty et al. 2002; Qiang et al. 2007), but the precise 
reason is not known. Knock down of GILZ prevented the transient increase of PP ARy as 
well as completely blocked induction of adiponectin during the late stage of adipogenesis 
(Figure 9b). 
GILZ is required for adipogenic gene expression in C3Hl OTJ/2 mesenchymal stem 
cells 
Figure 9 demonstrates that GILZ is required for conversion of 3T3-L1 
preadipocytes to adipocytes (Figure 9c) and expression of adipogenic genes including 
PPARy and adiponectin (Figures 9a and 9b). To eliminate or reduce the possibility that 
the effect is unique to 3T3-L1 cells, the fmdings were verified in C3H10T1/2 MSCs. 
As described in the Introduction, C3H10Tl/2 MSCs are pluripotent and able to 
differentiate to several lineages, including fat, bone, and muscle, depending on the 
induction conditions (Gimble et al. 1995; Gregoire et al. 1998). Similar to the induction 
of adipogenesis in 3T3-L1 preadipocytes, Dex, MIX, and insulin are used to stimulate 
conversion of committed C3H10Tl/2 MSCs to adipocytes. Compared to 3T3-Ll cells, a 
unique part of the induction protocol for C3H10T1 /2 MSCs is treatment with BMPs for 
three days before reaching confluency, which facilitates commitment of the cells to an 
adipocyte lineage (Tang et al. 2004; Tseng et al. 2008; Huang et al. 2009). BMPs are a 
group of morphogenetic proteins important for many biological functions, including early 
embryonic patterning and skeletal bone morphogenesis (Reddi 2005; Wagner et al. 
2010). Depending on the BMP used for pretreatments, C3H10Tl/2 MSCs can 
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differentiate into brown or white adipocytes: BMP7 can induce the former, while BMP4 
can induce the latter (Tseng et al. 2008; Huang et al. 2009). The BMP-stimulated MSCs 
can also be induced to differentiate into osteocytes by treatment with an osteogenic 
cocktail consisting of Dex at concentrations significantly lower than used for 
adipogenesis along with ascorbic acid and beta-glycerophosphate (Vemet et al. 2005; 
Wallet al. 2007; Matsumoto et al. 2010). 
Figure 10 shows that using the same shRNA lentiviruses as in the 3T3-L1 
preadipocytes, GILZ was knocked down at both the RNA and protein levels by more than 
70% in C3H10T1 /2 MSCs. Similar to the results shown in 3T3-L1 preadipocytes (Figure 
9), expression of GILZ was transiently induced during the BMP4-directed differentiation 
of the control cells to white adipocytes reaching a peak of expression at 2 days post DMI 
treatment. Furthermore, this program of expression was significantly attenuated in the 
knock down cells, which was also accompanied by a suppression of PP ARy and 
adiponectin expression (Figure 1 0). 
Figures 9 and 10 suggest that both 3T3-L1 preadipocytes and C3HlOT1/2 MSCs 
require GILZ to achieve the maximum expression of adipogenic genes during white 
adipogenesis. 
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Figure 10. GILZ is required for BMP4 induced white adipocyte differentiation in 
C3H10Tl/2 mesenchymal stem cells. 
C3Hl OTl/2 MSCs were infected with lentivirus corresponding to GILZ shRNA or 
control eGFP shRNA to generate a GILZ knock down cell line. The cells were 
differentiated to the white adipocytes lineage with BMP4 recombinant protein as detailed 
in methods. RNA or protein was extracted at the indicated times during the differentiation 
and (a) qPCR or (b) Western blotting was performed to assess RNA or protein 
expression. The specific differentiation procedures were described in the methods. For 
qPCR results, Y -axis shows the relative RNA expression. Results were mean (n = 2). 
Western blotting results were representative of two biological repetitions showing similar 
results. All the replicates were from different wells or plates of cells. Only one of the two 
replicates was shown. (c) Phase contrast microscopic photos were taken on the cells 
differentiated at day 8. 
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GILZ is required for BMP7 induced brown adipogenesis in C3Hl OTJ/2 mesenchymal 
stem cells 
In Figure 10, C3H1 OTl/2 cells were differentiated by pretreatment with BMP4, 
which has been shown to induce their commitment to the white adipocyte lineage (Tang 
et al. 2004). Next, it was asked whether GILZ was required for BMP7 driven 
differentiation of C3H10Tl/2 MSCs into brown adipocytes (Tseng et al. 2008). Brown 
adipocytes express several genes either exclusively or many times more abundant than in 
white cells including uncoupling protein-1 (UCP-1) and other mitochondrial proteins 
involved in beta-oxidation of lipids. The transcription factors controlling this selective 
program consist of factors also controlling white adipogenesis such as C/EBPa and 
PP ARy as well as factors unique to the brown program including PP ARy coactivator-1 
and PR domain containing 16 (PRDM16) (Seale et al. 2008; Seale et al. 2009; Qiang et 
al. 2012). Little is known about the early events controlling expression of these genes that 
eventually lead to UCP-1 expression. Since Dex is also used to induce brown adipocyte 
differentiation (Tseng et al. 2008; Mori et al. 2012); it was hypothesized that GILZ is also 
required for brown adipogenesis. 
Not many studies have been conducted to elucidate the effect of GR on brown 
adipocyte development. In one study, using a hibemoma-derived T37i cell line, 
Viengchareun et al. showed that RU-38486, a high affinity GR antagonist, rescues the 
UCP1 transcription blocked by aldosterone, and concluded that GR inhibits UCP1 
expression in brown cells (Viengchareun et al. 2001). It is possible that GILZ might 
73 
facilitate general adipocyte differentiation but expression of brown adipocyte genes such 
as UCP-1 could be blocked by GILZ. 
As Figure 11 shows, knock down of GILZ significantly attenuated the expression 
of the brown adipocyte marker UCP1, along with the adipogenic genes PPARy and 
adiponectin, suggesting that GILZ was contributing to the differentiation of C3H1 OT1 /2 
cells into brown adipocytes. 
It is worth noting that there was a low UCP-1 signal in confluent cells prior to 
induction (DO), which is likely due to non-specific detection of an unrelated protein co-
migrating with UCP-1. Others in the lab have also observed this band, but to screen other 
anti-UCP-1 antibodies would be costly. The antibody does detect an abundant protein in 
brown adipose tissue that is not expressed in white tissue, thus we are confident that its 
positive reactant induced in C3H10Tl/2 adipocytes is UCP-1. 
The above data suggest that GILZ provides a necessary function that facilitates 
adipocyte differentiation in both white and brown adipogenesis in 3T3-L1 preadipocytes 
and C3H10T1/2 MSCs, rather than specific to certain cell lines or adipocyte lineage. It is 
possible though that the mechanism involving the pro-adipogenic activity of GILZ is 
different in the separate cell lines. 
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Figure 11. GILZ is required for BMP7 induced brown adipogenesis in C3H10Tl/2 
mesenchymal stem cells. 
C3H1 OT1/2 GILZ KD or control cells were pretreated with 6.3 nM BMP7 or a vehicle 
control for three days. The BMPs were removed and the cells were differentiated with a 
normal differentiation cocktaii (DMI) plus 12.5 11M Indomethacin and 2 nM T3 . Two 
days after induction, cells were replenished with 10% FBS plus insulin for two more 
days. Then protein was extracted for western blotting at day 4 when mature adipocytes 
were observed. Phase contrast microscopic photos were taken right before the protein 
extraction. Western blotting results were representative of two biological repetitions 
showing similar results. All the replicates were from individual biological experiments, 
which were from different wells or plates of cells. Only one of the two replicates was 
shown. 
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GILZ OE has a minimal effect on normal adipogenesis in 3T3-Ll preadipocytes, but 
increases adipogenesis in C3Hl OTJ/2 mesenchymal stem cells 
According to the loss-of-function studies, GILZ was shown to be required for the 
differentiation of C3H10Tl/2 MSCs and 3T3-Ll preadipocytes into fully mature 
adipocytes. To gain more insight into this pro-adipogenic activity of GILZ, whether its 
forced OE could enhance white adipogenesis in 3T3-Ll and C3H10Tl/2 systems was 
tested (Figures 12 and 13). To this end, the cells were infected retro-virally with a Myc-
tagged GILZ expression vector to generate stable transgenic cell lines. The Myc-tag 
(molecular weight 2.4kD) was used to confirm the ectopic expression of GILZ in western 
blots using an anti-Myc antibody. 
In the western blot shown in Figure 12, two bands of GILZ were detected using 
anti-GILZ antibody with the lower one corresponding to endogenous protein and the 
upper one to the ectopic Myc-tagged protein, which was confirmed by using the anti-Myc 
antibody. Even with the extensive expression of the ectopic GILZ, the data show that it 
had a minimal effect on adipogenesis in 3T3-L1 preadipocytes as evidenced by a similar 
level of adipogenic gene expression as the control cells, except for a minor induction of 
adiponectin at D4 in the GILZ OE cells. This lack of effect by ectopic GILZ is likely due 
to the presence of sufficient quantities of endogenous GILZ and other cooperating factors 
during normal adipogenesis. In fact, the control cells as well as the GILZ OE cells 
underwent maximum differentiation based on the presence of lipid droplets in almost the 
entire population of each cell culture at 6 days after their induction (data not shown). 
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Figure 12. GILZ OE has minimal effect on normal adipogenesis in 3T3-L1 
preadipocytes. 
3T3-Ll preadipocytes were retro-virally infected with a GILZ expression vector or a 
control vector to generate stable cell lines as described in the Methods. The cells were 
differentiated for the indicated times and western blotting was performed to assess 
protein expression. Western blot results were representative of two biological repetitions 
showing similar results. All the replicates were from individual biological experiments, 
which were from different wells or plates of cells. Only one of the two replicates was 
shown. 
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Figure 13. 
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Figure 13. GILZ OE increases adipogenic gene expression during earlier phase of 
adipogenesis in C3H10Tl/2 mesenchymal stem cells. 
The GILZ OE and control cell lines described in Figure 13 were differentiated for four 
days when mature adipocytes were observed. QPCR was performed to assess RNA 
expression and western blotting was performed to assess protein expression. Y -axis 
shows the relative RNA expression. Two way ANOV A was conducted and the difference 
between control and GILZ OE were statistically significant with P < 0.05. Results were 
mean+SD (n = 3, *, P < 0.05). Student's t-test was used to assess the statistical 
significance of qPCR results. Western blotting results were representative for two 
biological repetitions showing similar results. All the replicates were from individual 
biological experiments, which were from different wells or plates of cells. Only one of 
the two replicates was shown. 
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Like the loss-of-function studies, it was then asked whether GILZ OE promotes 
adipogenesis in C3Hl OTl /2 cells. In contrast to results from 3T3-Ll preadipocytes, 
GILZ OE in the MSCs did enhance the expression of adipogenic genes, such as PP ARy 
and adiponectin, at both the RNA and protein levels. Figure 13 demonstrates an abundant 
expression of ectopic GILZ, which interestingly was also induced at the mRNA (Figure 
13 top panel) and protein (Figure 13 bottom panel) during early adipogenesis suggesting 
a possible post-transcriptional regulation of GILZ mRNA. Importantly, this enhancement 
of the ectopic protein resulted in a significant increase in PP ARy expression, which 
peaked at day 4. Adiponectin expression was also enhanced by the ectopic GILZ reaching 
levels higher than in control cells. 
It is interesting that GILZ promoted adipogenesis in C3H10Tl/2 MSCs and not in 
3T3-Ll preadipocytes (compare Figures 12 and 13). One explanation for this is that the 
C3H10Tl/2 MSCs are not committed to the adipocyte lineage and require exposure to a 
commitment factor such as BMP prior to adipogenic induction with Dex, MIX and 
insulin. GILZ might also participate in this process as well as during adipogenesis. 
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Discussion 
GILZ was identified as a gene rapidly induced by glucocorticoid and in the last 
few years, it has been shown that GILZ is animportant mediator of the anti-inflammatory 
activity of glucocorticoid (Berrebi et al. 2003; Asselin-Labat et al. 2004; Cohen et al. 
2004; Delfmo et al. 2006; Ayroldi et al. 2009) and is a potential therapeutic target for 
inflammatory related diseases, such as rheumatoid arthritis (Fan et al. 2012). As is shown 
in the previous studies and in these results, GILZ expression is induced by Dex and GR 
in adipocyte differentiation, both ofwhich are required for adipogenesis in vitro (Chapter 
1 and Asada et al. 2011 ). Consequently, it is expected that GILZ is a promising mediator 
for glucocorticoid's pro-adipogenic activity in adipogenesis. The goal of this study was to 
test the hypothesis that GILZ is required for adipogenesis. To this end, the present data 
show that GILZ is transiently induced during the early stage of adipogenesis; KD of 
GILZ in 3T3-Ll preadipocytes and in C3H10Tl/2 MSCs prevents differentiation in both 
cell lines as marked by the reduced expression of adipogenic genes. Forced expression of 
GILZ, on the other hand, has minimal effect on 3T3-Ll cell differentiation and 
adipogenic gene expression. Overall, the data suggest that GILZ, a target of Dex and GR, 
is a necessary component mediating the pro-adipogenic activity of glucocorticoid 
signaling including Dex and GR. While ectopic GILZ did not enhance adipogenesis in 
3T3-L1 cells, it did induce or accelerate adipogenic gene expression in C3H10Tl/2 
MSCs. 
An important characteristic of GILZ found in the study and also shown by others 
(Shi et al. 2002) is that the expression of GILZ during adipogenesis appears to be 
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transient- GILZ expression is upregulated during the first two days of adipogenesis, and 
then it is down regulated in the later phase. The bi-phasic expression of GILZ may 
suggest that it plays different roles at different stages of adipogenesis, with the early 
induction being critical for adipogenesis and the later expression being non-functional or 
even anti-adipogenic, which is similar to the expression profile of other transcription 
factors such as C/EBP~ and C/EBP8 (Mandrup et al. 1997). It is important to note that 
the transient pattern of expression correlated with treatment of preadipocytes with Dex. 
Its high level of expression occurred during the initial 2 days of differentiation when Dex 
was present and its extensive drop in expression occurred when DMI media was replaced 
with insulin containing media. Although no experiments have been done to verify this 
hypothesis, treatment with Dex in the later phase of adipogenesis (D4 or D6) should 
reveal whether GILZ expression could be reactivated. This correlation between the GILZ 
expression pattern and treatment with Dex suggests that GILZ plays an important role in 
mediating Dex/GR signaling in adipogenesis as in other systems (Ayroldi et al. 2009). 
This explains why GILZ is required for adipogenesis. The extensive drop in GILZ 
expression might be necessary because GILZ could block terminal adipogenesis through 
some unknown mechanism. Support for this idea comes from observations of others and 
these results showing that prolonged treatment with Dex beyond the initial two days 
inhibits adipogenesis (Pantoja et al. 2008). Lane and associates also reported that 
treatment with Dex (as well as insulin) in mature adipocytes inhibits expression of 
C/EBPa (Macdougald et al. 1994; MacDougald et al. 1995), which is required for the 
activation of PP ARy and adipogenesis (Farmer 2006). A possible inhibitory function of 
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GILZ in mature adipocytes might also explain the fmdings of Shi and collaborators who 
showed that OE of GILZ blocked adipogenesis (Shi et al. 2002). Of course, the 
subsidence of GILZ during later stage may have no or a minor effect on adipogenic gene 
expression as demonstrated in my studies shown in Figure 13. 
One of the key findings in this chapter is that GILZ was required for expression of 
adipogenic genes. GILZ is best known for mediating glucocorticoid's anti-inflammatory 
and immunosuppressive functions in different cell types (D'Adamio et al. 1997; Ayroldi 
et al. 2001; Berrebi et al. 2003; Yang et al. 2008; Cannarile et al. 2009). Studies using 
transgenic mice demonstrated that GILZ inhibited NF-KB nuclear translocation and its 
expression of inflammatory proteins including IL-6, TNFa and IFN-y in CD4+ T cells 
(Cawthorn et al. 2007), all of which have also been shown to inhibit adipogenesis in vitro 
(Xing et al. 1997; Cawthorn et al. 2007; Vidal et al. 2012). TNFa, for instance, is high in 
obese mice and considered to be a principal mediator of the obesity-associated insulin 
resistance (Hotamisligil et al. 1993). This activity likely results from its ability to 
suppress PP ARy activity through stimulation of the MEK/ERK pathway that leads to an 
inhibitory phosphorylation ofPPARy at S112 (Xing et al. 1997). The blockade ofTNFa 
in mice by either mutating the gene or deleting the gene results in the improvement or the 
restoration of insulin sensitivity (Uysal et al. 1997; Ventre et al. 1997). Therefore, it is 
possible that the proposed pro-adipogenic activities of GILZ are mediated through the 
inhibition of TNFa and other inflammatory proteins. Testing this hypothesis by 
generating an adipose-specific GILZ knock out mouse is a worthwhile project for future 
investigations. 
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Other than suppressing an anti-adipogenic inflammatory factor, another possible 
mechanism for GILZ's pro-adipogenic activity is its role in activating critical adipogenic 
transcription factors such as PP ARy and/or the C/EBPs (Ren et al. 2002) as suggested by 
the data in this chapter. As the upregulation of GILZ expression occurred rapidly after the 
induction with adipogenic cocktail, and the expression of PP ARy was induced later, it is 
possible that GILZ targets other earlier adipogenic inducers such as C/EBP~ and C/EBP8 
that activate PP ARy (Rosen et al. 2006). It is also important to note that both GILZ and 
the C/EBPs (C/EBP8 and C/EBP~) are leucine zipper proteins, which can form 
homodimers or heterodimers (Landschulz et al. 1988). It is possible therefore, that GILZ 
facilitates adipogenesis through a direct interaction with C/EBP8 and C/EBP~ to induce 
PP ARy expression during the early phase of adipogenesis. It has also been shown that 
Dex/GR regulates the expression of C/EBP8 and C/EBPa (MacDougald et al. 1994 ), . 
however, no GRE sequences has been found in the promoter regions of these genes (Cao 
et al. 1991; Christy et al. 1991 ). It is therefore possible that Dex/GR regulates C/EBP8 
and C/EBP~ expression through GILZ binding to the corresponding promoter/enhancers. 
In addition to regulating PP ARy gene expression, Hamm et al. showed that C/EBP~ can 
promote the production of PPARy ligands to stimulate the transcriptional activity of 
PPARy (Hamm et al. 2001). GILZ might be a component of this mechanism. 
Furthermore, studies by Hache and collaborators showed that C/EBP~ associates with a 
transcriptional corepressor complex containing mSin3A and histone deacetylase 1 
(HDACl) on C/EBP binding sites of C/EBPa. They further demonstrated that 
glucocorticoid dislodged the corepressor complex from C/EBP~ by facilitating the 
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degradation of HDACl in the proteasome, thus promoting the C/EBP~ dependent 
transcription of C/EBPa (Wiper-Bergeron et al. 2003). They also showed that 
glucocorticoids induced acetylation of C/EBP~ by GCN5, which was required for 
dislodgement of the HDACl corepressor (Wiper-Bergeron et al. 2007). An additional 
role for GILZ might be to mediate the effect of glucocorticoid in activating C/EBP~ 
transcriptional activity through its induction of GCN5. The possible involvement of GILZ 
in a C/EBP complex might also explain the differences between my fmdings and those of 
Shi and coworkers (Shi et al. 2002). For example, in their study the OE of GILZ might 
have squelched the activity of the C/EBPs rather than activate them. 
These studies also showed that GILZ was required for the BMP7-associated 
conversion of mesenchymal stem cells to brown adipocytes that express UCPl. The 
fmding is consistent with the fact that Dex, the activator of GILZ, is a component of the 
cocktail of hormones used to induce brown adipogenesis in the committed stem cells 
(Tseng et al. 2008; Mori et al. 2012). 
In addition to the KD of GILZ, OE of GILZ was also studied, and the results 
confirm the KD findings showing that GILZ is pro-adipogenic. An interesting finding is 
that GILZ OE has slightly different effect on adipogenic gene expression in 3T3-Ll cells 
compared to C3H10Tl/2 MSCs. In the latter cell line, GILZ significantly enhances 
expression of PP ARy and adiponectin. This effect is not observed in 3T3-Ll cells. There 
are several possibilities that may explain the differences. One is that in the multi-potential 
C3H10Tl/2 MSCs (Gregoire et al. 1998) GILZ induces the BMP-associated commitment 
to preadipocytes (Tang et al. 2004), which is obviously lacking in the already committed 
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3T3-Ll preadipocytes. Such a mechanism however would have to occur in response to 
basal levels of GILZ since glucocorticoids are not components of the commitment 
cocktail of inducers. It is more likely that GILZ plays a more prominent role during 
adipogenesis of the MSCs. For instance, 3T3-L1 preadipocytes are less dependent on 
hormones for initiation of differentiation requiring only Dex, MIX and insulin. The 
C3H10Tl/2 MSCs, however, require indomethacin and T3 in addition to DMI. To test 
whether the adipogenic potential of glucocorticoids depends on GILZ, I exposed 3T3-Ll 
preadipocytes to no or low doses of Dex and the results indicated that OE GILZ did not 
compensate for the removal or reduction of Dex (data not shown). These data suggest 
that there are add~tional downstream targets of Dex other than GILZ, and all are required 
to mediate Dex' s pro-adipogenic activity. The mechanisms responding to indomethacin 
and T3 might be regulated in part by GILZ. The potential role of glucocorticoids and GR 
in facilitating the action of indomethacin and T3 has not been investigated. To test this 
role of GILZ, the MSCs expressing ectopic GILZ could be exposed to suboptimal doses 
of indomethacin and/or T3. Such conditions might significantly enhance the effect of the 
glucocorticoid-associated transcription factor. To determine the stage of adipogenesis 
most affected by GILZ, an inducible OE system could be employed, e.g. tetracycline-
dependent transactivation of corresponding gene (Wu et al. 1996). 
The mechanism of Dex's pro-adipogenic activity has been reported and many 
effectors have been identified. In the in vitro cultured cell systems of adipogenesis, Dex 
induces expression of an early stage transcriptional inducer C/EBP8 (Cao et al. 1991). 
Dex also primes the preadipocytes to a committed state, while MIX and insulin have no 
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such capability (Pantoja et al. 2008). It is shown that Dex's effect on adipogenesis is, at 
least in part, through the acetylation of C/EBP~ (Wiper-Bergeron et al. 2007). To 
determine whether and which early adipogenic regulators were affected by GILZ, 
expression of the pro-adipogenic C/EBP8 and C/EBP~, as well as the anti-adipogenic 
Pref-1, among others, were analyzed. However, one cannot draw a definitive conclusion 
from the preliminary GILZ OE or its knock down results (data not shown). In future 
studies, it will be possible to identify targets of GILZ using ChiP-seq of preadipocytes 
undergoing early adipogenesis. 
Other than the major fmdings as discussed above, there also exist some interesting 
observations that are worth mentioning. GILZ expression appeared to be transient and to 
correlate with exposure to Dex. This pattern is consistent with the notion that the pro-
adipogenic activity of GILZ is restricted to the early phase, but also its expression needs 
to drop to facilitate a function of the mature adipocyte. As discussed above, it will be 
interesting to use conditional OE and/or KD systems to dissect the activities of GILZ in 
early versus late stages of adipogenesis. 
There is very little known about the physiological role of GILZ in controlling 
adipose tissue functions and energy balance since most mouse studies have addressed its 
importance in the immune system. Most notably, GILZ OE in transgenic mice, as 
discussed before, leads to the inhibition ofNF-KB nuclear translocation and expression of 
inflammatory genes like IL-6, TNFa and IFN-y (Xing et al. 1997; Cawthorn et al. 2007; 
Vidal et al. 2012; Wang et al. 2012). One could speculate from these results that GILZ 
will have an insulin-sensitizing activity in the mouse since these inflammatory proteins 
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have been shown to inhibit adipogenesis and induce insulin resistance. On the other hand, 
production of GILZ above a threshold level could also have negative effects on 
metabolism. For instance, prolonged exposure to excess glucocorticoids leads to 
Cushing's syndrome in human, whose symptoms include multiple metabolic disorders 
including obesity, hyperglycemia, and hypertension (Shibli-Rahhal et al. 2006; Hatipoglu 
2012). It is suggested that excess fat deposition in patients with Cushing's syndrome is 
due to elevated adipocyte lipoprotein lipase activity and low lipolytic activity (Rebuffe-
Scrive et al. 1988). As a mediator for Dex's pro-adipogenic activity in vitro, it is possible 
that GILZ may also link exposure to excess glucocorticoids and the development of 
Cushing's syndrome. To reveal GILZ's role in vivo will require tissue-selective 
expression and/or KD. This can be achieved for adipose tissue by using the adiponectin 
promoter transgenic expression of GILZ or Cre; the latter will facilitate removal of GILZ 
in a mouse with a floxed GILZ gene. Generation of corresponding mice might shed light 
on function of GILZ in vivo and possibly contribute to the treatment of Cushing's 
syndrome in human. 
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Chapter III: Identification of mechanisms by which On costa tin M 
(OSM) inhibits adipogenesis 
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Introduction 
In an attempt to identify signaling pathways that are suppressed during early 
adipogenesis and likely to be anti-adipogenic, I focused on OSM. Analysis of the 
microarray presented in Chapter 1 identified the Oncostatin receptor (OSMR) as a gene 
that is down-regulated extensively during the initial 4 days of differentiation. OSM is a 
member of the IL-6 family of gp130 cytokines. Both IL-6 and OSM have been shown to 
inhibit adipogenesis in vitro, and IL-6 may be a link between obesity and type II diabetes 
in humans (Gimble et al. 1994; Lagathu et al. 2003; Dandona et al. 2004; Miyaoka et al. 
2006; White et al. 2011). It is known that OSM production increases in many 
inflammation-related diseases (Tomita et al. 2009) and recent unpublished data (personal 
communication, Jacqueline Stephens, LSU) suggest that it is also elevated in obese 
individuals and therefore could possibly contribute to insulin resistance. Therefore, 
understanding the molecular mechanisms by which OSM signaling blocks adipogenesis 
might identify novel intracellular effectors of adipogenesis. 
Both IL-6 and OSM signal through several pathways but the most notable is the 
JAK/STAT pathway (Stephens et al. 1996; Stephens et al. 1999; Hogan et al. 2005; 
Zvonic et al. 2005; Richard et al. 2011; White et al. 2011). They also inhibit in vitro 
adipogenesis with OSM possessing the most potent anti-adipogenic activities among the 
IL-6 family members (Zvonic et al. 2005; White et al. 2011). IL-6 and OSM have been 
extensively studied in order to understand their roles in inflammation, cancer and acute 
phase responses (Silver et al. 2010; Dey et al. 2012). There are few studies, however, 
that have defined their anti-adipogenic properties. Of particular interest to me was a study 
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showing that IL-6 inhibits Dex-induced expressiOn of GILZ in multiple myeloma 
(Miyaoka et al. 2006; Grugan et al. 2008). Based on the data presented in Chapter 2 and 
the fact that OSM and IL-6 belong to the same family and activate common signaling 
pathways, I hypothesized that GILZ might be a target of the anti-adipogenic activity of 
OSM. 
Several studies have suggested that RAS/ERK as well as STAT5 signaling 
pathways may play important roles in mediating OSM's anti-adipogenic activities (Song 
et al. 2005; Miyaoka et al. 2006; Song et al. 2007). The identity of the targets of these 
activities and their role in regulating adipogenesis, however, is not known. I questioned, 
therefore, whether ERK and/or STAT5 mediate OSM's inhibitory activity by targeting 
the pro-adipogenic activity or expression of GILZ. 
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Results 
OSM inhibits adipogenesis 
To test the hypothesis that OSM inhibits adipogenesis through inhibition of GILZ, 
the first step was to confirm other studies (Miyaoka et al. 2006) by showing that OSM 
suppresses the differentiation of 3T3-L1 preadipocytes. It is also important to determine 
the required dose of OSM for its anti-adipogenic activity to assess whether the effect is 
physiological. Figure 14 shows that recombinant OSM suppressed expression of terminal 
adipogenesis in a dose-dependent manner. This result is in accordance with previous 
fmdings showing that 48 nM OSM is an effective dose (Miyaoka et al. 2006). The 
western blot in Figure 14 reveals that there was a slight induction of adipsin and 
adiponectin at 4.8 nM of OSM, but their production dropped significantly as the dose was 
increased reaching a plateau at 48 nM. I chose this dose for my studies because it 
effectively attenuated adipogenesis and fell well within a range of concentrations 
reported to exist in the circulation of humans (4.8 flM) with septic shock (Tomita et al. 
2009). Many other researchers have also used this concentration (Miyaoka et al. 2006). 
It is important to determine the precise time of action of OSM in order to provide 
some insight into potential target adipogenic regulators. 3T3-L1 preadipocytes were, 
therefore, exposed to OSM for periods of time throughout adipogenesis. The results in 
Figure 15 show that OSM attenuated expression of PP ARy as early as 48 hrs of 
differentiation, which was followed by an extensive decrease in adiponectin expression 
by 168 hrs. It was previously shown that OSM suppresses adipogenic gene expression 
(Miyaoka et al. 2006; Song et al. 2007; White et al. 2011); however, the expression 
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Figure 14. OSM dose-dependently inhibits adipogenesis. 
3T3-Ll preadipocytes were exposed to the indicated concentrations of OSM or vehicle 
(BSA) throughout the process of adipocyte differentiation. Protein expression was 
measured by western blotting at day 6 when mature adipocytes were seen. Western 
blotting results were representative of two biological repetitions showing similar results. 
"undiff' refers to undifferentiated 3T3-Ll preadipocytes. All the replicates were from 
individual biological experiments, which were from different wells or plates of cells. 
Only one of the two replicates was shown. 
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Figure 15. 
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Figure 15. Time course of inhibition of adipogenic gene expression by OSM during 
adipogenesis. 
3T3-Ll preadipocytes were treated with 48 nM recombinant OSM protein or vehicle 
(BSA) during adipogenesis. Protein was extracted at the indicated times, and expression 
of PPARy and adiponectin was measured by western blotting. Western blotting results 
are representative of two biological repetitions showing similar results. All the replicates 
were from individual biological experiments, which were from different wells or plates of 
cells. Only one of the two replicates was shown. Only one of the two replicates was 
shown. 
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pattern of adipogenic genes inhibited by OSM had not previously been elucidated. 
Therefore, the time course study provided additional information on the timing of 
inhibition by OSM. 
OSM transiently suppresses GILZ expression in 3T3-Ll preadipocytes and C3Hl OTl/2 
mesenchymal stem cells 
To identify the mechanisms facilitating the inhibitory action of OSM, I first 
questioned whether GILZ is a target of OSM signaling. Earlier investigators suggested 
that both ERK and STAT5 are mediators of the suppressive effects of OSM (Miyaoka et 
al. 2006; Song et al. 2007; White et al. 2011), but they did not identify the adipogenic 
regulator(s) responsive to these signaling molecules. It has been shown that STAT5 is a 
target of OSM (Richard et al. 2011), and OE of a dominant negative form of STAT5 can 
partially abolish OSM' s anti-adipogenic activity (Miyaoka et al. 2006). I questioned, 
therefore, whether GILZ responds to OSM-associated activation of STAT5. To begin to 
test my hypotheses, 3T3-L1 preadipocytes were treated with OSM and GILZ expression 
was measured at different times following induction of differentiation. Figure 16 shows 
that OSM significantly attenuated the early induction of GILZ during the first day of 
adipogenesis, but its expression reached the induced adipogenic levels of untreated cells 
by day 2. 
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Figure 16. OSM transiently suppresses GILZ expression during the early stage of 
differentiation of 3T3-L1 preadipocytes. 
3T3-Ll preadipocytes were treated with 48 nM recombinant OSM or vehicle (BSA) 
throughout their differentiation. Protein expression was measured at the indicated times 
by western blotting. Western blotting results were representative of two biological 
repetitions showing similar results. All the replicates were from individual biological 
experiments, which were from different wells or plates of cells. Only one of the two 
replicates was shown. 
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To show that this transient effect ofOSM was not unique to 3T3-Ll cells, I also analyzed 
GILZ expression in differentiating C3Hl0Tl /2 MSCs following exposure to OSM. 
Figure 17 show that OSM prevented the rapid induction of GILZ during the initial 3 hrs 
of differentiation, but as observed in Figure ·16, its expression reached the induced levels 
of untreated cells by 48 hrs. Different time points were sampled during the 48 hrs 
exposure periods due to the experiment design. Therefore, it is not possible to determine 
whether the transient pattern of GILZ expression is identical in both systems because. It 
is encouraging and important, however, that in both cases OSM did block the early 
induction of GILZ. 
The expression of GILZ during adipogenesis in 3T3-Ll cells and the MSCs 
follows a similar pattern consisting of an induction phase peaking at 2 days, and then 
gradually declining to pre-stimulation levels (Figures 8, 9 and 1 0). Based on this profile, I 
propose that the pro-adipogenic activity of GILZ occurs during the initial 2 days and 
OSM blocks the activity at this time, thus preventing adipogenesis. An early role for 
GILZ would be consistent with it facilitating the function of other pro-adipogenic 
transcription factors such as C/EBP8 or C/EBP~ that are required for expression of 
PP ARy, the master of adipogenesis. It is interesting that its expression subsides during 
terminal differentiation in a similar manner as that observed for the C/EBPs (Cao et al. 
1991; Wu et al. 1995; Yeh et al. 1995; Wu et al. 1996). 
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Figure 17. OSM transiently suppresses GILZ expression in C3H10Tl/2 
mesenchymal stem cells. 
CH310Tl //2 MSCs were treated with 48 nM recombinant OSM or vehicle (BSA) 
throughout their differentiation into white adipocytes (pretreated with BMP4). Protein 
expression was measured at the indicated times by western blotting. Western blotting 
results were the representative of two biological repetitions showing similar results. All 
the replicates were from individual biological experiments, which were from different 
wells or plates of cells. Only one of the two replicates was shown. 
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Lipopolysaccharide (LPS) does not suppress GILZ expression 
It is known that E. coli derived recombinant proteins can be contaminated with 
LPS and studies have shown that signaling pathways induced by LPS also inhibit 
adipogenesis (Mnicek et al. 2004). To rule out the possibility that LPS rather than OSM 
inhibited GILZ and adipogenesis, 3T3-L1 preadipocytes were treated with LPS inhibitor 
polymyxin B (PxB) or TAK-242 (TAK) for one hour pre-differentiation, then the cells 
were differentiated with normal induction cocktail in the presence or absence of either 48 
nM OSM or 1 00 ng/ml LPS. The cells were exposed to the LPS inhibitors five hours 
prior to treatment with the effectors to ensure complete inhibition of LPS signaling. I 
chose a concentration of LPS (1 00 ng/ml), which has been shown to be a very potent 
dose for many of its biological effects such as activation of IL-8 production (Pugin et al. 
1993) and to be well in excess of the stated levels of endotoxin contamination in the 
recombinant OSM (< 0.01 EU per 1 J..Lg or less than 0.01 %). 
Figure 18 shows that OSM suppressed GILZ expression as expected and the LPS 
inhibitors were incapable of preventing this suppression (compare lane 4 to 5 and 6). 
Consistent with this observation, it was also shown that LPS itself had no inhibitory 
effect (compare lane 2 and 5 and 8). Taken together, these data showed that the 
recombinant OSM was the principal inhibitor of GILZ expression and not any 
contaminating LPS. 
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Figure 18. LPS does not suppress GILZ expression. 
3T3-Ll preadipocytes were pretreated with LPS inhibitor PxB and TAK for one hour 
prior to their differentiation in the presence of 48 nM recombinant OSM or 1 00 ng/ml 
LPS along with the normal induction cocktail (Dex, MIX, and insulin). The inhibitors 
were exposed to the cells for an additional five hours following induction of 
adipogenesis. Protein expression was measured by western blotting. The experiment was 
done once. 
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OSM increases ERK and STAT5 phosphorylation 
Data shown in this chapter so far demonstrate that OSM suppressed GILZ during 
the first two days of adipogenesis in both 3T3-Ll preadipocytes and C3H10Tl /2 MSCs. I 
hypothesize, therefore, that these pathways might converge on the GILZ gene, blocking 
its induction in response to the adipogenic hormones. As reported by several 
investigators, ERK and STAT5 phosphorylation are transiently induced during the first 
hour of adipogenesis in 3T3-L1 preadipocytes (Figure 19), and are required for 
subsequent differentiation (Nanbu-Wakao et al. 2002; Prusty et al. 2002). Importantly, 
exposure to OSM enhanced the extent of their phosphorylation to levels several fold 
greater than in cells not exposed to the cytokine. 
Figure 19 shows that MEK phosphorylation of ERK and JAK phosphorylation of 
STAT5 occurs within the frrst hour of adipogenesis, which appears to coincide or slightly 
precede the decrease in GILZ expression in response to OSM (Figure 16). The temporal 
and sequential correlation of these events leads me to hypothesize that one or both of 
these signaling pathways mediated the inhibitory action of OSM. It has been shown that 
both ERK and STAT5 may inhibit GR activity (Rogatsky et al. 1998; Hu et al. 2009), 
which could inhibit GILZ expression. To test this idea, potent specific inhibitors of 
MEKIERK and JAK/STA T5 signaling were employed to determine whether they prevent 
the inhibition of GILZ expression by OSM. 
100 
Figure 19. 
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Figure 19. OSM increases ERK and STATS phosphorylation. 
3T3-Ll preadipocytes were treated with 48 nM OSM or vehicle (BSA) along with the 
induction cocktail (Dex, MIX, and insulin) for the indicated times during adipogenesis 
before extracting the protein. Protein expression was measured by western blotting. 
Western blotting results were the representative of two biological repetitions showing 
similar results. All the replicates were from individual biological experiments, which 
were from different wells or plates of cells. Only one of the two replicates was shown. 
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Chemical inhibitors suppress the induction of ERK or STATS phosphorylation by OSM 
To test the hypothesis that OSM inhibited GILZ expression through its induction 
of ERK and STAT5 phosphorylation, 3T3-Ll cells were pretreated with a MEK/ERK 
inhibitor U0126 or JAK!STAT5 inhibitors AG490 or WHI-P131 (WHIP) for 18 hours 
prior to treatment with the cocktail of hormones (DMI). Figure 20 shows that the 
inhibitors suppressed the phosphorylation of their corresponding targets. Specifically, 
ERK phosphorylation was induced during the first hour of exposure to the adipogenic 
cocktail and OSM enhanced this activity many fold. The MEK inhibitor (U0126, 10 J.!M) 
completely blocked the hormone-induced ERK phosphorylation and significantly 
attenuated the effect of OSM. Similarly, OSM induced STAT5 phosphorylation during 
the initial hour and both JAK/STAT inhibitors (10-50 J.!M AG490 or 2.25 mM WHIP) 
inhibited the phosphorylation. The effectiveness of both the MEK!ERK and JAK/STAT5 
inhibitors means that they can be used to modulate separately each of the corresponding 
signaling pathways in order to assess their importance in facilitating the inhibitory action 
ofOSM. 
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Figure 20. Chemical inhibitors suppress the induction of ERK or STATS 
phosphorylation. 
3T3-L1 preadipocytes were pretreated with vehicle, 10 ~M U0126 (MEK inhibitor), or 
indicated concentration of AG490 or WHI-P131 (both inhibitors of STAT5 activation) 
for 18 hours before cocktail induction. Then the cells were treated with 48 nM OSM or 
vehicle for one hour along with induction cocktails and chemical inhibitors. Protein 
expression was measured by western blotting. Western blotting results were 
representative of two biological repetitions showing similar results. All the replicates 
were from individual biological experiments, which were from different wells or plates of 
cells. Only one of the two replicates was shown. 
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MEKIERK inhibitor, U0126, attenuates the suppression ofGILZ by OSM 
To test the hypothesis that OSM inhibits GILZ expression through one or both of 
the MEK/ERK and JAK/STAT5 signaling pathways, 3T3-L1 preadipocytes were 
pretreated with each of the corresponding inhibitors prior to hormonal stimulation of the 
cells and cellular extracts were isolated at 1 hr and 6 hrs post-induction for western blot 
analysis. The data (Figure 21) confirms that U0126 and WHIP attenuated the OSM-
associated induction of ERK and STA T5 phosphorylation, respectively (Figure 21, top 
panel) during the initial hour of differentiation. Importantly, inhibition of the early 
activation of MEK/ERK signaling attenuated the suppression of GILZ expression by 
OSM (Figure 21, lower panel, compare lane 6 with lane 5). Inhibition of JAK/STAT, 
however, with WHIP had no observable effect on GILZ expression (Figure 21, lower 
panel, compare lane 7 to lane 5). 
GILZ OE prevents the inhibition of adipogenesis by OSM in 3T3-Ll preadipocytes 
Although OSM inhibits GILZ as well as adipogenesis (Figures 14-17), it does not 
necessarily follow that suppression of GILZ is the mechanism through which OSM 
blocks adipogenesis. To determine whether the anti-adipogenic action of OSM includes 
GILZ, control and GILZ OE 3T3-L1 preadipocytes (see Chapter 2) were induced to 
differentiate in the presence or absence of OSM. OE of GILZ from an ectopic promoter 
should not be subject to MEKIERK inhibition and, therefore, should overcome the 
inhibitory effects of OSM. 
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Figure 21. Pi-ERK inhibitor U0126 prevents the suppression of GILZ expression by 
OSM. 
3T3-L1 preadipocytes were pretreated with vehicle, 10 !-LM U0126 or 0.18 mM WHI-
p 131 for 18 hours before cocktail induction. The cells were then treated with 48 nM 
OSM or vehicle for one hour (panel a to detect Pi-ERK and Pi-STAT5) or six hours 
(panel b to detect GILZ) along with induction cocktail and chemical inhibitors. Protein 
expression was measured by western blotting. Western blotting results were the 
representative of two biological repetitions showing similar results. All the replicates 
were from individual biological experiments, which were from different wells or plates of 
cells. Only one of the two replicates was shown. 
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Figure 22 shows that similar to the results in Figures 14 and 15, OSM suppressed 
PP ARy and adiponectin expression at day 7 following hormonal induction as well as 
reduced the number of fully differentiated adipocytes (compare lane 9 to lane 7 of the 
western blot). GILZ was successfully OE as demonstrated by detection of a band using 
both anti-GILZ and anti-Myc antibodies. The western blot shown in Figure 22 was 
derived from a lower percentage polyacrylamide gel than that in the other figures; 
consequently, the endogenous and ectopic GILZ proteins could not be resolved into 
separate bands. However, the Myc signal provided additional evidence that GILZ was 
successfully OE in the GILZ OE cell line. It was shown that OE of GILZ prevented the 
inhibition of adiponectin and PP ARy by OSM (Figure 22, compare lane 10 to lane 9). 
. . 
These data suggest that GILZ is the target of OSM's anti-adipogenic activity in 3T3-Ll 
preadipocytes. 
GILZ OE prevents the inhibition of adipogenesis by OSM in C3Hl OTJ/2 mesenchymal 
stem cells 
To determine whether GILZ is also a target of OSM in other adipogenic systems, 
the experiment shown in Figure 22 was repeated using C3Hl OTl/2 MSCs. Figure 23 
demonstrates OE of the ectopic GILZ throughout differentiation of these cells, which 
appears to significantly reduce expression of the endogenous protein. This could result 
from a negative feedback mechanism. The presence of OSM had little effect on either the 
ectopic or endogenous GILZ. One would not expect down-regulation of the former and 
my previous analyses (Figure 17) showed that OSM only inhibits endogenous 
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Figure 22. GILZ OE prevents the inhibition of adipogenesis by OSM in 3T3-Ll 
preadipocytes. 
Empty vector control and GILZ OE 3T3-Ll preadipocytes were treated with or without 
48 nM OSM for the indicated times during adipogenesis. Protein expression was 
measured by western blotting (lower panel). Phase contrast microscopic photos were 
taken at day 7 (upper panel). Western blotting results were representative of two 
biological repetitions showing similar results. All the replicates were from individual 
biological experiments, which were from different wells or plates of cells. Only one of 
the two replicates was shown. 
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Figure 23. GILZ OE prevents the inhibition of adipogenesis by OSM in C3Hl0Tl/2 
mesenchymal stem cells. 
Empty vector control and GILZ OE C3H10Tl /2 MSCs were differentiated as described 
in the Methods. The cells were also treated with or without 48 nM OSM for the indicated 
times during adipogenesis. Protein expression was measured by western blotting. 
Western blotting results were representative of two biological repetitions showing similar 
results. All the replicates were from individual biological experiments, which were from 
different wells or plates of cells. Only one of the two replicates was shown. 
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GILZ during the initial 2 days of adipogenesis. Thus, any suppression would not be 
detected at the time (day 4) analyzed in Figure 23. OSM also had no detectable effect on 
PP ARy, but did reduce expression of both C/EBPa and adiponectin. As expected, the 
ectopic GILZ enhanced the production of PPARy, C/EBPa and adiponectin in the 
absence and presence of OSM. This prevented the inhibition of terminal adipogenesis 
(i.e. adiponectin production) by OSM. 
Figures 22 and 23 demonstrate that ectopic OE of GILZ prevented the inhibition 
of adipogenesis by OSM in both 3T3-Ll preadipocytes as well as C3H10Tl /2 MSCs. 
The fact that solely adding back GILZ prevented OSM' s inhibition on adipogenesis 
suggested that suppression ofGILZ was a major mediator ofthis inhibition. 
109 
Discussion 
The goal of the studies documented above was to identify the molecular 
mechanisms by which OSM inhibits adipogenesis. To this end, I confirm and extend 
previous studies by others (Miyaoka et al. , 2006; Song et al. , 2007) showing that OSM 
inhibits adipogenesis in both 3T3-Ll preadipocytes as well as C3H10Tl/2 MSCs by 
attenuating expression of the two principal adipogenic transcription factors, PP ARy and 
CIEBPa. This activity prevents the cells from progressing to a terminally differentiated 
state as evidenced by the significantly reduced level of adiponectin and adipsin 
expression. My novel data presented here demonstrate that OSM likely blocks production 
of the adipogenic transcription factors by transiently inhibiting expression of GILZ. The 
mechanism of inhibition includes activation of the MEKIERK signaling pathway by 
OSM since arrest of this pathway with a MEK inhibition UO 126 significantly attenuates 
the extent of GILZ inhibition by OSM. Additionally, I show that inhibition of 
adipogenesis by OSM can be partially rescued by the ectopic expression of GILZ. These 
data provide physiologically relevant information that contributes to our understanding of 
the mechanisms by which cytokines lead to aberrant adipose formation and function 
during obesity-associated inflammation. Much is known about the involvement of TNFa 
and various Cxcl inflammatory proteins in adipose inflammation but less is known about 
the gp130 family member, OSM. High circulating levels of OSM are often associated 
with sepsis and cancer (Tomita et al. , 2009; Wang et al. , 2012), but recent data (personal 
communication, Jacqueline Stephens, LSU) suggest that it is also elevated in obese 
individuals (humans . as well as mice) and, therefore, could possibly contribute to insulin 
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resistance. It is well accepted that another member of the gp130 family, IL-6 is an 
important contributor to insulin resistance in vivo (Gimble et al. 1994; Lagathu et al. 
2003; Dandona et al. 2004; Miyaoka et al. 2006; White et al. 2011), and it has been 
shown that IL-6 inhibits GILZ expression in other cell types (Grugan et al. 2008). In fact, 
the knowledge that IL-6, which shares similar signaling pathways as OSM and inhibits 
GILZ expression, first led me to hypothesize that OSM inhibits adipogenesis through the 
suppression of GILZ. 
It is worth noting that OSM only inhibits GILZ expression during the initial 2 
days of adipogenesis in both 3T3-L1 and C3H10Tl/2 cells. In both cells treated with 
OSM, GILZ production is restored to levels measured in untreated cells by 2-4 days. 
Additionally, the adipogenic expression of GILZ peaks soon after this 2-4 day period 
prior to terminal differentiation that occurs at 4-8 days. These two observations are 
consistent with the idea that GILZ functions early in adipogenesis to promote subsequent 
steps and that inhibition at this phase prevents terminal differentiation. It is also important 
to point out that OSM does not block GILZ expression beyond the early phase and an 
explanation for this transient response is that the receptors for OSM signal transduction, 
OSMR and gp130, are only expressed during this time. It is known that OSM exerts its 
biological signaling through the binding of the receptors OSMR and gpl30 (Gomez-
Lechon 1999). Using Northern blotting, Miyaoka et al. demonstrated that expression of 
OSMR and gp130 is most prominent during the first day of adipogenesis in 3T3-L1 
preadipocytes, after which time it falls extensively (Miyaoka et al. 2006). Therefore, the 
identification of GILZ targets will likely bridge these early and late phases. As described 
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m Chapter 2, expressiOn of a few genes including the pro-adipogenic C/EBPcS and 
C/EBP~ (Cao et al. 1991; Wu et al. 1996), as well as anti-adipogenic Pref-1 (Kim et al. 
2007) among others, was analyzed. However, they were not significantly influenced by 
either GILZ OE or its KD according to the preliminary investigation (data not shown). In 
future studies, it will be possible to confirm this and identify targets of GILZ using ChiP-
seq (Chromatin Immunoprecipitation sequencing) of preadipocytes undergoing early 
adipogenesis. 
In questioning what molecular mechanisms might be responsible for OSM' s 
inhibition of GILZ, MEK/ERK and JAK/ST AT5 signaling pathways were analyzed, and 
it was hypothesized that OSM inhibits GILZ through ERK and/or STAT5 activation. 
There are several lines of evidence from the previous literature. It has been shown that 
MEK/ERK and JAK/STAT5 pathways are potently activated by IL-6 family members, 
and they mediate, at least partially, OSM's anti-adipogenic activity (Miyaoka et al. 2006). 
Kim's group also performed independent studies and showed similar results (Song et al. 
2005; Song et al. 2007) in another cell line, hADSC (human Adipose-Derived Stem Cell). 
Therefore, it was questioned if they also mediate OSM's inhibitive activity on GILZ 
expression. Results in this Chapter show that MEK phosphorylation of ERK and JAK 
phosphorylation of STAT5 occurs within the first hour of adipogenesis, and a few hours 
prior to the first detectable decrease in GILZ expression in response to OSM. The 
temporal and sequential correlation of these events suggest that one or both of these 
signaling pathways is the mechanism mediating the inhibitory action of OSM on GILZ 
expression. A previous study has shown that OSM targets TIMPl gene through the 
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activation of ERK phosphorylation, and an ERK inhibitor can uncouple the induction of 
TIMP1 expression by OSM (Nemoto et al. 1996). Similarly, my data indicate that the 
ERK inhibitor U0126 can maintain some level of expression of GILZ in the presence of 
OSM, whereas, the STAT5 inhibitor WHIP was ineffective. 
ERK plays many important roles in growth, differentiation and development 
(Avruch 2007; Keshet et al. 2010). Consistent with previous studies (Tong et al. 2004; 
Pollack et al. 2007; Baker et al. 2008), here it was shown that the adipogenic inducers 
transiently stimulated ERK phosphorylation during the first few hours of adipogenesis, 
and OSM enhanced and prolonged this response (Figure 19). It has been suggested that 
ERK signaling regulates adipogenesis, but conflicting conclusions have resulted from the 
many studies on this topic (Sale et al. 1995; Hu et al. 1996; Camp et al. 1997; Prusty et 
al. 2002; Tang et al. 2003). Previous studies from our lab suggest that the rapid activation 
of MEKJERK signaling is pro-adipogenic and its prolongation by various factors is anti-
adipogenic (Prusty et al. 2002). It is now generally accepted that ERK is required for 
adipogenesis, but deregulation of its activation is anti-adipogenic (Bost et al. 2005; 
Miyaoka et al. 2006). By the same token, the uncontrolled activation of ERK activation 
by OSM may also lead to the suppression of GILZ. The results presented here are 
consistent with those earlier studies showing that the inhibitory action of OSM on GILZ 
and adipogenesis is likely due to its prolongation of MEK activity (Hu et al. 1996; Camp 
et al. 1997). Another line of evidence is that both ERK and GILZ converge on the 
glucocorticoid signaling pathway: glucocorticoid inhibits ERK phosphorylation and 
induces GILZ (Kassel et al. 2001; Beaulieu et al. 2010). A previous study by the Sul 
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group has shown that pref-1, a known inhibitor of adipogenesis, activates ERK 
phosphorylation, which is the molecular mechanism of how it inhibits adipocyte 
differentiation (Kim et al. 2007). Interesting, pref-1 expression is suppressed by Dex (Sul 
2009). It is reasonable to speculate, therefore, that pref-1 may suppress GILZ expression 
through the activation of ERK phosphorylation. In this case Dex promotes adipogenesis 
by inducing GILZ and attenuating pref-1 expression. The fact that the ERK inhibitor 
U0126 almost completely blocks MEK activity but only partially prevented the inhibitory 
action of OSM means that other signaling pathways must be involved in controlling 
GILZ expression. The identification of these pathways will be an interesting follow-up 
project. To my knowledge, my studies are the first to show that the MEKIERK pathway 
mediates in part the suppression of GILZ expression by OSM. Interestingly, it has been 
shown that GILZ inhibits ERK phosphorylation in NIH-3T3 cells and a hybridoma T-cell 
line 3DO (Ayroldi et al. 2002; Ayroldi et al. 2007). Therefore, there may exist reciprocal 
feedback suppression between ERK phosphorylation and GILZ expression. However, the 
detailed regulation between GILZ and ERK in adipocytes has not been elucidated, and 
may be an interesting follow-up project. 
In my study, the separate effects ofERK1 and ERK2 have not been elucidated. In 
the in vivo studies, the individual ERKs have been shown to play different roles in 
development and adipocytes. ERK2 knock out mice are embryonic lethal (Saba-El-Leil et 
al. 2003), ERK1 knock out mice, on the other hand, are viable and fertile, consistent with 
different roles for the two isoforms in development (Mazzucchelli et al. 2002). However 
ERKl has been shown to play important roles in the development of fat cells in vivo as 
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ERKI knock out mice show less adipocytes and decreased adiposity compared to the 
wild-type animals. ERKI knock out mice are also more resistant to obesity · and have 
improved insulin sensitivity when challenged with a high-fat diet (Bost et al. 2005). 
Furthermore, it was found that ERKI /2 activity is higher in type 2 diabetes patients 
compared to healthy individuals (Carlson et al. 2003). It will also be interesting to 
determine which isoform of ERK is the principal regulator for expression of GILZ. The 
fact that ERK is an important regulator of metabolism (Zhang et al. 2011; Traves et al. 
2012), my findings showing that GILZ is a target of ERK may contribute to our 
understanding of obesity and insulin resistance. 
Studies during the past years demonstrated that STAT5 signaling plays important 
roles in adipogenesis (Richard et al. 2011). It has been known for a long time that OSM 
induces STAT5 phosphorylation (Schindler et al. 1995); several groups also found that 
the suppression of ST AT5 signaling by introducing a dominant negative form of ST A T5 
or ST AT5 chemical inhibitors prevent the inhibition of adipogenic genes by OSM 
(Miyaoka et al. 2006; Song et al. 2007). Results in Chapter 2 collectively suggest that 
GILZ is a pro-adipogenic gene, and preliminary results demonstrated that the induction 
of STAT5 phosphorylation occurs slightly before the induction of STAT5 by OSM and 
adipogenic cocktail. Therefore, these observations led to my hypothesis that OSM 
suppresses GILZ expression through the activation of ST AT5 phosphorylation. However, 
the present data shown do not support this hypothesis or the studies by others since 
inhibition of STAT5 activity did not prevent the inhibitory effects of OSM on GILZ. In 
fact, this observation is consistent with a large group of studies demonstrating the pro-
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adipogenic, rather than anti-adipogenic, roles of STAT5 in adipogenesis: 1) it has been 
shown that in cultured cells STAT5 expression increases during adipogenesis (Stephens 
et al. 1996) and its activation (phosphorylation) occurs during the first several hours of 
differentiation (Nanbu-Wakao et al. 2002); 2) a dominant negative form of STAT5 
inhibits PP ARy activity (Kawai et al. 2007) and ectopic STAT5 expression induces 
adipogenesis in 3T3-L1 and 3T3-F442A preadipocyte (Shang et al. 2003 ; Wakao et al. 
2011) and in non-precursor fibroblast cells (BALB/c and NIH-3T3) (Floyd et al. 2003). It 
is worth noting that there are distinct expression patterns and functions of ST AT5 
expression and phosphorylation during preadipocyte differentiation. Its phosphorylation 
occurs rapidly in response to the adipogenic inducers but its production does not increase 
until the activation of PP ARy (Richard et al. 2011 ). In fact, studies from this group 
demonstrated that PP ARy induces STAT5 in a ligand dependent manner (Stephens et al. 
1999). To my knowledge, no previous studies have been reported to examine if ST AT5 
phosphorylation affects GILZ expression. Many studies have investigated the interaction 
between GRand STAT5, the first of which was in 1996 (Stocklin et al. 1996). It has been 
shown that GR binds to STAT5, resulting in enhancement of STAT5's DNA binding 
activity without affecting STAT5 protein expression and this effect is through the 
prolongation of STAT5 phosphorylation (Wyszomierski et al. 1999). Additional studies 
by others, Stephens and coworkers (Baugh et al. 2007) also showed that STAT5A forms 
a complex with GRin 3T3-L1 adipocytes, and it is phosphorylated in the complex found 
in nucleus. They showed a correlation between formation of the complex in the nucleus 
and phosphorylation of ST AT5A. In the paper, it was not discussed if the interaction 
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changes the activity of GR or expression of its downstream effectors; however, it was 
shown that the activation of STAT5A does not change the total amount of GR in nucleus 
(Baugh et al. 2007). This is consistent with my data indicating that the induced 
phosphorylation of STAT5 by OSM is not the cause of the suppression of GILZ, a target 
of GR. This suggests that although the association of STAT5 with GR induces the 
binding to target genes, its phosphorylation by OSM appears to have no effect on 
expression of target genes, at least GILZ. 
In conclusion, this is the first evidence identifying GILZ as a pro-adipogenic 
effector, which is the target for the anti-adipogenic activity of OSM. 
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FUTURE DIRECTIONS 
The glucocorticoid-signaling pathway plays a crucial role in the in vitro 
development of fat cells, and is associated with the metabolic syndrome. Moreover, it has 
also been implicated in the development of other cell types, like bone cells (Nishimura et 
al. 2000; Shaker et al. 2005; Woolf 2007). My particular interest is to understand how 
components of the glucocorticoid-signaling pathway, especially GILZ, can affect these 
aforementioned processes. This thesis laid out a basic framework for the glucocorticoid-
GR-GILZ axis and OSM-ERK-GILZ axis in the in vitro adipocyte development as 
summarized in Figure 24, and one of the key fmdings here is the identification of GILZ 
as an important mediator for Dex/GR' s pro-adipogenic and OSM's anti-adipogenic 
activity in the development of fat cells. This study introduces a new pro-adipogenic factor 
in the network of adipogenesis. It may also contribute to our understanding of various 
metabolic diseases, including, obesity, insulin resistance and Cushing' s syndrome. 
Significant progress has been made in the past several years; however, there are still 
many questions worth future investigation. 
This dissertation started with the identification of gene programs down regulated 
during the early phase of adipogenesis. Chapter 1 demonstrated that Dex-GR plays a 
principal role in suppressing selected cytokine/chemokine genes and is required for 
adipogenesis. However, recombinant cytokines/chemokines failed to suppress adipocyte 
gene expression. It is suggested that the choice of the three representatives, Ccl2, Cxcll 
and Cxcl5, is acceptable for studying glucocorticoid-associated gene regulation, but not 
for understanding the role of glucocorticoids in mediating the early phase of 
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adipogenesis. In the future, other genes could be chosen within the cytokine/chemokine 
gene program to test if their suppression 
Figure 24. 
OSMR/gp130 
······~· 
I\ 
! 1 Others? 
Figure 24. Working model for the studies. 
L 1 preadipocyte 
C3H10T1/2 MSC 
WAT, BAT 
Dex-GR-GILZ signaling pathway plays an essential role in facilitating adipogenesis. 
OSM suppresses adipogenesis by suppressing expression of GILZ, which is mediated 
partially by the activation of ERK phosphorylation. 
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mediate glucocorticoids' role in the early phase of adipogenesis. Other gene programs 
that I would most likely focus on if I undertook further studies would include the 
extracellular matrix gene program (like fibronectin, collagens, MMP3, MMP14, and 
TIMP1). Some studies, for instance, have suggested a role for fibronectin in facilitating 
the anti-adipogenic activity ofPrefl (Wang et al. 2010). 
Chapter 2 profiled the roles of GILZ, a downstream target of Dex and GR, in 
adipogenesis using multiple cultured cell models and found that GILZ is required for 
adipogenesis. Chapter 3 demonstrated that the inflammatory IL-6 family member 
Oncostatin M (OSM) inhibits adipogenesis through the suppression of GILZ, which is 
partially mediated by MEK-associated phosphorylation of ERK. An intriguing question 
for me is: why is GILZ required for adipogenesis or how does it promote adipogenesis. 
The identification of targets of GILZ will be important and feasible to achieve using 
microarrays of RNA from particular stages of in vitro differentiation. A critical time to 
analyze RNA expression will be immediately at the peak of GILZ expression and prior to 
transcription of PP ARy (D2 to D4). As discussed previously, the pro-adipogenic 
transcription factors C/EBP8 and C/EBP~, as well as the anti-adipogenic Pref-1 , are 
potential candidate, as they have all been shown to be targets of glucocorticoid 
(MacDougald et al. 1994; Smas et al. 1999; Wiper-Bergeron et al. 2003; Wiper-Bergeron 
et al. 2007). Biochemical experiments such as qPCR assays and western blot can be used 
to check the RNA and protein expression of these genes in GILZ KD and GILZ OE cells. 
Promoter luciferase assays can also be used to study if GILZ KO or OE affects the 
promoter activity of these genes. In future studies, it will also be possible to verify if 
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GILZ binds to these promoters and to identify additional targets of GILZ using ChiP-seq 
(Chromatin Immunoprecipitation sequencing) of preadipocytes undergoing early 
adipogenesis. 
Another interesting follow up study is to examine if GILZ promotes adipocyte 
differentiation through GILZ's anti-inflammatory activity (D'Adamio et al. 1997; Ayroldi 
et al. 2001; Berrebi et al. 2003; Yang et al. 2008; Cannarile et al. 2009). Transgenic mice 
demonstrate the potential role of GILZ in inhibiting NF -KB nuclear translocation and 
expression of inflammatory genes like IL-6, TNFa and IFN-y in CD4+ T cells 
(Cawthorn et al. 2007), all of which have been known to inhibit adipogenesis in vitro 
(Xing et al. 1997; Cawthorn et al. 2007; Vidal et al. 2012). Especially for TNFa, it has 
been shown to inhibit PP ARy (Xing et al. 1997); its expression is increased in obese 
mouse models and it acts as a mediator for obese induced insulin resistance (Hotamisligil 
et al. 1993). The blockade of TNFa in mice by either mutating the gene or deleting it 
results in improvement and/ or restoration of insulin sensitivity (U ysal et al. 1997; Ventre 
et al. 1997). Therefore, it is likely that the proposed GILZ's pro-adipogenic activities are 
coupled with its ability to increase insulin sensitivity, both of which are through the 
inhibition of inflammatory genes. If this is the case, I suggest that activation of GILZ 
shares similar effects as treating preadipocytes/adipocytes with the thiazolidinedione 
(TZD) class of anti-diabetic drugs. TZDs are potent synthetic PP ARy agonists (Chiarelli 
et al. 2008), which have been shown to drastically induce fat cell development and 
suppress inflammatory genes in vitro (Wang et al. 2008; Duan et al. 2009; Olefsky et al. 
2010). In humans, TZDs increase insulin sensitivity, but lead to weight-gain of patients 
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(Fonseca 2003; Raji et al. 2003; Dandona et al. 2004). The insulin sensitizing activity of 
the TZDs involves their action on adipose tissue including suppression of inflammatory 
proteins in resident adipose macrophages (Hallet al. 2007; Heilbronn et al. 2008). There 
are no studies addressing the potential insulin sensitizing activity of GILZ in people or 
mice. I suggest that this activity, if functioning in people, will involve inhibition of the 
aforementioned inflammatory genes. A strategy to address the importance of GILZ in 
overall metabolism will be to generate cell type specific GILZ knockout mice. It will be 
particularly important to knockout GILZ in preadipocytes and macrophages since these 
two cell types represent the principal inflammatory axis in obese adipose tissue. Mice 
expressing Cre in these cells (prefl-promoter for preadipocytes and Lyz M promoter for 
macrophages) can be crossed with a mouse in which the GILZ gene is floxed to produce 
a powerful in vivo model system. It is possible that the preadipocyte-specific knockout 
mice will be leaner than the wild type controls following a high-fat diet feeding since the 
development of fat cells will be impaired without GILZ. Consequently, the KO mice will 
be less likely to develop insulin resistance because they will not accumulate as much fat 
as the controls. In the case of the macrophage KO mice, they are likely to be lean and 
severely insulin resistant because the enhanced secretion of inflammatory proteins from 
adipose macrophages will inhibit adipogenesis, but also promote insulin resistance. In the 
longer run, a GILZ specific agonist can be screened to test its effect in diabetes disease 
model such as db/ db mice. db/ db mice will develop insulin resistance and diabetes due to 
the deletion of Leptin receptor (Kobayashi et al. 2000) and higher expression of 
inflammation genes (Xu et al. 2003). Treatment of diabetic mice with GILZ agonist may 
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result in weight-gain, but with lower expressiOn of inflammatory genes and better 
metabolism profile, which will be similar to the treatment with TZD class anti-diabetic 
drugs (Day 1999) and also similar to the phenotype in Brd2 disruption heterozygous mice 
(Denis 201 0). 
In addition to fat development, another possible future direction is to examine 
roles of glucocorticoid and GILZ in the determination and differentiation of other cell 
types, like bone cells. Dex has been shown to play an important role in bone development 
in vitro and in vivo (Nishimura et al. 2000; Shaker et al. 2005; Woolf 2007). It has been 
known for a long time that long term chronic glucocorticoid therapy correlates with the 
loss of bone density (osteoporosis) (Locascio et al. 1990; Nishimura et al. 2000). 
Glucocorticoid induced osteoporosis (GIO) is one of the most serious complications of 
Cushing's syndrome. The exact mechanism of how glucocorticoid regulates bone 
metabolism is not completely understood. Studies have suggested that glucocorticoids 
lead to decreases in bone formation through suppression of osteoblastogenic 
differentiation and osteoblast function as well as induction of osteoblast apoptosis (Lekva 
et al. 2010; Toth et al. 2013). Lekva and coworkers demonstrated that GILZ is one of the 
two most up-regulated genes in bone biopsies of patients with Cushing's syndrome after 
surgical treatment (Lekva et al. 2010). Additionally, this report showed that GILZ is 
involved in the osteoblast differentiation and maturation: GILZ expression is modulated 
by Dex in a time- and dose- dependent fashion in human fetal osteoblasts (hFOB); and 
KD of GILZ in hFOB results in a decrease of osteoblast related genes such as alkaline 
phosphatase (ALP), c-FOS, runt-related transcription factor 2 (RUNX2) and osteocalcin 
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(OC) (Lekva et al. 2010). Another group, He and coworkers recently showed that GILZ 
OE promotes osteogenic differentiation in mouse MSCs, and it antagonizes TNFa's anti-
osteogenic activity (He et al. 2012). The exact role of glucocorticoid and GILZ in bone 
differentiation still requires further investigation. Based on the fact that GILZ is required 
for the differentiation of adipocyte in vitro, it will be interesting to pursue studies on the 
role of GILZ in regulating MSCs to other lineages including bone. It has been suggested 
that suppression of osteoblast differentiation of bone marrow stromal cells is coupled 
with the induction of adipocyte differentiation as a result of a decrease of BMP2, 
Wnt/beta-catenin pathway and an increase of PP ARy2 and C/EBP proteins (Canalis et al. 
2007; Pierotti et al. 2008). In mice excess glucocorticoid can also lead to the early 
activation of adipogenesis and suppression of osteogenesis (Y ao et al. 2008). Therefore, 
it will be interesting to examine if the differential regulation of bone and fat development 
by Dex is through GILZ. Data in this dissertation have shown that GILZ is required for 
differentiation of CH31 OTl/2 MSCs to both white and brown adipocytes. And in follow 
up experiments, similar methods could be used to test role of GILZ in osteogenesis using 
the same C3H10Tl/2 MSCs. 
Regarding bone differentiation, another direction worth pursuing is the role of 
OSM in osteogenesis in vitro. A report published by the Kim group suggests a reciprocal 
effect of OSM on adipogenesis and osteogenesis. They showed that OSM inhibits 
adipocyte differentiation and at the same time promotes bone differentiation in human 
adipose tissue-derived stem cells (Song et al. 2007). It will be interesting in future studies 
to identify the targets of OSM in bone progenitors that promote differentiation, especially 
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to test the hypothesis that target genes may include GILZ. It has been shown in Chapter 3 
that OSM targets GILZ in adipogenesis. And as discussed before, GILZ may play an 
important role in bone development other than fat. It is therefore possible that attenuation 
of GILZ by OSM is required for bone development and such a mechanism might signify 
differences in commitment of MSCs to fat versus bone. 
Besides what has been discussed, there are other directions worth pursuing: to 
examine if GILZ is a target of IL-6 in inducing insulin resistance and type 2 diabetes; to 
explore roles of Dex-GR-GILZ in the development of Cushing' s syndrome; to study if 
GILZ interacts with other leucine-zipper proteins like C/EBP8 and C/EBP~; to test if the 
mineralocorticoid receptor (MR) is involved in adipogenesis and if it is through GILZ. 
Beyond that, GILZ has been implicated as a therapeutic target for many inflammation 
related diseases (Fan et al. 2012) and my studies raise the possibility that it might also be 
a therapeutic target for obesity, insulin resistance and diabetes. 
125 
LIST of JOURNAL ABBREVIATIONS 
Acta Med Scand Suppl 
AmJMed 
Am J Physiol 
Ann Intern Med 
Ann Ital Med Int 
Ann N Y Acad Sci 
Annu Rev Irnmunol 
Annu Rev Physiol 
Br J Nutr 
Br Med Bull 
BMJ 
Cell Mol Life Sci 
Clin Endocrinol 
Clin Endocrinol Metab 
Curr Opin Lipidol 
Curr Opin Nephrol Hypertens 
Curr Pharm Des 
Discov Med 
Endocrinol Metab Clin North Am 
Acta Medica Scandinavica Supplementum 
American Journal of Medicine 
American Journal of Physiology 
Annals of Internal Medicine 
Annali Italiani di Medicina Interna 
Annals of the New York Academy of Sciences 
Annual Review of Immunology 
Annual Review of Physiology 
British Journal of Nutrition 
British Medical Bulletin 
British Medical Journal 
Cellular and Molecular Life Sciences 
Clinical Endocrinology 
Clinical Endocrinology & Metabolism 
Current Opinion in Lipidology 
Current Opinion in Nephrology and 
Hypertension 
Current Pharmaceutical Design 
Discovery Medicine 
Endocrinology and Metabolism Clinics of North 
126 
EMBORep 
Exp Biol Med 
Genes Dev 
Int J Biochem Cell Biol 
In Vitro Cell Dev Biol Anim 
FASEB J 
Int JObes 
JAMA 
J Anat 
J Biol Chern 
J Cell Biol 
J Cell Biochem 
J Cell Commun Signal. 
J Clin Endocrinol Metab 
J Clin Invest 
J Endocrinol 
J Immunol 
JNutr 
J Proteome Res 
America 
EMBO Report 
Experimental Biology and Medicine 
Genes & Development 
The International Journal ofBiochemistry & 
Cell Biology 
In Vitro Cellular & Developmental Biology 
F ASEB Journal 
International Journal of Obesity 
Journal of the American Medical Association 
Journal of Anatomy 
Journal ofBiological Chemistry 
The Journal of Cell Biology 
Journal of Cellular Biochemistry 
Journal of Cell Communication 
The Journal of Clinical Endocrinology & 
Metabolism 
The Journal of Clinical Investigation 
Journal ofEndocrinology 
Journal oflmmunology 
Journal ofNutrition 
Journal of Pro teo me Research 
127 
Lab Invest 
Mediators Inflamm 
Methods Mol Biol 
Morb Mortal Wkly Rep 
Mol Biol Cell 
Mol Endocrinol 
N Engl JMed 
Nat Cell Biol 
Nat Genet 
Nat Protoc 
Nat Rev Genet 
Nucleic Acids Res 
Obes Rev 
Osteoporos Int 
Orv Hetil 
Physiol Endocrinol Metab 
PPARRes 
Proc Natl Acad Sci USA 
Proc Nutr Soc 
Sci. STKE 
Sports Med 
Laboratory Investigation 
Mediators of Inflammation 
Methods in Molecular Biology 
Morbidity and Mortality Weekly Report 
Molecular Biology of the _Cell 
Molecular Endocrinology 
The New England Journal of Medicine 
Nature Cell Biology 
Nature Genetics 
Nature Protocols 
Nature Reviews Genetics 
Nucleic Acids Research 
Obesity Reviews 
Osteoporosis International 
Orvosi Hetilap 
Physiology Endocrinology and Metabolism 
PP AR Research 
Proceedings of the National Academy of 
Sciences of the United States of America 
Proceedings of the Nutrition Society 
Signal Transduction Knowledge Environment 
Sports Medicine 
128 
V asc Health Risk Manag Vascular Health and Risk Management 
129 
REFERENCES 
Sherry et al. 2010. "Vital signs: state-specific obesity prevalence among adults--- United 
States, 2009." Morb Mortal Wkly Rep 59(30): 951-955. 
Aas, A.M., J. Ohrvik, K. Malmberg, L. Ryden, K. I. Birkeland, et al. (2009). "Insulin-
induced weight gain and cardiovascular events in patients with type 2 diabetes. A report 
from the DIGAMI 2 study." Diabetes, Obesity and Metabolism 11(4): 323-329. 
Ahima, R. S. (2006). "Adipose tissue as an endocrine organ." Obesity 14: 242-249. 
Alangari, A. A. (2010). "Genomic and non-genomic actions of glucocorticoids in 
asthma." Annals of Thoracic Medicine 5(3): 133-139. 
Allison, D. B., K. R. Fontaine, J. E. Manson, J. Stevens and T. B. Vanltallie (1999). 
"Annual deaths attributable to obesity in the United States." JAMA 282(16): 1530-1538. 
Asada, M., A. Rauch, H. Shimizu, H. Maruyama, S. Miyaki, et al. (2011). "DNA 
binding-dependent glucocorticoid receptor activity promotes adipogenesis via Kruppel-
like factor 15 gene expression." Lab Invest 91(2): 203-215. 
Ashwell, J.D., F. W . Lu and M.S. Vacchio (2000). "Glucocorticoids in T cell 
development and function*." Annu Rev Immunol18: 309-345. 
Asselin-Labat, M.-L., M. David, A. Biola-Vidarnment, D. Lecoeuche, M.-C. Zennaro, et 
al. (2004). "GILZ, a new target for the transcription factor Fox03, protects T 
lymphocytes from interleukin-2 withdrawal-induced apoptosis." Blood 104(1): 215-223. 
A vruch, J. (2007). "MAP kinase pathways: The first twenty years." Biochimica Et 
Biophysica Acta-Molecular Cell Research 1773(8): 1150-1160. 
Ayroldi, E., G. Migliorati, S. Bruscoli, C. Marchetti, 0. Zollo, et al. (2001). "Modulation 
ofT-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of 
nuclear factor kappa B." Blood 98(3): 743-753 . 
Ayroldi, E. and C. Riccardi (2009). "Glucocorticoid-induced leucine zipper (GlLZ): a 
new important mediator of glucocorticoid action." FASEB J 23(11): 3649-3658. 
Ayroldi, E., 0. Zollo, A. Bastianelli, C. Marchetti, M. Agostini, et al. (2007). "GILZ 
mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras 
signaling." J Clin Invest 117(6): 1605-1615. 
130 
Ayroldi, E., 0. Zollo, A. Macchiarulo, B. DiMarco, C. Marchetti, et al. (2002). 
"Glucocorticoid-induced leucine zipper inhibits the raf-extracellular signal-regulated 
kinase pathway by binding to Raf-1." Molecular and Cellular Biology 22(22): 7929-7941. 
Balhoff, J.P. and J. M. Stephens (1998). "Highly Specific and Quantitative Activation of 
STATs in 3T3-L1 Adipocytes." Biochemical and Biophysical Research Communications 
247(3): 894-900. 
Bamberger, C. M., A.M. Bamberger, M. de Castro and G. P. Chrousos (1995). 
"Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action 
in humans." J Clin Invest 95(6): 2435-2441. 
Bamberger, C. M., H. M. Schulte and G. P. Chrousos (1996). "Molecular Determinants 
of Glucocorticoid Receptor Function and Tissue Sensitivity to Glucocorticoids." 
Endocrine Reviews 17(3): 245-261. 
Barnes, P. J. and I. M. Adcock (2009). "Glucocorticoid resistance in inflammatory 
diseases." Lancet 373(9678): 1905-1917. 
Bartelt, A. and J. Heeren (2012). "The holy grail of metabolic disease: brown adipose 
tissue." Curr Opin Lipidol. 
Baugh, J. E., Jr., Z. E. Floyd and J. M. Stephens (2007). "The modulation of 
STAT5A/GR complexes during fat cell differentiation and in mature adipocytes." 
Obesity (Silver Spring) 15(3): 583-590. 
Bell, C. G., A. J. Walley and P. Froguel (2005). "The genetics ofhuman obesity." Nat 
Rev Genet 6(3): 221-234. 
Bemot, D., E. Barruet, M. Poggi, B. Bonardo, M.-C. Alessi, et al. (2010). "Down-
regulation of Tissue Inhibitor ofMetalloproteinase-3 (TIMP-3) Expression Is Necessary 
for Adipocyte Differentiation." J Biol Chern 285(9): 6508-6514. 
Bemot, D., E. Barruet, M. Poggi, B. Bonardo, M. C. Alessi, et al. (2010). "Down-
regulation oftissue inhibitor ofmetalloproteinase-3 (TIMP-3) expression is necessary for 
adipocyte differentiation." J Bio1 Chern 285(9): 6508-6514. 
Berrebi, D., S. Bruscoli, N. Cohen, A. Foussat, G. Migliorati, et al. (2003). "Synthesis of 
glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and 
immunosuppressive mechanism shared by glucocorticoids and IL-10." Blood 101(2): 
729-738. 
Bogner-Strauss, J. G., A. Prokesch, F. Sanchez-Cabo, D. Rieder, H. Hackl, et al. (2010). 
"Reconstruction of gene association network reveals a transmembrane protein required 
for adipogenesis and targeted by PPARgarnma." Cell Mol Life Sci 67(23): 4049-4064. 
131 
Bomsztyk, K. , B. Toivola, D. W. Emery, J. W. Rooney, S. K. Dower, et al. (1990) . "Role 
of Camp in Interleukin-1-Induced Kappa-Light Chain Gene-Expression in Murine B-Cell 
Line." J Biol Chern 265(16): 9413-9417. 
Bost, F., M. Aouadi, L. Caron, P. Even, N. Belmonte, et al. (2005). "The Extracellular 
Signal-Regulated Kinase Isoform ERK1 Is Specifically Required for In Vitro and In 
Vivo Adipogenesis." Diabetes 54(2): 402-411. 
Boumpas, D. T. , G. P. Chrousos, R. L. Wilder, T. R. Cupps and J. E. Balow (1993). 
"Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates." 
Ann Intern Med 119(12): 1198-1208. 
Bowers, R. R. , J. W. Kim, T. C. Otto and M.D. Lane (2006). "Stable stem cell 
commitment to the adipocyte lineage by inhibition of DNA methylation: role of the 
BMP-4 gene." Proc Natl Acad Sci US A 103(35): 13022-13027. 
Bowers, R. R. and M.D. Lane (2008). "Wnt signaling and adipocyte lineage 
commitment." Cell Cycle 7(9): 1191-1196. 
Burton, G. R. , Y. Guan, R. Nagarajan and R. E. McGehee Jr (2002). "Microarray analysis 
· of gene expression during early adipocyte differentiation." Gene 293(1-2): 21-31. 
Burton, G. R. , R. Nagarajan, C. A. Peterson and R. E. McGehee Jr (2004). "Microarray 
analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis." Gene 
329(0): 167-185. 
Camp, H. S. and S. R. Tafuri (1997). "Regulation of peroxisome proliferator-activated 
receptor gamma activity by mitogen-activated protein kinase." J Biol Chern 272(16): 
10811-10816. 
Canalis, E., G. Mazziotti, A. Giustina and J. P. Bilezikian (2007). "Glucocorticoid-
induced osteoporosis: pathophysiology and therapy." Osteoporos Int 18(1 0): 1319-1328. 
Cannarile, L., S. Cuzzocrea, L. Santucci, M. Agostini, E. Mazzon, et al. (2009). 
"Glucocorticoid-Induced Leucine Zipper Is Protective in Th1-Mediated Models of 
Colitis." Gastroenterology 136(2): 530-541. 
Cannarile, L. , 0. Zollo, F. D'Adamio, E. Ayroldi, C. Marchetti, et al. (2001). "Cloning, 
chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid 
hormone-induced gene." Cell Death and Differentiation 8(2): 201-203. 
Cao, Z., R. M. Umek and S. L. McKnight (1991). "Regulated expression ofthree C/EBP 
isoforms during adipose conversion of3T3-L1 cells." Genes Dev 5(9): 1538-1552. 
132 
Carlson, C. J. , S. Koterski, R. J. Sciotti, G. B. Poccard and C. M. Rondinone (2003). 
"Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 
2 diabetes: potential role ofp38 in the downregulation ofGLUT4 expression." Diabetes 
52(3): 634-641. 
Cawthorn, W. P., F. Heyd, K. Hegyi and J. K. Sethi (2007). "Tumour necrosis factor-
alpha inhibits adipogenesis via a beta-catenin/TCF4(TCF7L2)-dependent pathway." Cell 
Death and Differentiation 14(7): 1361-1373. 
Charo, I. F. and R. M. Ransohoff (2006). "The many roles of chemokines and chemokine 
receptors in inflammation." N Engl J Med 354(6): 610-621. 
Chavey, C., G. Lazennec, S. Lagarrigue, C. Clape, I. Iankova, et al. (2009). "CXC Ligand 
5 Is an Adipose-Tissue Derived Factor that Links Obesity to Insulin Resistance." Cell 
Metabolism 9(4): 339-349. 
Chavey, C., G. Lazennec, S. Lagarrigue, C. Clape, I. Iankova, et al. (2009). "CXC Ligand 
5 Is an Adipose-Tissue Derived Factor that Links Obesity to Insulin Resistance." Cell 
Metabolism 9(4): 339-349. 
Chen, G., C. Liu, J. Yao, Q. Jiang, N. Chen, et al. (2010). "Overweight, obesity, and their 
associations with insulin resistance and beta-cell function among Chinese: a cross-
sectional study in China." Metabolism 59(12): 1823-1832. 
Chiarelli, F. and D. DiMarzio (2008). "Peroxisome proliferator-activated receptor-
gamma agonists and diabetes: current evidence and future perspectives." Vase Health 
Risk Manag 4(2): 297-304. 
Christy, R. J., K. H. Kaestner, D. E. Geiman and M.D. Lane (1991). "CCAAT/enhancer 
binding protein gene promoter: binding of nuclear factors during differentiation of3T3-
L1 preadipocytes." Proc Natl Acad Sci US A 88(6): 2593-2597. 
Cohen, N., A. Emilie and J. Morisset (2004). "Modulation of glucocorticoid-induced 
leucine zipper (GILZ) synthesis on macrophages functions." Immunology 2004: 
Cytokine Network, Regulatory Cells, Signaling, and Apoptosis: 81-85. 
Coppack, S. W. (2001). "Pro-inflammatory cytokines and adipose tissue." Proc Nutr Soc 
60(3): 349-356. 
D'Adamio, F., 0. Zollo, R. Moraca, E. Ayroldi, S. Bruscoli, et al. (1997). "A New 
Dexamethasone-Induced Gene of the Leucine Zipper Family Protects T Lymphocytes 
from TCR/CD3-Activated Cell Death." Immunity 7(6): 803-812. 
Dandona, P., A. Aljada and A. Bandyopadhyay (2004). "Inflammation: the link between 
insulin resistance, obesity and diabetes." Trends in Immunology 25(1 ): 4-7. 
133 
Damay, B. G. and B. B. Aggarwal (1997). "Early events in lNF signaling: A story of 
associations and dissociations." Journal ofLeukocyte Biology 61(5): 559-566. 
Darnell, J. E. (1997). "STATs and gene regulation." Science 277(5332): 1630-1635. 
Darnell, J. E., I. M. Kerr and G. R. Stark (1994). "Jak-Stat Pathways and Transcriptional 
Activation in Response to Ifns and Other Extracellular Signaling Proteins." Science 
264(5164): 1415-1421. 
Day, C. (1999). "Thiazolidinediones: a new class of antidiabetic drugs." Diabet Med 
16(3): 179-192. 
de Kloet, E. R., M. S. Oitzl and M. Joels (1999). "Stress and cognition: are 
corticosteroids good or bad guys?" Trends in Neurosciences 22(10): 422-426. 
Deeb, S. S., L. Fajas, M. Nemoto, J. Pihlajamaki, L. Mykkanen, et al. (1998). "A 
Pro12Ala substitution in PPAR[gamma]2 associated with decreased receptor activity, 
lower body mass index and improved insulin sensitivity." Nat Genet 20(3): 284-287. 
Delfino, D. V., M. Agostini, S. Spinicelli, C. Vacca and C. Riccardi (2006). "Inhibited 
cell death, NF-kappaB activity and increased IL-10 in TCR-triggered thymocytes of 
transgenic mice overexpressing the glucocorticoid-induced protein GILZ." Int 
lmmunopharmacol 6(7): 1126-1134. 
Delfmo, D. V., M. Agostini, S. Spinicelli, P. Vito and C. Riccardi (2004). "Decrease of 
Bcl-xL and augmentation ofthymocyte apoptosis in GILZ overexpressing transgenic 
mice." Blood 104(13): 4134-4141. 
Delfino, D. V., M. Agostini, S. Spinicelli, P. Vito and C. Riccardi (2004). "Decrease of 
Bcl-xL and augmentation ofthymocyte apoptosis in GILZ overexpressing transgenic 
mice." Blood 104(13): 4134-4141. 
Denis, G. V. (2010). "Bromodomain coactivators in cancer, obesity, type 2 diabetes, and 
inflammation." Discov Med 10(55): 489-499. 
Dey, G., A. Radhakrishnan, N. Syed, J. K. Thomas, A. Nadig, et al. (2012). "Signaling 
network ofOncostatin M pathway." J Cell Commun Signal. 
Dhillon, A. S., S. Hagan, 0. Rath and W. Kolch (2007). "MAP kinase signalling 
pathways in cancer." Oncogene 26(22): 3279-3290. 
Ding, D. C., W. C. Shyu and S. Z. Lin (2011). "Mesenchymal stem cells." Cell 
Transplant 20(1): 5-14. 
Dionne, I. J., M. J. Garant, A. A. Nolan, T. I. Pollin, D. G. Lewis, et al. (2002). 
"Association between obesity and a polymorphism in the beta(l)-adrenoceptor gene 
134 
(Gly389Arg ADRB1) in Caucasian women." International Journal of Obesity 26(5): 633-
639. 
Dixon, J. B. (2010). "The effect of obesity on health outcomes." Molecular and Cellular 
Endocrinology 316(2): 104-108. 
Dobson, M.G., C. P. F. Redfern, N. Unwin and J. U. Weaver (2001). "The N363S 
Polymorphism of the Glucocorticoid Receptor: Potential Contribution to Central Obesity 
in Men and Lack of Association with Other Risk Factors for Coronary Heart Disease and 
Diabetes Mellitus." Journal of Clinical Endocrinology & Metabolism 86(5): 2270-2274. 
Donath, M. Y. and S. E. Shoelson (2011). "Type 2 diabetes as an inflammatory disease." 
Nature Reviews Immunology 11(2): 98-107. 
Drewnowski, A. (2004). "Obesity and the food environment: Dietary energy density and 
diet costs." American Journal ofPreventive Medicine 27(3, Supplement): 154-162. 
Drewnowski, A. and S. Specter (2004). "Poverty and obesity: the role of energy density 
and energy costs." The American Journal of Clinical Nutrition 79(1): 6-16. 
Duan, S. Z., M.G. Usher and R. M. Mortensen (2009). "PPARs: the vasculature, 
inflammation and hypertension." Curr Opin Nephrol Hypertens 18(2): 128-133. 
Duncan, B., M. Schmidt, J. Pankow, C. Ballantyne, D. Couper, et al. (2003). "Low-grade 
systemic inflammation and the development of type 2 diabetes mellitus- The ARIC 
study." Diabetes 52: A58-A58. 
Duncan, B. B., M. I. Schmidt, J. S. Pankow, C. M. Ballantyne, D. Couper, et al. (2003). 
"Low-grade systemic inflammation and the development of type 2 diabetes- The 
atherosclerosis risk in communities study." Diabetes 52(7): 1799-1805. 
Fain, J. N. (2006). "Release of interleukins and other inflammatory cytokines by human 
adipose tissue is enhanced in obesity and primarily due to the nonfat cells." Interleukins 
74: 443-477. 
Fajas, L., D. Auboeuf, E. Raspe, K. Schoonjans, A.M. Lefebvre, et al. (1997). "The 
organization, promoter analysis, and expression of the human PP ARgamma gene." J Biol 
Chern 272(30): 18779-18789. 
Fan, H. and E. F. Morand (2012). "Targeting the side effects of steroid therapy in 
autoimmune diseases: the role ofGILZ." Discovery Medicine 13(69): 11. 
Farmer, S. R. (2006). "Transcriptional control of adipocyte formation." Cell Metabolism 
4( 4): 263-273. 
135 
Feng, T. S., E. Szabo, E. Dziak and M. Opas (2010). "Cytoskeletal Disassembly and Cell 
Rounding Promotes Adipogenesis from ES Cells." Stem Cell Reviews and Reports 6(1 ): 
74-85. 
Floyd, Z. E. and J. M. Stephens (2003). "STAT5A promotes adipogenesis in 
nonprecursor cells and associates with the glucocorticoid receptor during adipocyte 
differentiation." Diabetes 52(2): 308-314. 
Fonseca, V. (2003). "Effect ofthiazolidinediones on body weight in patients with 
diabetes mellitus." Am J Med 115 Suppl 8A: 42S-48S. 
Frodl, T., A. Carballedo, M. M. Hughes, K. Saleh, A. Fagan, et al. (2012) . "Reduced 
expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6levels are 
associated with reduced hippocampal volumes in major depressive disorder." Transl 
Psychiatry 2: e88. 
Galic, S., J. S. Oakhill and G. R. Steinberg (2010). "Adipose tissue as an endocrine 
organ." Molecular and Cellular Endocrinology 316(2): 129-139. 
Gimble, J. M., C. Morgan, K. Kelly, X. Wu, V. Dandapani, etal. (1995). "Bone 
moq)hogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells." J 
Cell Biochem 58(3): 393-402. 
Gimble, J. M., A. A. Ptitsyn, B. C. Goh, T. Hebert, G. Yu, et al. (2009). "Delta sleep-
inducing peptide and glucocorticoid-induced leucine zipper: potential links between 
circadian mechanisms and obesity?" Obes Rev 10 Suppl2: 46-51. 
Gimble, J. M. , F. Wanker, C. S. Wang, H. Bass, X. Y. Wu, et al. (1994). "Regulation of 
Bone-Marrow Stromal Cell-Differentiation by Cytokines Whose Receptors Share the 
Gp130 Protein." Journal of Cellular Biochemistry 54(1): 122-133. 
Golay, A. and J. Ybarra (2005). "Link between obesity and type 2 diabetes." Best 
Practice &amp; Research Clinical Endocrinology &amp; Metabolism 19(4): 649-663. 
Green, H. and 0. Kehinde (1975). "An established preadipose cell line and its 
differentiation in culture. II. Factors affecting the adipose conversion." Cell 5(1 ): 19-27. 
Green, H. and 0. Kehinde (1975). "An established preadipose cell line and its 
differentiation in culture. II. Factors affecting the adipose conversion." Cell5(1): 19-27. 
Green, H. and M. Meuth (1974). "An established pre-adipose cell line and its 
differentiation in culture." Cell3(2): 127-133. 
136 
Gregoire, F., C. Genart, N. Hauser and C. Remacle (1991). "Glucocorticoids induce a 
drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell 
precursors." Experimental Cell Research 196(2): 270-278. 
Gregoire, F. M. (2001). "Adipocyte differentiation: from fibroblast to endocrine cell." 
Exp Biol Med (Maywood) 226(11): 997-1002. 
Gregoire, F. M., C. M. SMAS and H. S. SUL (1998). "Understanding Adipocyte 
Differentiation." Physiological Reviews 78(3): 783-809. 
Grenier, A., M. Dehoux, A. Boutten, M. Arce-Vicioso, G. Durand, et al. (1999). 
"Oncostatin M production and regulation by human polymorphonuclear neutrophils." 
Blood 93(4): 1413-1421. 
Grugan, K. D., C. Ma, S. Singhal, N. L. Krett and S. T. Rosen (2008). "Dual regulation of 
glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-
kinase/ AKT pathways in multiple myeloma." The Journal of Steroid Biochemistry and 
Molecular Biology 110(3-5): 244-254. 
Gustafson, B., S. Gogg, S. Hedjazifar, L. Jenndahl, A. Hammarstedt, et al. (2009). 
"Inflammation and impaired adipogenesis in hypertrophic obesity in man." Am J Physiol 
Endocrinol Metab 297(5): E999-E1003. 
Hall, J. M. and D.P. McDonnell (2007). "The molecular mechanisms underlying the 
pro inflammatory actions of thiazolidinediones in human macro phages." Mol Endocrinol 
21 (8): 1756-1768. 
Hamm, J. K., B. H. Park and S. R. Farmer (2001). "A role for C/EBPbeta in regulating 
peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 
preadipocytes." J Biol Chern 276(21): 18464-18471. 
Hatipoglu, B. A. (2012). "Cushing's syndrome." Journal of Surgical Oncology 106(5): 
565-571. 
Hauner, H. , G. Entenmann, M. Wabitsch, D. Gaillard, G. Ailhaud, et al. (1989). 
"Promoting Effect ofGlucocorticoids on the Differentiation ofHuman Adipocyte 
Precursor Cells Cultured in a Chemically Defined Medium." Journal of Clinical 
Investigation 84(5): 1663-1670. 
Hayashi, R. , H. Wada, K. Ito and I. M. Adcock (2004). "Effects of glucocorticoids on 
gene transcription." European Journal of Pharmacology 500(1-3): 51-62. 
He, L., N. Yang, C. M. !sales and X. M. Shi (2012). "Glucocorticoid-induced leucine 
zipper (GILZ) antagonizes TNF-alpha inhibition of mesenchymal stem cell osteogenic 
differentiation." PLoS One 7 (3): e31717. 
137 
Heaton, J. M. (1972). "The distribution ofbrown adipose tissue in the human." J Anat 
112(Pt 1): 35-39. 
Hecht, K., J. Carlstedt-Duke, P. Stiema, J.-A. Gustafsson, M. Bronnegard, et al. (1997). 
"Evidence That the ~-Isoform of the Human Glucocorticoid Receptor Does Not Act as a 
Physiologically Significant Repressor." J Bioi Chern 272( 42): 26659-26664. 
Heilbronn, L. K. and L. V. Campbell (2008). "Adipose tissue macrophages, low grade 
inflammation and insulin resistance in human obesity." Curr Pharm Des 14(12): 1225-
1230. 
Heimich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, et al. (2003). 
"Principles of interleukin (IL )-6-type cytokine signalling and its regulation." Biochemical 
Joumal374: 1-20. 
Hills, A. P., N. A. King and T. P. Armstrong (2007). "The contribution of physical 
activity and sedentary behaviours to the growth and development of children and 
adolescents: implications for overweight and obesity." Sports Med 37(6): 533-545. 
Hirsch, J. and B. Batchelor (1976). "Adipose tissue cellularity in human obesity." Clin 
Endocrinol Metab 5(2): 299-311. 
Hogan, J. C. and J. M. Stephens (2005). "The regulation of fatty acid synthase by 
STAT5A." Diabetes 54(7): 1968-1975. 
Holland, W. L. , B. T. Bilanan, L. P. Wang, G. Yuguang, K. M. Sargent, et al. (2011). 
"Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 
requires saturated fatty acid-induced cerarnide biosynthesis in mice." J Clin Invest 
121(5): 1858-1870. 
Hollenberg, S.M., C. Weinberger, E. S. Ong, G. Cerelli, A. Oro, et al. (1985). "Primary 
structure and expression of a functional human glucocorticoid receptor eDNA." Nature 
318(6047): 635-641. 
Hosack, D. A. , G. Dennis, B. T. Sherman, H. C. Lane and R. A. Lempicki (2003). 
"Identifying biological themes within lists of genes with EASE." Genome Biology 4( 1 0). 
Hotamisligil, G. S. , N . S. Shargill and B. M. Spiegelman (1993). "Adipose expression of 
tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance." Science 
259(5091): 87-91. 
Hou, S. X., Z. Zheng, X. Chen and N. Perrimon (2002). "The JAK/STAT Pathway in 
Model Organisms: Emerging Roles in Cell Movement." Developmental Cell3(6): 765-
778. 
138 
Hu, E. D. , J. B. Kim, P. Sarraf and B. M. Spiegelman (1996). "Inhibition of adipogenesis 
through MAP kinase-mediated phosphorylation ofPPAR gamma." Science 274(5295): 
2100-2103. 
Hu, F., T. W. Pace and A. H. Miller (2009). "Interferon-alpha inhibits glucocorticoid 
receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells." Brain 
Behav Immun 23(4): 455-463. 
Huang da, W. , B. T. Sherman and R. A. Lempicki (2009). "Bioinformatics enrichment 
tools: paths toward the comprehensive functional analysis of large gene lists." Nucleic 
Acids Res 37(1): 1-13. 
Huang da, W., B. T. Sherman and R. A. Lempicki (2009). "Systematic and integrative 
analysis oflarge gene lists using DAVID bioinformatics resources." Nat Protoc 4( 1 ): 44-
57. 
Huang, H. Y., T. J. Song, X. Li, L. L. Hu, Q. He, et al. (2009). "BMP signaling pathway 
is required for commitment of C3H1 OTl/2 pluripotent stem cells to the adipocyte 
lineage." Proceedings of the National Academy of Sciences of the United States of 
America 106(31): 12670-12675. 
Hull, D. (1966). "The structure and function of brown adipose tissue." Br Med Bull 
22(1): 92-96. 
Ibrahim, M. M. (2010). "Subcutaneous and visceral adipose tissue: structural and 
functional differences." Obesity Reviews 11(1): 11-18. 
Ihle, J. N., B. A. Witthuhn, F. W. Quelle, K. Yamamoto and 0 . Silvennoinen (1995). 
"Signaling Through the Hematopoietic Cytokine Receptors." Annual Review of 
Immunology 13(1): 369-398. 
Kahn, S. E. , R. L. Hull and K. M. Utzschneider (2006). "Mechanisms linking obesity to 
insulin resistance and type 2 diabetes." Nature 444(7121): 840-846. 
Keller, D. C., X. X. Du, E. F. Srour, R. Hoffman and D. A. Williams (1993). 
"Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term 
marrow cultures." Blood 82(5): 1428-1435. 
Kershaw, E. E. and J. S. Flier (2004). "Adipose Tissue as an Endocrine Organ." Journal 
of Clinical Endocrinology & Metabolism 89(6): 2548-2556. 
Keshet, Y. and R. Seger (2010). "The MAP kinase signaling cascades: a system of 
hundreds of components regulates a diverse array of physiological functions." Methods 
Mol Biol661: 3-38. 
139 
Kim, K.-A., J.-H. Kim, Y. Wang and H. S. Sul (2007). "Pref-1 (Preadipocyte Factor 1) 
Activates the MEKJExtracellular Signal-Regulated Kinase Pathway To Inhibit Adipocyte 
Differentiation." Molecular and Cellular Biology 27(6): 2294-2308. 
Klaus, S. (2004). "Adipose tissue as a regulator of energy balance." Current Drug Targets 
5(3): 241-250. 
Klemm, D. J., J. W. Leitner, P. Watson, A. Nesterova, J. E.-B. Reusch, ·et al. (2001). 
"Insulin-induced Adipocyte Differentiation." J Biol Chern 276(30): 28430-28435. 
Kobayashi, K., T. M. Forte, S. Taniguchi, B. Y. Ishida, K. Oka, et al. (2000). "The db/db 
mouse, a model for diabetic dyslipidemia: molecular characterization and effects of 
Western diet feeding." Metabolism 49(1): 22-3 L 
Kratchmarova, I. , D. E. Kalume, B. Blagoev, P. E. Scherer, A. V. Podtelejnikov, et al. 
(2002). "A proteomic approach for identification of secreted proteins during the 
differentiation of 3 T3-L 1 preadipocytes to adipocytes." Molecular & Cellular Proteomics 
1(3): 213-222. 
Lagathu, C., J. P. Bastard, M. Auclair, M. Maachi, J. Capeau, et al. (2003). "Chronic 
interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in 
adipocyte: prevention by rosiglitazone." Biochemical and Biophysical Research 
Communications 311(2): 372-379. 
Landschulz, W. H., P. F. Johnson and S. L. McKnight (1988). "The leucine zipper: a 
hypothetical structure common to a new class of DNA binding proteins." Science 
240(4860): 1759-1764. 
Leaman, D., S. Leung, X. Li and G. Stark (1996). "Regulation of STAT-dependent 
pathways by growth factors and cytokines." FASEB J 10(14): 1578-1588. 
Lee, M. J. and S. K. Fried (2007). "Modulation of glucocorticoid receptors in human 
adipose tissue by tumor necrosis factor alpha." Diabetes 56: A364-A365. 
Lefterova, M. I. and M. A. Lazar (2009). "New developments in adipogenesis." Trends in 
Endocrinology &amp; Metabolism 20(3): 107-114. 
Lekva, T., J. Bollerslev, C. Kristo, 0. K. Olstad, T. Ueland, et al. (2010). "The 
glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful 
treatment of patients with endogenous Cushing's syndrome and may play a role in 
glucocorticoid-induced osteoporosis." J Clin Endocrinol Metab 95(1): 246-255. 
Li, Y. , F. Zhai, X. Yang, E. G. Schouten, X. Hu, et al. (2007). "Determinants of 
childhood overweight and obesity in China." Br J Nutr 97(1): 210-215. 
140 
Litthauer, D. and G. Serrero (1992). "The primary culture of mouse adipocyte precursor 
cells in defmed medium." Comparative Biochemistry and Physiology Part A: Physiology 
101(1): 59-64. 
Locascio, V. , E. Bonucci, B. Imbimbo, P. Ballanti, S. Adami, et al. (1990). "Bone Loss in 
Response to Long-Term Glucocorticoid Therapy." Bone and Mineral8(1): 39-51. 
Lowenberg, M. , A. P. Verhaar, G. R. van den Brink and D. W. Hommes (2007). 
"Glucocorticoid signaling: a nongenomic mechanism forT-cell immunosuppression." 
Trends in Molecular Medicine 13(4): 158-163 . 
Luyckx, V. A. , L. V. Cairo, C. A. Compston, W. L. Phan and T. F. Mueller (2009). 
"Oncostatin M pathway plays a major role in the renal acute phase response." Am J 
Physiol Renal Physiol296(4): F875-883. 
Macdougald, 0. A., P. Cornelius, F. T. Lin, S. S. Chen and M.D. Lane (1994). 
"Glucocorticoids Reciprocally Regulate Expression of the Ccaat/Enhancer-Binding 
Protein-Alpha and Protein-Delta Genes in 3t3-L1 Adipocytes and White Adipose-
Tissue." J Biol Chern 269(29): 19041-19047. 
MacDougald, 0. A., P . Cornelius, F. T. Lin, S. S. Chen and M.D. Lane (1994). 
"Glucocorticoids reciprocally regulate expression ofthe CCAAT/enhancer-binding 
protein alpha and delta genes in 3T3-L1 adipocytes and white adipose tissue." J Biol 
Chern 269(29): 19041-19047. 
MacDougald, 0. A., P. Cornelius, R. Liu and M. D. Lane (1995). "Insulin regulates 
transcription ofthe CCAAT/enhancer binding protein (C/EBP) alpha, beta, and delta 
genes in fully-differentiated 3T3-L1 adipocytes." J Biol Chern 270(2): 647-654. 
MacDougald, 0. A. and S. Mandrup (2002). "Adipogenesis: forces that tip the scales." 
Trends in Endocrinology and Metabolism 13(1 ): 5-11. 
Malik, N. , J. C. Kallestad, N . L. Gunderson, S.D. Austin, M.G. Neubauer, et al. (1989). 
"Molecular-Cloning, Sequence-Analysis, and Functional Expression of a Novel Growth-
Regulator, Oncostatin-M." Molecular and Cellular Biology 9(7): 2847-2853. 
Marnmes, 0., D. Betoulle, R. Aubert, V. Giraud, S. Tuzet, et al. (1998). "Novel 
polymorphisms in the 5' region ofthe LEP gene: association with leptin levels and 
response to low-calorie diet in human obesity." Diabetes 47(3): 487-489. 
Mandrup, S. and M.D. Lane (1997). "Regulating adipogenesis." J Biol Chern 272(9): 
5367-5370. 
Mariman, E. and P. Wang (2010). "Adipocyte extracellular matrix composition, 
dynamics and role in obesity." Cellular and Molecular Life Sciences 67(8): 1277-1292. 
141 
Marshall, S. (2006). "Role of Insulin, Adipocyte Hormones, and Nutrient-Sensing 
Pathways in Regulating Fuel Metabolism and Energy Homeostasis: A Nutritional 
Perspective of Diabetes, Obesity, and Cancer." Sci. STKE 2006(346): re7-. 
Matsumoto, T., M. Ii, H. Nishimura, T. Shoji, Y. Mifune, et al. (2010). "Lnk-dependent 
axis of SCF -cKit signal for osteogenesis in bone fracture healing." Journal of 
Experimental Medicine 207(10): 2207-2223. 
Mazzucchelli, C. , C. Vantaggiato, A. Ciamei, S. Fasano, P. Pakhotin, et al. (2002). 
"Knockout ofERK1 MAP kinase enhances synaptic plasticity in the striatum and 
facilitates striatal-mediated learning and memory." Neuron 34(5): 807-820. 
McManus, R. (2003). "Mechanisms of steroid action and resistance in inflammation and 
disease." J Endocrinol 178(1): 1-4. 
Menzaghi, C. , T. Ercolino, R. DiPaola, A. H. Berg, J. H. Warram, et al. (2002). "A 
Haplotype at the Adiponectin Locus Is Associated With Obesity and Other Features of 
the Insulin Resistance Syndrome." Diabetes 51(7): 2306-2312. 
Mikkelsen, T. S., Z. Xu, X. L. Zhang, L. Wang, J. M. Gimble, et al. (2010). 
"Comparative Epigenomic Analysis ofMurine and Human Adipogenesis." Cell143(1): 
156-169. 
Miyaoka, Y., M. Tanaka, T. Naiki and A. Miyajima (2006). "Oncostatin M inhibits 
adipogenesis through the RAS/ERK and STAT5 signaling pathways." J Biol Chern 
281(49): 37913-37920. 
Mohamed-Ali, V., J. H. Pinkney and S. W. Coppack (1998). "Adipose tissue as an 
endocrine and paracrine organ." International Journal of Obesity 22(12): 1145-1158. 
Molina, H., Y. Yang, T. Ruch, J.-W. Kim, P. Mortensen, et al. (2008). "Temporal 
Profiling of the Adipocyte Proteome during Differentiation Using a Five-Plex SILAC 
Based Strategy." Journal ofProteome Research 8(1): 48-58. 
Moller, D. E. and J. S. Flier (1991). "Insulin resistance--mechanisms, syndromes, and 
implications." N Engl J Med 325(13): 938-948. 
Montague, C. T., J. B. Prins, L. Sanders, J. Zhang, C. P. Sewter, et al. (1998). "Depot-
related gene expression in human subcutaneous and omental adipocytes." Diabetes 47(9): 
1384-1391. 
Mori, M. , H. Nakagami, G. Rodriguez-Araujo, K. Nimura andY. Kaneda (2012). 
"Essential role for miR-196a in brown adipogenesis of white ·fat progenitor cells." PLoS 
Biol10(4): e1001314. 
142 
Morisco, C., G. Lembo and B. Trimarco (2006). "Insulin Resistance and Cardiovascular 
Risk: New Insights From Molecular and Cellular Biology." Trends in Cardiovascular 
Medicine 16(6): 183-188. 
Morrison, R. F. and S. R. Farmer (1999). "Role ofPPARgamma in regulating a cascade 
expression of cyclin-dependent kinase inhibitors, p 18(INK4c) and p21 (Wafl /Cip 1 ), 
during adipogenesis." J Biol Chern 274(24): 17088-17097. 
Mnicek, T., B. Cannon and J. Houstek (2004). "IL-l and LPS but not IL-6 inhibit 
differentiation and downregulate PPAR gamma in brown adipocytes." Cytokine 26(1): 9-
15. 
Nanbu-Wakao, R., Y. Morikawa, I. Matsumura, Y. Masuho, M.A. Muramatsu, et al. 
(2002). "Stimulation of3T3-Ll adipogenesis by signal transducer and activator of 
transcription 5." Mol Endocrinol16(7): 1565-1576. 
Neeck, G. (2002). "Fifty years of experience with cortisone therapy in the study and 
treatment of rheumatoid arthritis." Neuroendocrine Immune Basis ofthe Rheumatic 
Diseases Ii, Proceedings 966: 28-38. 
Nemoto, 0., H. Yamada, M. Mukaida and M. Shimmei (1996). "Stimulation ofTIMP-1 
production by oncostatin M in human articular cartilage." Arthritis and Rheumatism 
39( 4): 560-566. 
Newton, R. (2000). "Molecular mechanisms of glucocorticoid action: what is important?" 
Thorax 55(7): 603-613 . 
Nielsen, S. J. , A.M. Siega-Riz and B. M. Popkin (2002). "Trends in Energy Intake in 
U.S. between 1977 and 1996: Similar Shifts Seen across Age Groups." Obesity 10(5): 
370-378. 
Nishimura, J. and S. Ikuyama (2000). "Glucocorticoid-induced osteoporosis: 
pathogenesis and management." Journal ofBone and Mineral Metabolism 18(6): 350-
352. 
Ntambi, J. M. and K. Young-Cheul (2000). "Adipocyte differentiation and gene 
expression." J Nutr 130(12): 3122S-3126S. 
Oakley, R. H. , M. Sar and J. A. Cidlowski (1996). "The human glucocorticoid receptor 
beta isoform - Expression, biochemical properties, and putative function." J Biol Chern 
271(16): 9550-9559. 
Olefsky, J. M. and C. K. Glass (2010). "Macrophages, Inflammation, and Insulin 
Resistance." Annual Review of Physiology 72(1): 219-246. 
143 
Olefsky, J. M. and C. K. Glass (2010). "Macrophages, inflammation, and insulin 
resistance." Annu Rev Physiol 72: 219-246. 
Oppert, J. M. , M. C. Vohl, M. Chagnon, F. T. Dionne, A.M. Cassarddoulcier, et al. 
(1994). "DNA Polymorphism in the Uncoupling Protein (Ucp) Gene and Human-Body 
Fat." International Journal of Obesity 18(8): 526-531. 
Otto, T. C. and M. D. Lane (2005). "Adipose development: From stem cell to adipocyte." 
Critical Reviews in Biochemistry and Molecular Biology 40(4): 229-242. 
Pantoja, C., J. T. Huff and K. R. Yamamoto (2008). "Glucocorticoid Signaling Defines a 
Novel Commitment State during Adipogenesis In Vitro." Molecular Biology of the Cell 
19(1 0): 4032-4041. 
Pantoja, C. , J. T. Huff and K. R. Yamamoto (2008). "Glucocorticoid signaling defines a 
novel commitment state during adipogenesis in vitro." Mol Bioi Cell19(10): 4032-4041. 
Park, H.-K., M. Qatanani, E. R. Briggs, R. S. Ahima and M.A. Lazar (2011). 
"Inflammatory Induction of Human Resistin Causes Insulin Resistance in Endotoxemic 
Mice." Diabetes 60(3): 775-783 . 
Pickup, J. C. (2004). "Inflammation and activated innate immunity in the pathogenesis of 
type 2 diabetes." Diabetes Care 27(3): 813-823 . 
Pierotti, S., L. Gandini, A. Lenzi and A. M. Isidori (2008). "Pre-receptorial regulation of 
steroid hormones in bone cells: insights on glucocorticoid-induced osteoporosis." J 
Steroid Biochem Mol Bioi 1 08(3-5) : 292-299. 
Plum, L., B. F. Belgardt, Br, xFc and J. C. ning (2006). "Central insulin action in energy 
and glucose homeostasis ." J Clin Invest 116(7): 1761-1766. 
Prusty, D. , B.-H. Park, K. E. Davis and S. R. Farmer (2002). "Activation ofMEKIERK 
Signaling Promotes Adipogenesis by Enhancing Peroxisome Proliferator-activated 
Receptor y (PPARy) and C/EBPa Gene Expression during the Differentiation of3T3-L1 
Preadipocytes." J Bioi Chern 277(48): 46226-46232. 
Pugin, J ., C. C. Schurermaly, D. Leturcq, A. Moriarty, R. J. Ulevitch, et al. (1993). 
"Lipopolysaccharide Activation of Human Endothelial and Epithelial-Cells Is Mediated 
by Lipopolysaccharide-Binding Protein and Soluble Cd14." Proceedings of the National 
Academy of Sciences of the United States of America 90(7): 2744-2748. 
Pujols, L., J. Mullol, J. Roca-Ferrer, A. Torrego, A. Xaubet, et al. (2002). "Expression of 
glucocorticoid receptor a- and ~-isoforms in human cells and tissues." American Journal 
of Physiology- Cell Physiology 283( 4): C1324-C1331. 
144 
Qi, L. , M. Saberi, E. Zmuda, Y. Wang, J. Altarejos, et al. (2009). "Adipocyte CREB 
promotes insulin resistance in obesity." Cell Metabolism 9(3): 277-286. 
Qiang, L., H. Wang and S. R. Farmer (2007). "Adiponectin secretion is regulated by 
SIRTl and the endoplasmic reticulum oxidoreductase erol-1 alpha." Molecular and 
Cellular Biology 27(13): 4698-4707. 
Qiang, L. , L. Wang, N. Kon, W. Zhao, S. Lee, et al. (2012). "Brown remodeling of white 
adipose tissue by SirT1-dependent deacetylation ofPpargamma." Cell150(3) : 620-632. 
Rajala, M. W. and P. E. Scherer (2003). "Minireview: The Adipocyte-At the Crossroads 
of Energy Homeostasis, Inflammation, and Atherosclerosis." Endocrinology 144(9): 
3765-3773. 
Raji, A. , E. W. Seely, S. A. Bekins, G. H. Williams and D. C. Simonson (2003). 
"Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive 
patients." Diabetes Care 26(1): 172-178. 
Reaven, G. M. (1988). "Role oflnsulinResistance inHuman Disease." Diabetes 37(12): 
1595-1607. 
Rebuffe-Scrive, M. , M. KROTKIEWSKI, J. ELFVERSON and P. BJQRNTORP (1988). 
"Muscle and Adipose Tissue Morphology and Metabolism in Cushing's Syndrome." 
Journal of Clinical Endocrinology & Metabolism 67(6): 1122-1128. 
Reddi, A. H. (2005). "BMPs: From bone morphogenetic proteins to body morphogenetic 
proteins." Cytokine & Growth Factor Reviews 16(3): 249-250. 
Ren, D. L. , T. N. Collingwood, E . J. Rebar, A. P. Wolffe and H. S. Camp (2002). "PPAR 
gamma knockdown by engineered transcription factors: exogenous PP AR gamma 2 but 
not PPAR gamma 1 reactivates adipogenesis." Genes & Development 16(1): 27-32. 
Reusch, J. E. , L. A. Colton and D. J. Klemm (2000). "CREB activation induces 
adipogenesis in 3T3-Ll cells." Mol Cell Biol20(3): 1008-1020. 
Revollo, J. R. and J. A. Cidlowski (2009). "Mechanisms generating diversity in 
glucocorticoid receptor signaling." Ann NY Acad Sci 1179: 167-178. 
Reyne, Y. , J. Nougues and J.-P. Dulor (1989). "Differentiation of rabbit adipocyte 
precursor cells in a serum-free medium." In Vitro Cellular & Developmental Biology-
Plant 25(8): 747-752. 
Reznikoff, C. A. , D. W. Brankow and C. Heidelberger (1973). "Establishment and 
characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence 
inhibition of division." Cancer Res 33(12): 3231-3238. 
145 
Richard, A. J. and J. M. Stephens (2011). "Emerging roles of JAK-STAT signaling 
pathways in adipocytes." Trends in Endocrinology & Metabolism 22(8): 325-332. 
Ringold, G. M., A. B. Chapman, D. M. Knight and F. M. Torti (1986). "Hormonal 
Control of Adipogenesisa." Annals ofthe New York Academy of Sciences 478(1): 109-
119. 
Rochford, J. J., R. K. Semple, M. Laudes, K. B. Boyle, C. Christodoulides, et al. (2004). 
"ETO/MTG8 is an inhibitor of C/EBPbeta activity and a regulator of early adipogenesis." 
Mol Cell Biol 24(22): 9863-9872. 
Rogatsky, I., S. K. Logan and M. J. Garabedian (1998). "Antagonism of glucocorticoid 
receptor transcriptional activation by the c-Jun N-terminal kinase." Proc Natl Acad Sci U 
SA 95(5): 2050-2055. 
Romero, Y., M. Vuandaba, P. Suarez, C. Grey, P. Calve!, et al. (2012). "The 
Glucocorticoid-Induced Leucine Zipper (GILZ) Is Essential for Spermatogonial Survival 
and Spermatogenesis." Sexual Development 6(4): 169-177. 
Rosen, E. D. and B. M. Spiegelman (2006). "Adipocytes as regulators of energy balance 
and glucose homeostasis." Nature 444(7121): 847-853. 
Ross, R., D. Dagnone, P. J. H. Jones, H. Smith, A. Paddags, et al. (2000). "Reduction in 
Obesity and Related Comorbid Conditions after Diet-Induced Weight Loss or Exercise-
Induced Weight Loss in Men." Annals oflntemal Medicine 133(2): 92-103. 
Ross, S. E., N: Hemati, K. A. Longo, C. N. Bennett, P. C. Lucas, et al. (2000). "Inhibition 
of adipogenesis by Wnt signaling." Science 289(5481): 950-953. 
Rubin, C. S., A. Hirsch, C. Fung and 0. M. Rosen (1978). "Development ofHormone 
Receptors and Hormonal Responsiveness Invitro - Insulin Receptors and Insulin 
Sensitivity in Preadipocyte and Adipocyte Forms of3t3-L1 Cells." J Biol Chern 253(20): 
7570-7578. 
Rull, A., J. Camps, C. Alonso-Villaverde and J. Joven (201 0). "Insulin resistance, 
inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the 
regulation of metabolism." Mediators Inflamm 2010. 
Russell-Jones, D. and R. Khan (2007). "Insulin-associated weight gain in diabetes-
causes, effects and coping strategies." Diabetes, Obesity and Metabolism 9(6): 799-812. 
Saba-El-Leil, M. K., F. D . Vella, B. Vemay, L. Voisin, L. Chen, et al. (2003). "An 
essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast 
development." EMBO Rep 4(10): 964-968. 
146 
Sale, E. M., P. G. P. Atkinson and G. J. Sale (1995). "Requirement of Map Kinase for 
Differentiation of Fibroblasts to Adipocytes, for Insulin Activation of P90 S6 Kinase and 
for Insulin or Serum Stimulation of DNA-Synthesis." Embo Journal14(4): 674-684. 
Saltiel, A. R. and C. R. Kahn (2001). "Insulin signalling and the regulation of glucose and 
lipid metabolism." Nature 414(6865): 799-806. 
Samuel, V. T., K. F. Petersen and G. I. Shulman "Lipid-induced insulin resistance: 
unravelling the mechanism." The Lancet 375(9733): 2267-2277. 
Sapolsky, R. M., L. M. Romero and A. U. Munck (2000). "How Do Glucocorticoids 
Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and 
Preparative Actions." Endocrine Reviews 21(1): 55-89. 
Sartipy, P. and D. J. Loskutoff (2003). "Monocyte chemoattractant protein 1 in obesity 
and insulin resistance." Proc Natl Acad Sci US A 100(12): 7265-7270. 
Schindler, C. and J. E. Darnell (1995). "Transcriptional Responses to Polypeptide 
Ligands: The JAK-STAT Pathway." Annual Review of Biochemistry 64(1): 621-652. 
Schindler, C. W. (2002). "Series Introduction: JAK-STAT signaling in human disease." J 
Clin Invest 109(9): 1133-1137. 
Schupp, M., A. G. Cristancho, M. I. Lefterova, E. A. Hanniman, E. R. Briggs, et al. 
(2009). "Re-expression ofGATA2 cooperates with peroxisome proliferator-activated 
receptor-gamma depletion to revert the adipocyte phenotype." J Biol Chern 284(14): 
9458-9464. 
Schupp, M., A. G. Cristancho, M. I. Lefterova, E. A. Hanniman, E. R. Briggs, et al. 
(2009). "Re-expression of GAT A2 Cooperates with Peroxisome Proliferator-activated 
Receptor-y Depletion to Revert the Adipocyte Phenotype." J Biol Chern 284(14): 9458-
9464. 
Seale, P., B. Bjork, W. Yang, S. Kajimura, S. Chin, et al. (2008). "PRDM16 controls a 
brown fat/skeletal muscle switch." Nature 454(7207): 961-967. 
Seale, P., S. Kajimura and B. M. Spiegelman (2009). "Transcriptional control of brown 
adipocyte development and physiological function--of mice and men." Genes Dev 23(7): 
788-797. 
Shaker, J. L. and B. P. Lukert (2005). "Osteoporosis associated with excess 
glucocorticoids." Endocrinol Metab Clin North Am 34(2): 341-356, viii-ix. 
147 
Shi, X. , M. Hamrick and C. M. Isales (2007). "Energy Balance, Myostatin, and GILZ: 
Factors Regulating Adipocyte Differentiation in Belly and Bone." PPAR Res 2007: 
92501. 
Shi, X. , W. Shi, B. Song, Q. Li, M. Wan, et al. (2002). "A glucocorticoid-induced leucine 
zipper protein GILZ inhibits adipocyte differentiation." Journal of Bone and Mineral 
Research 17: S291-S291. 
Shibli-Rahhal, A. , M. VanBeek and J. A. Schlechte (2006). "Cushing's syndrome." 
Clinics in Dermatology 24(4): 260-265. 
Shulman, G. I. (2000). "Cellular mechanisms of insulin resistance." J Clin Invest 1 06(2) : 
171-176. 
Silver, J. S. and C. A. Hunter (2010). "gp130 at the nexus of inflammation, 
autoimmunity, and cancer." Journal of Leukocyte Biology 88(6): 1145-1156. 
Singh, R. , Y. Xiang, Y. Wang, K. Baikati, A.M. Cuervo, et al. (2009). "Autophagy 
regulates adipose mass and differentiation in mice." J Clin Invest 119(11): 3329-3339. 
Sjostrom, L. (1972). "Adult human adipose tissue cellularity and metabolism with special 
reference to obesity and fatty acid synthesis de novo." Acta Med Scand Suppl 544: 1-52. 
Smas, C. M., L. Chen, L. Zhao, M.-J. Latasa and H. S. Sul (1999). "Transcriptional 
Repression ofpref-1 by Glucocorticoids Promotes 3T3-L1 Adipocyte Differentiation." J 
Bioi Chern 274(18): 12632-12641. 
Smas, C. M. and H. S. Sul (1995). "Control of Adipocyte Differentiation." Biochemical 
Journal309: 697-710. 
Song, H. Y. , E. S. Jeon, J. S. Jung and J. H. Kim (2005). "Oncostatin M induces 
proliferation ofhuman adipose tissue-derived mesenchymal stem cells." International 
Journal ofBiochemistry & Cell Biology 37(11): 2357-2365. 
Song, H. Y. , E. S. Jeon, J. Kim, J. S. Jung and J. H. Kim (2007). "Oncostatin M promotes 
osteogenesis and suppresses adipogenic differentiation of human adipose tissue-derived 
mesenchymal stem cells." Journal of Cellular Biochemistry 101(5): 1238-1251. 
Song, H. Y., M. R. Kim, M. J. Lee, E. S. Jeon, Y. C. Bae, et al. (2007). "Oncostatin M 
decreases adiponectin expression and induces dedifferentiation of adipocytes by JAK3-
and MEK-dependent pathways." Int J Biochem Cell Bioi 39(2): 439-449. 
Song, I.-H. and F. Buttgereit (2006). "Non-genomic glucocorticoid effects to provide the 
basis for new drug developments." Molecular and Cellular Endocrinology 246(1-2): 142-
146. 
148 
Souk:as, A., N.D. Socci, B. D. Saatkamp, S. Novelli and J. M. Friedman (2001). "Distinct 
transcriptional profiles of adipogenesis in vivo and in vitro." J Biol Chern 276(36): 
34167-34174. 
Spiegelman, B. M. and S. R. Farmer (1982). "Decreases in Tubulin and Actin Gene-
Expression Prior to Morphological-Differentiation of3t3 Adipocytes." Cell29(1): 53-60. 
Stahn, C. and F. Buttgereit (2008). "Genomic and nongenomic effects of 
glucocorticoids." Nature Clinical Practice Rheumatology 4(10): 525-533. 
Stephens, J. M. , S. J. Lumpkin and J. B. Fishman (1998). "Activation of Signal 
Transducers and Activators of Transcription 1 and 3 by Leukemia Inhibitory Factor, 
Oncostatin-M, and Interferon-yin Adipocytes." J Biol Chern 273(47): 31408-31416. 
Stephens, J. M. , R. F. Morrison and P. F. Pilch (1996). "The expression and regulation of 
STATs during 3T3-L1 adipocyte differentiation." J Biol Chern 271(18): 10441-10444. 
Stephens, J. M., R. F. Morrison, Z. Wu and S. R. Farmer (1999). "PPARy Ligand-
Dependent Induction of ST AT1 , STAT5A, and STAT5B during Adipogenesis." 
Biochemical and Biophysical Research Communications 262(1): 216-222. 
Sturgill, T. W. (2008). "MAP kinase: It ' s been longer than fifteen minutes." Biochemical 
and Biophysical Research Communications 371(1): 1-4. 
Suganami, T., J. Nishida andY. Ogawa (2005). "A paracrine loop between adipocytes 
and macrophages aggravates inflammatory changes - Role of free fatty acids and tumor 
necrosis factor alpha." Arteriosclerosis Thrombosis and Vascular Biology 25(10): 2062-
2068. 
Suryawan, A., L. V. Swanson and C. Y. Hu (1997). "Insulin and hydrocortisone, but not 
triiodothyronine, are required for the differentiation of pig preadipocytes in primary 
culture." Journal of Animal Science 75(1): 105-111. 
Suzawa, M. , I. Takada, J. Yanagisawa, F. Ohtake, S. Ogawa, et al. (2003). "Cytokines 
suppress adipogenesis and PPAR-gamma function through the TAK1 /TAB1/NIK 
cascade." Nat Cell Biol 5(3): 224-230. 
Taga, T. (1997). "The signal transducer gp130 is shared by interleukin-6 family of 
haematopoietic and neurotrophic cytokines." Annals of Medicine 29(1): 63-72. 
Taga, T. and T. Kishimoto (1997). "gp130 and the interleukin-6 family ofcytokines." 
Annual Review of Immunology 15: 797-819. 
149 
Tang, Q.-Q. , T. C. Otto and M. D. Lane (2003). "Mitotic clonal expansion: A 
synchronous process required for adipogenesis." Proceedings ofthe National Academy of 
Sciences 100(1): 44-49. 
Tang, Q.-Q. , T. C. Otto and M.D. Lane (2004). "Commitment ofC3H10Tll2 pluripotent 
stem cells to the adipocyte lineage." Proceedings ofthe National Academy of Sciences of 
the United States of America 101 (26): 9607-9611. 
Tang, Q. Q. and M.D. Lane (2012). "Adipogenesis: From Stem Cell to Adipocyte." 
Annual Review of Biochemistry, Vol 81 81: 715-736. 
Tang, Q. Q. , T. C. Otto and M.D. Lane (2004). "Commitment ofC3H10Tl/2 pluripotent 
stem cells to the adipocyte lineage." Proceedings ofthe National Academy of Sciences of 
the United States of America 101(26): 9607-9611. 
Tilg, H. and A. R. Moschen (2006). "Adipocytokines: mediators linking adipose tissue, 
inflammation and immunity." Nature Reviews Immunology 6(10): 772-783. 
Todaro, G. J. and H. Green (1963). "Quantitative studies ofthe growth of mouse embryo 
cells in culture and their development into established lines." J Cell Biol 17: 299-313. 
Tomita, T. , A. Yamada, M. Miyakoshi, T. Kido, F. Sheikh, et al. (2009). "Oncostatin M 
Regulates Secretoglobin 3A1 and 3A2 Expression in a Bidirectional Manner." American 
Journal of Respiratory Cell and Molecular Biology 40(5): 620-630. 
Tong, Q. , G. Dalgin, H. Xu, C. N. Ting, J. M. Leiden, et al. (2000). "Function of GAT A 
transcription factors in preadipocyte-adipocyte transition." Science 290(5489): 134-138. 
Toth, M. and A. Grossman (2013). "Glucocorticoid-induced osteoporosis: lessons from 
cushing's syndrome." Clin Endocrinol (Oxf). 
Tracey, K. J. (2002) . "The inflammatory reflex ." Nature 420(6917): 853-859. 
Trayhurn, P. and J. H. Beattie_ (2001). "Physiological role of adipose tissue: white adipose 
tissue as an endocrine and secretory organ." Proceedings ofthe Nutrition Society 60(3): 
329-339. 
Trayhurn, P. and I. S. Wood (2004). "Adipokines: inflammation and the pleiotropic role 
of white adipose tissue." British Journal ofNutrition 92(3): 347-355. 
Tseng, Y.-H. , E. Kokkotou, T. J. Schulz, T. L. Huang, J. N. Winnay, et al. (2008). "New 
role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure." 
Nature 454(7207): 1000-1004. 
150 
Unguryte, A., E. Bemotiene and A. Venalis (2010). "Human mesenchymal adipose 
stromal cells from mature adipocyte fraction." Central European Journal ofBiology 5(1): 
47-58. 
Uysal, K. T. , S.M. Wiesbrock, M. W. Marino and G. S. Hotamisligil (1997). "Protection 
from obesity-induced insulin resistance in mice lacking TNF-alpha function." Nature 
389(6651): 610-614. 
Ventre, J., T. Doebber, M. Wu, K. MacNaul, K. Stevens, et al. (1997). "Targeted 
disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and 
nonobese mice." Diabetes 46(9): 1526-1531. 
Vemet, D., G. Nolazco, L. Cantini, T. R. Magee, A. Qian, et al. (2005). "Evidence that 
osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: 
Implications for Peyronie disease." Biology of Reproduction 73(6): 1199-1210. 
Vidal, C. , S. Bermeo, W. Li, D. Huang, R. Kremer, et al. (2012). "Interferon gamma 
inhibits adipogenesis in vitro and prevents marrow fat infiltration in oophorectomized 
mice." STEM CELLS 30(5): 1042-1048. 
Viengchareun, S., P. Penfornis, M. C. Zennaro and M. Lombes (2001). 
"Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in 
brown adipocytes." Am J Physiol Endocrinol Metab 280(4): E640-649. 
Wagner, D. 0., C. Sieber, R. Bhushan, J. H. Borgermann, D. Graf, et al. (2010). "BMPs: 
From Bone to Body Morphogenetic Proteins." Science Signaling 3(1 07). 
Wall, M. E., A. Rachlin, C. A. Otey and E. G. Loboa (2007). "Human adipose-derived 
adult stem cells upregulate palladin during osteogenesis and in response to cyclic tensile 
strain." American Journal of Physiology-Cell Physiology 293(5): C1532-C1538. 
Wang, H. and S. R. Farmer (2008). "Identification of a domain within peroxisome 
proliferator-activated receptor gamma regulating expression of a group of genes 
containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in 
adipocytes." Mol Cell Biol28(1): 188-200. 
Wang, H. , L. Qiang and S. R. Farmer (2008). "Identification of a domain within 
peroxisome proliferator-activated receptor gamma regulating expression of a group of 
genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in 
adipocytes." Mol Cell Biol 28(1 ): 188-200. 
Wang, Y. , Y. Y. Ma, X. L. Song, H. Y. Cai, J. C. Chen, et al. (2012). "Upregulations of 
glucocorticoid-induced leucine zipper by hypoxia and glucocorticoid inhibit 
proinflammatory cytokines under hypoxic conditions in macrophages." J Immunol 
188(1): 222-229. 
151 
Wang, Y. and H. S. Sui (2009). "Pref-1 Regulates Mesenchymal Cell Commitment and 
Differentiation through Sox9." Cell Metabolism 9(3): 287-302. 
Wang, Y. and H. S. Sui (2009). "Pref-1 regulates mesenchymal cell commitment and 
differentiation through Sox9." Cell Metab 9(3): 287-302. 
Wang, Y. , L. Zhao, C. Smas and H. S. Sul (2010). "Pref-1 interacts with fibronectinto 
inhibit adipocyte differentiation." Mol Cell Biol30(14): 3480-3492. 
Warriar, N., C. Yu and M. V. Govindan (1994). "Hormone binding domain of human 
glucocorticoid receptor. Enhancement oftransactivation function by substitution mutants 
M565R and A573Q." J Bioi Chern 269(46): 29010,.29015. 
White, U. A. and J. M. Stephens (2010). "Neuropoietin activates STAT3 independent of 
LIFR activation in adipocytes." Biochemical and Biophysical Research Communications 
395(1): 48-50. 
White, U. A. and J. M. Stephens (2011). "The gp130 receptor cytokine family: regulators 
of adipocyte development and function." Curr Pharm Des 17( 4): 340-346. 
White, U. A. and J. M. Stephens (2011). "The gp130 Receptor Cytokine Family: 
Regulators of Adipocyte Development and Function." Current Pharmaceutical Design 
17(4): 340-346. 
White, U. A. , W. C. Stewart, R. L. Mynatt and J. M. Stephens (2008). "Neuropoietin 
Attenuates Adipogenesis and Induces Insulin Resistance in Adipocytes." J Bioi Chern 
283(33): 22505-22512. 
White, U. A., W. C. Stewart and J. M. Stephens (2011). "Gp130 cytokines exert 
differential patterns of crosstaik in adipocytes both in vitro and in vivo." Obesity (Silver 
Spring) 19(5): 903-910. 
White, U. A., W. C. Stewart and J. M. Stephens (2011). "Gp130 Cytokines Exert 
Differential Patterns of Crosstalk in Adipocytes Both In Vitro and In Vivo." Obesity 
19(5): 903-910. 
Williams, P. T. and P. D. Wood (2005). "The effects of changing exercise levels on 
weight and age-related weight gain." Int JObes 30(3): 543-551. 
Williams, R. L., D. J. Hilton, S. Pease, T. A. Willson, C. L. Stewart, et al. (1988). 
"Myeloid-Leukemia Inhibitory Factor Maintains the Developmental Potential of 
Embryonic Stem-Cells." Nature 336(6200): 684-687. 
152 
Wiper-Bergeron, N., H. A. Salem, J. J. Tomlinson, D. Wu and R. J. Hache (2007). 
"Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation 
ofC/EBPbeta by GCN5 ." Proc Natl Acad Sci US A 104(8): 2703-2708. 
Wiper-Bergeron, N., H. A. Salem, J. J. Tomlinson, D. M. Wu and R. J. G. Hache (2007) . 
"Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation 
ofC/EBP beta by GCN5." Proceedings ofthe National Academy of Sciences ofthe 
United States of America 1 04(8): 2703-2708. 
Wiper-Bergeron, N., D. M. Wu, L. Pope, C. Schild-Poulter and R. J . G. Hache (2003). 
"Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 
complex." Embo Joumal22(9): 2135-2145. 
Wolf, G. (1999). "The molecular mechanism ofthe stimulation ofadipocyte 
differentiation by a glucocorticoid." Nutrition Reviews 57(10): 324-326. 
Wong, P. K., I. K. Campbell, P . J. Egan, M. Ernst and I. P. Wicks (2003). "The role of 
the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover." 
Arthritis and Rheumatism 48(5): 1177-1189. 
Woolf, A. D. (2007). "An update on glucocorticoid-induced osteoporosis." Curr Opin 
Rheumatol19(4): 370-375. 
Wu, Y. (2006). "Overweight and obesity in China." BMJ 333(7564): 362-363. 
Wu, Z., Y. Xie, N. L. Bucher and S. R. Farmer (1995). "Conditional ectopic expression 
of C/EBP beta in NIH-3T3 cells induces PP AR gamma and stimulates adipogenesis." 
Genes Dev 9(19): 2350-2363. 
Wu, Z. D., N. L. R. Bucher and S. R. Farmer (1996). "Induction of peroxisome 
proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into 
adipocytes is mediated by C/EBP beta, C/EBP delta, and glucocorticoids." Molecular and 
Cellular Biology 16(8): 4128-4136. 
Xing, H., J.P. Northrop, J. R. Grove, K. E. Kilpatrick, J. L. Su, et al. (1997) . "TNF alpha-
mediated inhibition and reversal of adipocyte differentiation is accompanied by 
suppressed expression of PP ARgamma without effects on Pref-1 expression." 
Endocrinology 138(7): 2776-2783. 
Xu, H. , G. T. Barnes, Q. Yang, G. Tan, D. Yang, et al. (2003). "Chronic inflammation in 
fat plays a crucial role in the development of obesity-related insulin resistance." J Clin 
Invest 112(12): 1821-1830. 
Yamashita, A., Y. Soga, Y. Iwamoto, T. Asano, Y. Li, et al. (2008). "DNA microarray 
analyses of genes expressed differentially in 3T3-L1 adipocytes co-cultured with murine 
153 
macrophage cell line RA W264.7 in the presence of the toll-like receptor 4ligand 
bacterial endotoxin." Int JObes (Lond) 32(11): 1725-1729. 
Y anagiya, T. , A. Tanabe and K. Horta (2007). "Gap-junctional communication is 
required for mitotic clonal expansion during adipogenesis." Obesity 15(3): 572-582. 
Yanai, N. and M. Obinata (2001). "Oncostatin m regulates mesenchymal cell 
differentiation and enhances hematopoietic supportive activity of bone marrow stromal 
cell lines." In Vitro Cell Dev Biol Anim 37(10): 698-704. 
Yang, N. , W. Zhang and X. M. Shi (2008). "Glucocorticoid-induced leucine zipper 
(GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-
2 expression." J Cell Biochem 103(6): 1760-1771. 
Yang, Y. H. , D. Aeberli, A. Dacumos, J. R. Xue and E. F. Morand (2009). "Annexin-1 
Regulates Macrophage IL-6 and TNF via Glucocorticoid-Induced Leucine Zipper." The 
Journal oflmmunology 183(2): 1435-1445. 
Yao, W. , Z. Cheng, C. Busse, A. Pharo, M . C. Nakamura, et al. (2008). "Glucocorticoid 
excess in mice results in early activation of osteoclastogenesis and adipogenesis and 
prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone 
tissue from glucocorticoid-treated mice." Arthritis and Rheumatism 58(6): 1674-1686. 
Yeh, W. C. , Z. Cao, M. Classon and S. L. McKnight (1995). "Cascade regulation of 
terminal adipocyte differentiation by three members of the C/EBP family of leucine 
zipper proteins." Genes Dev 9(2): 168-181. 
Yiannakouris, N. , M. Yannakoulia, L. Melistas, J. L. Chan, D. Klimis-Zacas, et al. 
(2001). "The Q223R Polymorphism of the Leptin Receptor Gene Is Significantly 
Associated with Obesity and Predicts a Small Percentage of Body Weight and Body 
Composition Variability." Journal of Clinical Endocrinology & Metabolism 86(9): 4434-
4439. 
Yin, T. G. , K. Miyazawa andY. C. Yang (1992). "Characterization oflnterleukin-11 
Receptor and Protein Tyrosine Phosphorylation Induced by Interleukin-11 in Mouse 3t3-
Ll Cells." J Biol Chern 267(12): 8347-8351. 
Yu, C. Y. , 0. Mayba, J. V. Lee, J. Tran, C. Harris, et al. (2010). "Genome-wide analysis 
of glucocorticoid receptor binding regions in adipocytes reveal gene network involved in 
triglyceride homeostasis." PLoS One 5(12) : e15188. 
Zhong, J. , S. A. Krawczyk, R. Chaerkady, H. Huang, R. Goel, et al. (2010). "Temporal 
profiling ofthe secretome during adipogenesis in humans." J Proteome Res 9(10) : 5228-
5238. 
154 
Ziemke, F. and C. S. Mantzoros (2010). "Adiponectin in insulin resistance: lessons from 
translational research." The American Journal of Clinical Nutrition 91(1): 258S-261S. 
Zimmerlin, L. , V. S. Dannenberg, M. E. Pfeifer, E. M. Meyer, B. Peault, et al. (2010). 
"Stromal Vascular Progenitors in Adult Human Adipose Tissue." Cytometry Part A 
77A(l): 22-30. 
Zvonic, S. , J. E. Baugh, P. Arbour-Reily, R. L. Mynatt and J. M. Stephens (2005). 
"Cross-talk among gp130 cytokines in adipocytes." J Biol Chern 280(40): 33856-33863. 
155 
CURRICULUM VITAE 
HengGuo 
 hguo@bu.edu 
 
Education Boston University, Boston, MA 
Ph.D. in Biochemistry (2007-present, expected in 2013) 
• Study the mechanism of fat cell development, specifically the role of 
glucocorticoid signaling in adipogenesis. 
Wuhan University, Wuhan, China 
B.Sc. in Biological Sciences (May 2005) 
• Awarded the highest scholarship for high 2001 National College 
Entrance Examination scores. 
Publications Wesley CS, Guo H, Chaudhry KA, Thali MJ, Yin JC, Clason T, Wesley 
UV. Loss of PTB or negative regulation of Notch mRNA reveals 
distinct zones of Notch and actin protein accumulation in Drosophila 
embryo. PLoS One. 2011; 6(7):e21876 
Guo H. Application of bonding technology in life science and medicine. 
Adhesion in China. 2004; 4:36-37 
156 
Experience Boston University, Boston, MA 
PhD Candidate (2007-present) 
Activities 
• Advisor: Stephen Farmer 
• Use in vitro cultured cell models to study the functions and regulations 
of inflammatory genes in adipocyte differentiation. 
• Generate mutated PPARgamma, targets of TZD class anti-diabetic 
drugs such as A vandia, and their roles in fat cells development. 
University of Vermont, Burlington, VT 
Graduate Student (2005-2007) 
• Advisor: Cedric Wesley 
• Conducted research on the novel roles of gene delta independent of 
notch signaling in the development of fruit fly. 
Teaching Assistant (2006-2007) 
• Mentored more than 50 undergraduate students in the course Biology of 
Microorganisms. 
Annual Henry I. Russek Student Achievement Day, Boston, MA 
Poster Presenter (May 2012) 
• Presented my research in the format of poster and answered questions 
from audience. 
157 
Skills 
Annual Harvard China Review Conference, Cambridge, MA 
Volunteer (Mar. 2008) 
• Guided the conference speakers and guests for registration, direction and 
other assistance work. 
American Association for the Advancement of Science Annual 
Meeting, Boston, MA 
Student Session Aide (Feb. 2008) 
• Monitored sessions, estimated attendance, evaluated audience interest, 
session content, and speaker performance. 
Computer: proficient in Mac and PC, MS Word, Excel, Power Point, 
Photoshop, Endnote, etc 
Language: fluent in English and Mandarin Chinese 
158 
